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Thesis summary 
22q11.2 Deletion Syndrome (22q11.2DS) is one of the strongest known risk factors for 
schizophrenia. The syndrome provides a rare opportunity to prospectively examine development 
that precedes schizophrenia. 22q11.2DS is also associated with a range of psychiatric disorders and 
cognitive deficits. The overall aim of this thesis is to examine the neuropsychiatric phenotype of 
22q11.2DS through a developmental lens. This thesis uses data from Cardiff University’s ECHO 
(Experiences of CHildren with cOpy number variants) study which includes a longitudinal cohort of 
children with 22q11.2DS. Development in 22q11.2DS is contrasted to that of the unaffected siblings 
of children with 22q11.2DS. 
First psychopathology is examined longitudinally across early adolescence in 22q11.2DS. Children 
with 22q11.2DS have a significant burden of psychopathology across early adolescence, including 
attention-deficit/hyperactivity disorder (ADHD), anxiety disorders and autism spectrum disorder 
(ASD). There is a striking increase in the prevalence of psychotic experiences and a decrease in ADHD 
prevalence. The ASD phenotype is examined further using a diagnostic interview of developmental 
history. ASD and subthreshold phenomenology is found to be highly prevalent in the early 
development of children with 22q11.2DS. 
Next cognitive development in 22q11.2DS is considered and contrasted to that in unaffected 
siblings. Cognitive deficits across a range of domains are present in 22q11.2DS. Cognitive 
development in 22q11.2DS is found to be similar to that reported in children who later develop 
idiopathic schizophrenia. 
This is followed by an exploration of the relations between psychopathology and cognitive 
development in 22q11.2DS. Cognitive development is found to predict the emergence of psychotic 
experiences and the persistence of ADHD in 22q11.2DS.  
This thesis extends what is known about the development of the neuropsychiatric phenotype in 
22q11.2DS. Furthermore, findings give an insight into the developmental pathways associated with a 
high risk of developing schizophrenia.  
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1. Introduction: 22q11.2 Deletion Syndrome 
1.1 22q11.2 Deletion Syndrome background 
1.1.1 Genetic characterization and prevalence 
22q11.2 Deletion Syndrome is a submicroscopic microdeletion at region q11.2 on one copy of 
human  chromosome 22 (Drew, Crabtree et al. 2011) and occurs at a frequency of approximately 1 in 
4000 live births (Scambler 2000). Population-based prevalence rates reported vary from 1 in 2000 to 
1 in 7000 and are highly dependent on ascertainment method. It is likely many individuals remain 
undiagnosed and it has been estimated that the true population prevalence is around 1 in 1600 live 
births (Shprintzen 2008). There is a high selection pressure on this locus due to its negative effect on 
reproductive fitness, however it persists in the population due to a high ‘de novo’ mutation rate 
(Rees, Moskvina et al. 2011). The majority of cases occur ‘de novo’, only in 5-10% of cases is the 
deletion inherited from an affected parent (Williams 2011). Regions of low copy repeats flanking the 
q11.2 region increase the likelihood of non-allelic homologous recombination resulting in a deletion 
during meiosis (Edelmann, Pandita et al. 1999, Kurahashi, Shaikh et al. 2000, Bittel, Yu et al. 2009). 
87% of deletions include a common 3 Megabase (Mb) region which includes at least 48 known 
genes, 8% span a smaller 1.5 Mb region (nested within the 3Mb region) which contains at least 28 
genes (Shaikh, Kurahashi et al. 2000) and the remainder are atypical deletions (Urban, Korbel et al. 
2006).  
22q11.2 Deletion Syndrome is also known as DiGeorge syndrome or Velo-cardio-facial syndrome 
(VCFS). These other names refer to clinical presentations that were found in 1992 to have the same 
underlying genetic aetiology (Driscoll, Budarf et al. 1992, Driscoll, Spinner et al. 1992, Scambler, Kelly 
et al. 1992). For the purposes of this thesis I will use the term 22q11.2 Deletion Syndrome 
(22q11.2DS). 22q11.2DS is an example of a copy number variant (CNV). CNVs are structural genomic 
variations that are >1 kilobase in size and occur in the form of deletions and duplications (Lee and 
Scherer 2010, Malhotra and Sebat 2012). 
1.1.2 Phenotype of 22q11.2DS 
The phenotype is highly variable and exhibits incomplete penetrance with some individuals not 
surviving the neonatal period and others who remain relatively unaffected (McDonald‐McGinn and 
Zackai 2008, Shprintzen 2008). Multiple organ systems can be affected and common clinical features 
include heart and velopharyngeal defects, immunodeficiency, hypocalcaemia, short stature and 
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cognitive impairment (Shprintzen, Goldberg et al. 1978, Ryan, Goodship et al. 1997, Scambler 2000, 
Kobrynski and Sullivan 2007).  It is also associated with a striking elevated risk for neuropsychiatric 
disorder (Schneider, Debbané et al. 2014). The phenotype shows marked variable expression, over 
180 clinical features have been identified though no single feature occurs in all cases (Robin and 
Shprintzen 2005, Shprintzen 2008). Phenotypic variability could in theory be caused by deletion size, 
breakpoint heterogeneity, genomic variation outside the q11.2 region, environmental and stochastic 
factors (Drew, Crabtree et al. 2011). However, phenotypic severity has not been found to correlate 
with deletion size and it has been argued that the 1.5Mb region contains the causative genes 
(Carlson, Sirotkin et al. 1997). 
1.1.3 Diagnosis of 22q11.2DS 
A range of techniques have traditionally been used to identify the deletion, ranging from 
fluorescence in situ hybridization (FISH) analysis, quantitative polymerase chain reaction (PCR), 
comparative genome hybridization (CGH) and genome-wide arrays of single nucleotide 
polymorphisms (SNPs) (Williams 2011). Individuals can be referred for medical genetic testing for a 
wide variety of reasons and at a range of ages, from embryo to adulthood. Pre-implantation genetic 
diagnosis of embryos is available for couples where one of the parents is known to be affected by 
22q11.2DS (Iwarsson, Ahrlund-Richter et al. 1998). Prenatal testing can occur if there are pregnancy 
difficulties or physical abnormalities in the foetus (Driscoll 2001).  However most individuals are 
diagnosed at a young age after birth (Swillen, Vogels et al. 2000), those identified as infants often 
present with congenital cardiac anomalies (Momma 2010), cleft palate, feeding difficulties with 
nasal reflux and neonatal hypocalcaemia (Vogels, Schevenels et al. 2014). Those identified after the 
age of two often present with speech-language impairment, developmental delay or learning 
difficulties and recurrent infections (Lima, Følling et al. 2010). In a minority of cases individuals are 
not identified until adulthood, particularly if they have no obvious physical features. Referral in these 
cases is mainly because of familial occurrence, cardiac defects and comorbid intellectual disability 
and psychiatric disorder (Vogels, Schevenels et al. 2014).  
1.2 Neuropsychiatric phenotype of 22q11.2DS  
There is a strong consensus that 22q11.2DS greatly increases risk of neuropsychiatric disorder across 
the lifespan (Schneider, Debbané et al. 2014). Regardless of ascertainment method, at least 60% of 
individuals with 22q11.2DS meet diagnostic criteria for one or more psychiatric disorder (Green, 
Gothelf et al. 2009, Antshel, Shprintzen et al. 2010, Fung, McEvilly et al. 2010). There are many 
studies reporting prevalence of psychiatric disorder in 22q11.2DS, though one study I will refer back 
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to is an international, multi-site study of psychiatric morbidity by members of the International 
22q11.2DS Brain and Behaviour Consortium (IBBC) that describes prevalence in 22q11.2DS stratified 
by age. 1402 individuals are included in this cross-sectional study which is the largest of its kind 
(Schneider, Debbané et al. 2014). I will refer back to this as the IBBC study.  
1.2.1 Schizophrenia 
Schizophrenia is characterised by delusions, hallucinations, negative symptoms (i.e. diminished 
emotional expression or avolition), and disorganized speech and behaviour. Level of functioning in 
work, interpersonal relations, or self-care is impaired relative to before onset (American Psychiatric 
Association 2013). Psychosis is not exclusive to schizophrenia and occurs in various diagnostic 
categories of psychotic disorder (see (van Os and Kapur 2009) for a review). 
22q11.2DS is one of the strongest known genetic risk factors for schizophrenia (Jonas, Montojo et al. 
2014).  This association was first established in 1992 when it was reported that some adults with the 
clinical VCFS presentation developed schizophrenia (Shprintzen, Goldberg et al. 1992), the same year 
that the VCFS clinical presentation was associated with 22q11.2 deletion (Driscoll, Spinner et al. 
1992, Scambler, Kelly et al. 1992). There are several lines of evidence that support this initial finding. 
1. Bidirectional association between 22q11.2DS and schizophrenia  
There is a bidirectional association in that 22q11.2DS frequency is elevated in schizophrenia and 
schizophrenia prevalence is elevated in 22q11.2DS. Large cohorts of idiopathic schizophrenia 
patients and population controls have been screened for CNVs and it has been reported that 
22q11.2DS is enriched in schizophrenia cases occurring in 0.2-0.3% of cases compared to 0.0% in 
controls (Stefansson, Rujescu et al. 2008, Levinson, Duan et al. 2011, Malhotra and Sebat 2012, 
Rees, Walters et al. 2014). Furthermore, clinical studies of 22q11.2DS consistently replicate high 
rates of schizophrenia (Pulver, Nestadt et al. 1994, Murphy, Jones et al. 1999, Bassett, Chow et 
al. 2005, Gothelf, Eliez et al. 2005, Ikeda, Williams et al. 2010, Monks, Niarchou et al. 2014, 
Schneider, Debbané et al. 2014).   
2. Schizophrenia in 22q11.2DS does not differ from idiopathic schizophrenia 
A valid concern is that schizophrenia is somewhat different in 22q11.2DS and that the clinical 
presentation could represent a genetic subtype or be attributed to other features of the 
syndrome. However clinical studies of 22q11.2DS do not report this. Individuals appear to have a 
typical form of schizophrenia as indicated by their level of functioning, need for psychiatric 
hospitalizations and antipsychotic treatment (Bassett, Hodgkinson et al. 1998). Furthermore, 
4 
 
22q11.2DS individuals do not differ from idiopathic schizophrenia patients in terms of manifest 
symptom clusters or symptom severity (Bassett, Chow et al. 2003, Monks, Niarchou et al. 2014).  
3. 22q11.2DS increases risk of phenomena across the psychotic continuum 
Psychotic phenomenology in clinical samples exists on a continuum, varying in terms of 
conviction, pre-occupation and implausibility (Strauss 1969, Van Os, Hanssen et al. 2000). 
Psychosis can be present at the level of disorder, schizophrenia and other defined psychotic 
disorders, but also at subclinical levels, referred to as psychotic experiences, psychosis 
proneness, schizotypy or at high risk states (Meehl 1962, Crow 1998, van Os, Linscott et al. 
2009). Prevalence of all these phenomena is greatly elevated in 22q11.2DS. Approximately 20-
30% of adults with 22q11.2DS develop schizophrenia, 30-40% when broadened to any psychotic 
disorder (Murphy, Jones et al. 1999, Monks, Niarchou et al. 2014, Schneider, Debbané et al. 
2014), whereas lifetime prevalence in the general population is 0.30-0.66% and 2.3-3.5% 
respectively (Perälä, Suvisaari et al. 2007, McGrath, Saha et al. 2008, van Os and Kapur 2009). 
22q11.2DS adults without schizophrenia have higher schizotypy scores than population controls 
(Monks, Niarchou et al. 2014). Psychotic symptomatology is greater in 22q11.2DS adults when 
compared to adults with general developmental disability (Gothelf, Eliez et al. 2005). 
Adolescents and young adults with 22q11.2DS are at elevated risk of developing a prodromal 
psychosis syndrome (Shapiro, Cubells et al. 2011) and half report psychotic-like experiences 
(Baker and Skuse 2005) whereas the population prevalence of such experiences is 5% (van Os, 
Linscott et al. 2009).  
4. Biological plausibility 
Within the 22q11.2 deletion there are many genes implicated in brain functioning. Of particular 
interest is COMT (catechol-O-methyltransferase) which encodes a postsynaptic enzyme that 
modulates prefrontal cortical dopamine clearance (Yavich, Forsberg et al. 2007). Common 
variation of this gene modulates activity of the enzyme and thus dopamine clearance. The 
COMT-val allele (codon 18) has been associated with higher COMT enzyme activity in 
dorsolateral prefrontal cortex (Chen, Lipska et al. 2004). In 22q11.2DS hemizygosity of this gene 
may lead to dopamine dysregulation which is well documented to contribute to the aetiology of 
schizophrenia (Howes and Kapur 2009). Hemizygosity may also mean genetic variation in COMT 
genotype on the intact chromosome has more of an effect on phenotypic expression (Jonas, 
Montojo et al. 2014). 
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PRODH (Proline dehydrogenase 1) encodes an enzyme that converts proline to glutamate, the 
dysfunction of which has been linked to schizophrenia development (Jacquet, Raux et al. 2002). 
Common variation of this gene has been associated with schizophrenia (Li, Ma et al. 2004, 
Sullivan, Lin et al. 2008) and brain structural differences (Kempf, Nicodemus et al. 2008), 
specifically, the schizophrenia-risk allele has been associated with decreased striatal volume and 
increased striatal-frontal functional connectivity. 
PIK4CA (phosphatidyl-inositol-4-kinase-catalytic-α) encodes a catalytic enzyme in the 
phosophatidylinositol pathway which is involved in synaptic transmission and signal transduction 
(Jungerius, Hoogendoorn et al. 2008) and has been identified as potential schizophrenia 
susceptibility gene (Saito, Stopkova et al. 2003). 
Although these are plausible causal genes for schizophrenia risk in 22q11.2DS (Prasad, Howley et 
al. 2008), in reality findings are inconsistent regarding the role of COMT (Murphy, Jones et al. 
1999, Gothelf, Eliez et al. 2005) and PIK4CA (Vorstman, Chow et al. 2009, Ikeda, Williams et al. 
2010), and negative regarding the role of PRODH (Gothelf, Eliez et al. 2005) in 22q11.2DS 
psychosis development. 
5. 22q11.2DS is enriched in child-onset schizophrenia cohorts 
Child-onset schizophrenia is defined as onset before the age of 12 and is associated with greater 
disease severity (Gordon, Frazier et al. 1994). It is rare, with an estimated prevalence of 1 in 
30000 births (Jacobsen and Rapoport 1998). Early studies report cases of 22q11.2DS within 
child-onset schizophrenia cohorts (Yan, Jacobsen et al. 1998, Usiskin, Nicolson et al. 1999). More 
recently it was established that 22q11.2 deletion was the most frequent genetic variant in child-
onset schizophrenia, occurring in 4.0% of cases, a rate that is much higher than the frequency of 
22q11.2DS in adult onset schizophrenia (0.3-1%) (Ahn, Gotay et al. 2014), thus indicating that 
22q11.2DS is associated with an earlier age of onset and greater severity of schizophrenia. 
6. Duplication of the 22q11.2 region is protective of schizophrenia 
As well as deletions, duplication events can occur of the 22q11.2 region (Portnoï 2009). The 
phenotype of 22q11.2 Duplication Syndrome is variable and can include physical manifestations 
and neuropsychiatric disorder (Kaminsky, Kaul et al. 2011, Malhotra and Sebat 2012, Van 
Campenhout, Devriendt et al. 2012). There is recent evidence that 22q11.2 duplications are 
protective of schizophrenia as they occur less frequently in schizophrenia cases than in controls 
(0.014% vs 0.085%) (Rees, Kirov et al. 2014). This is the first protective variant to be described 
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for schizophrenia and further demonstrates the strong relationship that copy number variation 
of the 22q11.2 region has with schizophrenia risk. 
Thus, the association between 22q11.2DS and schizophrenia is well established. It also appears to be 
the most specific neuropsychiatric phenotype associated with 22q11.2DS as it is has been suggested  
that it is the only disorder that appears to be found at a much higher rate in comparison to other 
genetic and developmental disorders associated with intellectual disability (Gothelf, Feinstein et al. 
2007, Karayiorgou, Simon et al. 2010). Nonetheless prevalence of other neuropsychiatric disorders in 
22q11.2DS is high. Below I review other aspects of the neuropsychiatric phenotype of 22q11.2DS.  
1.2.2 Intellectual disability, cognitive deficits and adaptive functioning 
Intellectual disability (ID) is a condition with a developmental onset that includes both intellectual 
and adaptive functioning deficits in conceptual, social and practical domains (American Psychiatric 
Association 2013). 
Intellectual and adaptive functioning is highly variable in 22q11.2DS. I will review ID and broader 
cognitive deficits present in 22q11.2DS as well as adaptive functioning and psychoeducational 
deficits. 
1. ID prevalence in 22q11.2DS 
Reported prevalence of mild to moderate ID in 22q11.2DS varies from 30% to 55% (Swillen, 
Devriendt et al. 1997, Bassett, Hodgkinson et al. 1998, Moss, Batshaw et al. 1999, Niklasson, 
Rasmussen et al. 2001, Niklasson, Rasmussen et al. 2002, De Smedt, Devriendt et al. 2007, 
Niklasson, Rasmussen et al. 2009, Butcher, Chow et al. 2012, Niarchou, Zammit et al. 2014). Few 
individuals have moderate to severe ID (Swillen, Devriendt et al. 1997, Bassett, Hodgkinson et al. 
1998, Niklasson, Rasmussen et al. 2009). It is important to note that the majority of studies 
diagnose ID on the basis of IQ score, 55-70 for mild, 40-54 for moderate, and <40 for severe ID. 
However, IQ score alone is not sufficient for DSM-5 criteria. Diagnosis of ID requires clinical 
assessment as well as standardised intelligence testing and adaptive functioning deficits in 
conceptual, social and practical domains must be present (American Psychiatric Association 
2013). DSM-5 advocates defining severity of ID on the basis of adaptive functioning and not IQ 
score as IQ measures are less valid at the lower range. 
2. Frequency of ID in 22q11.2DS 
22q11.2DS has an elevated incidence in combined ID/developmental delay/congenital 
malformation cohorts compared to controls (0.61% vs 0.0%, p=8.4×10-72), which is at a higher 
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incidence and significance level than for 22q11.2DS in schizophrenia (0.30% vs 0.0%, p=1.0×10-30) 
(Malhotra and Sebat 2012). 
3. Neurocognitive deficits 
Average IQ in 22q11.2DS is consistently reported to be approximately 70 (Swillen, Devriendt et 
al. 1997, Moss, Batshaw et al. 1999, Niklasson, Rasmussen et al. 2001, Niklasson, Rasmussen et 
al. 2002, Niklasson, Rasmussen et al. 2009, Butcher, Chow et al. 2012, Schneider, Debbané et al. 
2014). There is great variability in IQ with one study reporting a range of 53 to 109 (Niarchou, 
Zammit et al. 2014). There is a suggestion that verbal IQ is higher than performance IQ (Moss, 
Wang et al. 1995, Swillen, Devriendt et al. 1997, Moss, Batshaw et al. 1999, Woodin, Wang et al. 
2001), though no difference has also been reported (Niarchou, Zammit et al. 2014). Many 
studies report that children with 22q11.2DS decline in IQ with age (Gothelf, Eliez et al. 2005, 
Gothelf, Penniman et al. 2007, Antshel, Shprintzen et al. 2010, Duijff, Klaassen et al. 2012, Duijff, 
Klaassen et al. 2013, Gothelf, Schneider et al. 2013, Schneider, Schaer et al. 2014, Vorstman, 
Breetvelt et al. 2015), though not all studies (Schaer, Debbané et al. 2009, Hooper, Curtiss et al. 
2013) and the magnitude of decline reported is highly variable (discussed in greater depth in 
Chapter 5). 
22q11.2DS individuals are impaired across numerous neurocognitive domains including 
executive function, attention, working memory, verbal and nonverbal memory, visuospatial 
processing, visuomotor functioning, processing speed and social cognition (Woodin, Wang et al. 
2001, Henry, Van Amelsvoort et al. 2002, Sobin, Kiley-Brabeck et al. 2004, Bish, Chiodo et al. 
2007, Majerus, Van der Linden et al. 2007, Rockers, Ousley et al. 2009, Campbell, Azuma et al. 
2010, Cabaral, Beaton et al. 2012, Gur, Yi et al. 2014, Niarchou, Zammit et al. 2014). There is 
evidence that impairments across neurocognitive domains are not strongly inter-correlated in 
22q11.2DS and are relatively independent of intellectual ability (Niarchou, Zammit et al. 2014), a 
finding which is consistent to that reported in children with idiopathic neuropsychiatric disorder 
(Rommelse, Altink et al. 2008). 
One study has compared ability in 22q11.2DS individuals across a wide range of domains in 
contrast to individuals with developmental delay and to typically developing controls. This 
comparison allowed deficits specific to 22q11.2DS to be distinguished from the nonspecific 
effects of developmental delay in 22q11.2DS. They found that deficits in face memory, social 
cognition and complex cognition (reasoning tasks) were specific to 22q11.2DS (Gur, Yi et al. 
2014).  
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4. Psychoeducational ability 
Children with 22q11.2DS have deficits in academic achievement that persist into adolescence 
(Hooper, Curtiss et al. 2013). Their academic profile has been suggested to be consistent with 
the diagnosis of non-verbal learning disability as non-verbal deficits are greater than verbal 
deficits (Moss, Batshaw et al. 1999, Swillen, Vandeputte et al. 1999). In particular children 
exhibit difficulties in mathematics but relative strengths in reading and spelling (Moss, Batshaw 
et al. 1999, De Smedt, Swillen et al. 2009). Nonetheless there is great variability in academic 
achievement and some individuals go on to complete Bachelor’s and Master’s degrees 
(McDonald‐McGinn and Zackai 2008). 
5. Adaptive functioning 
The IBBC study finds that 22q11.2DS individuals are approximately two standard deviations 
below the general population on adaptive functioning measures (Schneider, Debbané et al. 
2014). Intellectual functioning is a predictor of adaptive functioning in adulthood but not in 
childhood (Butcher, Chow et al. 2012), instead anxiety has been highlighted as important for 
functioning in childhood (Angkustsiri, Leckliter et al. 2012). However intellectual functioning only 
appears to explain a small proportion of the variance in adaptive functioning (Schneider, 
Debbané et al. 2014).  
6. Real-life deficits 
22q11.2DS adults experience many real-life deficits. A low proportion of individuals are 
financially independent, develop long term romantic relationships or live away from family. 
These difficulties appear independent of diagnosis as they are present in 22q11.2DS individuals 
without ID and schizophrenia. Relative strengths are found in activities of daily living and 
employment, with 35% to 65% (Mcdonald-Mcginn, Tonnesen et al. 2001, Butcher, Chow et al. 
2012) of adults in employment. Types of jobs reported are diverse, however few individuals are 
financially independent suggesting work is low wage, part-time, or temporary. A proportion of 
adults show adaptive functioning higher than expected for their level of intellectual functioning 
suggesting that for some individuals effective management of their condition and appropriate 
social and vocational support may promote improved functioning (Butcher, Chow et al. 2012).  
1.2.3 Autism spectrum disorder 
Autism spectrum disorder (ASD) is characterised by persistent deficits in social communication and 
social interaction and by restricted, repetitive patterns of behaviour (American Psychiatric 
Association 2013). 
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Children with 22q11.2DS exhibit many difficulties in social behaviour and language development 
(Golding-Kushner, Weller et al. 1984, Swillen, Devriendt et al. 1997, Heineman-de Boer, Van Haelst 
et al. 1998, Woodin, Wang et al. 2001, Niklasson, Rasmussen et al. 2002, Baker and Skuse 2005, 
Kiley-Brabeck and Sobin 2006, Shashi, Veerapandiyan et al. 2012), though there is uncertainty to 
what extent this is autism spectrum disorder (Eliez 2007).  
1. ASD prevalence in 22q11.2DS  
Reports of prevalence vary considerably from 10%-50% (Fine, Weissman et al. 2005, Vorstman, 
Morcus et al. 2006, Antshel, Aneja et al. 2007, De Smedt, Devriendt et al. 2007, Niklasson, 
Rasmussen et al. 2009, Niklasson and Gillberg 2010, Schneider, Debbané et al. 2014) though all 
greater than population prevalence of 1% (Baird, Simonoff et al. 2006, Kogan, Blumberg et al. 
2009). Inconsistency in prevalence is likely due to the range of assessment tools and 
ascertainment methods employed by studies. A recent study found prevalence drops to 0% 
when both measures of clinical history and direct observation are utilised (Angkustsiri, Goodlin-
Jones et al. 2014), though their sample may not be representative as prevalence on the basis of 
just clinical history was lower than other studies (Vorstman, Breetvelt et al. 2013, Niarchou, 
Zammit et al. 2014). The IBBC study of 22q11.2DS unexpectedly found ASD prevalence to peak in 
adolescence. This could reflect that autism measures often index severity of other 
neuropsychiatric disorders (Angkustsiri, Goodlin-Jones et al. 2014, Cooper, Martin et al. 2014, 
Schneider, Debbané et al. 2014). 
2. Frequency of 22q11.2DS in ASD 
It has been claimed that 22q11.2DS is not enriched in ASD cases (Karayiorgou, Simon et al. 2010, 
Hiroi, Takahashi et al. 2013), however this has been on the basis of older studies with small 
sample sizes. A meta-analysis of several studies reveals that the frequency of 22q11.2DS is 
significantly increased in ASD (0.07% cases vs 0% controls), albeit at a frequency and significance 
level much lower than for other genetic variants in ASD and for 22q11.2DS in schizophrenia (ASD 
vs schizophrenia; frequency 0.07% vs 0.30%, p-value 0.002 vs 1.0×10-30) (Malhotra and Sebat 
2012).  
3. Comparison of ASD in 22q11.2DS and idiopathic ASD 
Only one study has compared ASD features present in children with 22q11.2DS and ASD to those 
present in idiopathic ASD. The two groups did not differ in severity of social interaction deficits 
and restricted, repetitive patterns of behaviour, but the idiopathic ASD group did have greater 
communication deficits. In terms of symptom profile they differed on 2 out of 12 domains with 
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the idiopathic ASD group more likely to have idiosyncratic speech and deficits in socioemotional 
reciprocity (Kates, Antshel et al. 2007).  
4. Lack of gender difference in ASD prevalence 
The well documented male preponderance for ASD (Baron-Cohen 2002) is not observed in 
22q11.2DS. This could be a consequence of the strong pathogenicity conferred by 22q11.2DS or 
that neuropsychiatric disorders which do not exhibit gender differences are misdiagnosed as 
ASD (Vorstman, Morcus et al. 2006, Schneider, Debbané et al. 2014). 
5. Features of 22q11.2DS may be misdiagnosed as autism.  
It has been argued that other features of 22q11.2DS underlie deficits in social behaviour and 
language development.  
i. These deficits may be indicative of prepsychotic phenomena (Vorstman, Morcus et al. 
2006, Eliez 2007) as many studies have found that individuals with idiopathic 
schizophrenia exhibit social and language deficits during childhood (Clegg, Hollis et al. 
2005, Rutter, Kim‐Cohen et al. 2006). Analogous concerns are present in the child-onset 
schizophrenia literature where early development is reminiscent of ASD but may be 
better conceptualised as part of the premorbid phase (Sporn, Addington et al. 2004). In 
contrast there are case studies of individuals with ASD being misdiagnosed with 
psychosis (Van Schalkwyk, Peluso et al. 2014). It is important to emphasise that social 
deficits are not synonymous with ASD and they differentially predict schizophrenia risk 
trajectories in 22q11.2DS. Deterioration in social functioning precedes psychosis onset in 
22q11.2DS (Yuen, Chow et al. 2013) whereas 22q11.2DS individuals with ASD in 
childhood do not show increased risk for psychosis in adulthood (Vorstman, Breetvelt et 
al. 2013).   
 
ii. It has been argued that anxiety in 22q11.2DS contributes to a false elevation of ASD 
prevalence in the syndrome (Angkustsiri, Goodlin-Jones et al. 2014). Although anxiety is 
a common comorbidity in children with idiopathic ASD (Kim, Szatmari et al. 2000), this 
does not necessarily mean that ASD and anxiety diagnoses have to be mutually 
exclusive. Also, unlike anxiety disorders, ASD diagnosis requires symptoms to be present 
during the early developmental period (American Psychiatric Association 2013). 
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iii. Misdiagnosis has been attributed to physical speech difficulties which are common in 
22q11.2DS due to cleft palate and velopharyngeal dysfunction (Eliez 2007). However, 
communication deficits do not show diagnostic specificity in distinguishing 22q11.2DS 
children with and without autism, rather it is the ability for make-believe play that is 
crucial (Kates, Antshel et al. 2007).  
Overall there is some evidence for a bidirectional association of 22q11.2DS and ASD, albeit not as 
strong as the association with schizophrenia. However, the clinical presentation of ASD is potentially 
less severe than that in idiopathic ASD. To some the question whether social and communication 
deficits present in 22q11.2DS constitutes ASD may seem arbitrary and an issue of classification. 
There are those who propose the complexities of the 22q11.2DS phenotype would be better 
conceptualised using dimensional measures rather than diagnostic categories (Baker and Vorstman 
2012, Doherty and Owen 2014). However diagnostic categories are currently clinical psychiatry’s 
means for informing treatment. Future work is needed to fully clarify the clinical presentation of ASD 
in 22q11.2DS to better inform treatment recommendations and care delivery (Angkustsiri, Goodlin-
Jones et al. 2014). 
1.2.4 Attention-deficit/hyperactivity disorder 
Attention-Deficit/Hyperactivity Disorder (ADHD) is a persistent pattern of inattention and/or 
hyperactivity-impulsivity that interferes with functioning or development (American Psychiatric 
Association 2013). 
1. ADHD prevalence in 22q11.2DS 
Reported prevalence in 22q11.2DS ranges from 12% to 68% (Arnold, Siegel-Bartelt et al. 2001, 
Feinstein, Eliez et al. 2002, Gothelf, Gruber et al. 2003, Antshel, AbdulSabur et al. 2005, Baker 
and Skuse 2005, Sobin, Kiley-Brabeck et al. 2005, Zagursky, Weller et al. 2006, De Smedt, 
Devriendt et al. 2007, Lewandowski, Shashi et al. 2007, Green, Gothelf et al. 2009, Jolin, Weller 
et al. 2009, Niklasson, Rasmussen et al. 2009, Sobin, Kiley-Brabeck et al. 2009, Antshel, 
Shprintzen et al. 2010, Stoddard, Niendam et al. 2010, Niarchou, Zammit et al. 2014) which is 
elevated in comparison to the general population prevalence of 5% (Polanczyk, de Lima et al. 
2007). Lower estimates from this range are similar to ADHD prevalence reported in children with 
intellectual disability (Dekker and Koot 2003). 
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2.  ADHD persistence across the lifespan  
The IBBC study examined ADHD prevalence across the lifespan and found a rate of 37% in 
childhood, 24% in adolescence and 16% in adulthood (Schneider, Debbané et al. 2014). The 65% 
persistence rate from childhood to adolescence is consistent with longitudinal findings in 
22q11.2DS (Antshel, Hendricks et al. 2013). This longitudinal course appears typical of that 
observed in idiopathic ADHD (70%) (Langley, Fowler et al. 2010) and persistence in both groups 
is predicted by the same factors (Antshel, Hendricks et al. 2013). 
3. ADHD in 22q11.2DS in comparison to idiopathic ADHD 
Children with 22q11.2DS and ADHD appear to have a different profile of ADHD symptoms and 
comorbidity in comparison to children with idiopathic ADHD (Antshel, Faraone et al. 2007). The 
inattentive subtype is more common in children with 22q11.2DS and they are less likely to 
display symptoms of hyperactivity and impulsivity (Schneider, Debbané et al. 2014). In particular 
symptoms relating to academic inattention are highly reported in 22q11.2DS. Academic 
struggles are a prominent feature of 22q11.2DS (Moss, Batshaw et al. 1999) and this could be 
partly caused by inattention, but alternatively in some cases ADHD diagnosis could simply index 
academic difficulties. Children with idiopathic ADHD have higher rates of comorbid major 
depression and disruptive behaviour disorders in comparison to children with ADHD and 
22q11.2DS. There is also a suggestion that ADHD diagnosis captures features of 22q11.2DS that 
emerge during adolescence. A longitudinal study of 22q11.2DS found that 5 individuals gained 
the diagnosis of ADHD during adolescence, though all exhibited subthreshold symptoms at time 
1 (Antshel, Hendricks et al. 2013).  
4. Frequency of 22q11.2DS in ADHD 
22q11.2DS is reported in ADHD cases, but at rates that are not significantly higher than in 
controls (Williams, Franke et al. 2012). However there could be ascertainment bias as the 
differing ADHD profile in 22q11.2DS may mean individuals are less likely to be included in 
genome-wide CNV studies. 
5. Sex difference in ADHD prevalence 
Unlike in ASD, ADHD in 22q11.2DS shows a male preponderance (Schneider, Debbané et al. 
2014), as also observed in the general population (Merikangas, He et al. 2010). 
Overall the symptom profile in 22q11.2DS differs from that in idiopathic ADHD but the level of 
persistence into adolescence is consistent with idiopathic ADHD. 
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1.2.5 Disruptive disorders 
Oppositional Defiance Disorder (ODD) is the persistent pattern of angry/irritable mood, defiant 
behaviour, or vindictiveness.  
Conduct Disorder (CD) is the persistent pattern of behaviour in which the rights of others and societal 
norms or rules are violated (American Psychiatric Association 2013). 
1. ODD 
Reported ODD prevalence in 22q11.2DS varies from 5% to 43% (Papolos, Faedda et al. 1996, 
Arnold, Siegel-Bartelt et al. 2001, Feinstein, Eliez et al. 2002, Antshel, Fremont et al. 2006, 
Vorstman, Morcus et al. 2006, Green, Gothelf et al. 2009, Jolin, Weller et al. 2009, Sobin, Kiley-
Brabeck et al. 2009, Antshel, Shprintzen et al. 2010, Romanos, Ehlis et al. 2010, Stoddard, 
Niendam et al. 2010, Niarchou, Zammit et al. 2014). The IBBC study found childhood prevalence 
to be slightly higher than in the general population (14% (Schneider, Debbané et al. 2014) vs 8% 
(Kessler, Avenevoli et al. 2012)) but similar in comparison to children with intellectual disability 
(14% (Dekker and Koot 2003)). ODD in 22q11.2DS may not be similar to idiopathic ODD; it has 
been suggested that impairment is only present within the family context, whereas outside the 
family children are introverted (Schneider, Debbané et al. 2014). The frequency of 22q11.2DS in 
ODD and CD patients is unknown. 
2. No evidence for transition of ODD to CD 
A large proportion of individuals with idiopathic ODD develop CD (Rowe, Costello et al. 2010, 
American Psychiatric Association 2013), yet CD is rarely diagnosed in 22q11.2DS. The IBBC study 
identified no child onset CD cases and a rate of 1.5% in adults (Schneider, Debbané et al. 2014). 
Smaller clinical samples report no cases (Arnold, Siegel-Bartelt et al. 2001, Baker and Skuse 2005, 
Antshel, Fremont et al. 2006, Green, Gothelf et al. 2009, Sobin, Kiley-Brabeck et al. 2009, 
Antshel, Shprintzen et al. 2010) except in one study where 4 out of 13 individuals met criteria for 
CD (Romanos, Ehlis et al. 2010). These findings suggest the developmental course of ODD in 
22q11.2DS differs from idiopathic ODD. 
3. Sex difference in disruptive disorders 
There is a male preponderance for disruptive disorders in 22q11.2DS (Schneider, Debbané et al. 
2014), consistent with findings in the general population (Maughan, Rowe et al. 2004). 
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1.2.6 Anxiety disorders 
Anxiety disorders involve excessive fear and the anticipation of future threat and cause behavioural 
disturbance. Fear or anxiety has to be excessive or persisting beyond developmentally appropriate 
periods (American Psychiatric Association 2013). 
1. Anxiety disorder prevalence in 22q11.2DS 
Reported prevalence varies from 5% to 60% (Arnold, Siegel-Bartelt et al. 2001, Baker and Skuse 
2005, Lewandowski, Shashi et al. 2007, Green, Gothelf et al. 2009, Jolin, Weller et al. 2009, 
Sobin, Kiley-Brabeck et al. 2009, Antshel, Shprintzen et al. 2010, Stoddard, Niendam et al. 2010, 
Niarchou, Zammit et al. 2014). The IBBC study found anxiety disorders are particularly prevalent 
during childhood (36%) and adolescence (34%) and they persist into adulthood (25%) (Schneider, 
Debbané et al. 2014). The frequency of 22q11.2DS in anxiety disorder patients is unknown. 
2. Individual anxiety disorders 
Disorders reported include separation anxiety disorder, specific phobia, social phobia, panic 
disorder, post-traumatic stress disorder, obsessive-compulsive disorder and generalized anxiety 
disorder. Many individuals meet criteria for multiple anxiety disorders. Most frequent in 
childhood and adolescence are generalized anxiety disorder, specific phobia and social phobia. 
In adulthood generalized anxiety disorder and panic disorder are the most frequent. Only social 
phobia and generalized anxiety disorder are overrepresented in 22q11.2DS relative to 
individuals with intellectual disability (Schneider, Debbané et al. 2014). This along with the high 
prevalence of ASD indicates that social difficulties are a core deficit in 22q11.2DS that transcends 
diagnostic boundaries (Baker and Vorstman 2012).  
3. Impairment of Anxiety Disorders in 22q11.2DS 
In 22q11.2DS, anxiety disorders have the greatest negative effect on daily living skills when 
compared to mood disorders and schizophrenia spectrum disorders (Schneider, Debbané et al. 
2014).  
1.2.7 Mood disorders 
The presence of sad, empty, or irritable mood which is accompanied by somatic and cognitive 
changes that significantly affects the individual’s capacity to function (American Psychiatric 
Association 2013). 
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1. Mood disorder prevalence in 22q11.2DS 
The reported rate of mood disorder in 22q11.2DS varies from 3% to 64% (Arnold, Siegel-Bartelt 
et al. 2001, Niklasson, Rasmussen et al. 2002, Baker and Skuse 2005, Vorstman, Morcus et al. 
2006, Lewandowski, Shashi et al. 2007, Green, Gothelf et al. 2009, Niklasson, Rasmussen et al. 
2009, Sobin, Kiley-Brabeck et al. 2009, Antshel, Shprintzen et al. 2010, Stoddard, Niendam et al. 
2010). The IBBC study finds mood disorders emerge during late adolescence and reach a 
prevalence of 20% in adulthood with major depressive disorder accounting for the majority of 
cases whereas bipolar disorder and dysthymia occur infrequently (Schneider, Debbané et al. 
2014). In contrast early studies of 22q11.2DS report high rates of bipolar disorder (Papolos, 
Faedda et al. 1996, Gothelf, Frisch et al. 1999), albeit in small cohorts. This may reflect 
ascertainment or diagnosis issues of early studies. Alternatively it may reflect that individuals 
with 22q11.2DS experience periods of mood liability without meeting criteria for manic or 
hypomanic episodes (Schneider, Debbané et al. 2014). The extent to which 22q11.2DS directly 
contributes to mood disorders is uncertain as rates of mood disorders are known to be elevated 
in individuals with somatic disorders (Kroenke and Rosmalen 2006). 
2. Frequency of 22q11.2DS in mood disorder 
22q11.2DS has an elevated incidence in mood disorder patients compared to controls (0.05% vs 
0.00%, p=8.0×10-5), though at a lower incidence and significance level than for 22q11.2DS in 
schizophrenia (0.30% vs 0.00%, p=1.0×10-30) (Malhotra and Sebat 2012). 
1.2.8 Substance-related disorders 
A problematic pattern of alcohol or drug use leading to clinically significant impairment or distress 
(American Psychiatric Association 2013). 
Prevalence of substance related disorders is low, with the majority of studies reporting 0%-7% 
(Gothelf, Penniman et al. 2007, Antshel, Shprintzen et al. 2010, Stoddard, Niendam et al. 2010, 
Schneider, Debbané et al. 2014). An exception is an early small study that reported 3 out of 14 adults 
had alcohol abuse or dependence (Pulver, Nestadt et al. 1994).  Of individuals who do report 
substance misuse the majority abused alcohol, whereas drug use disorders are rare. 
1.2.9 Comorbidity 
High rates of comorbidity are observed in individuals with 22q11.2DS. In children there is substantial 
comorbidity between ADHD, anxiety disorder, ASD and ODD (Niarchou, Zammit et al. 2014). In 
adults overlap is reported between anxiety, mood and psychotic disorders (Schneider, Debbané et 
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al. 2014). However there is evidence that not all features overlap as schizophrenia and ASD in 
22q11.2DS appear to be distinct phenotypic manifestations (Vorstman, Breetvelt et al. 2013). Also 
22q11.2DS has independent effects on intellectual impairment and psychopathology, in that IQ does 
not mediate risk for psychopathology (Niarchou, Zammit et al. 2014).  
1.3 Summary 
22q11.2DS is associated with a wide range of physical abnormalities and neuropsychiatric problems. 
There is elevated prevalence of schizophrenia, ID, cognitive deficits, ASD, ADHD, ODD, anxiety and 
mood disorders. Some disorders such as CD and substance-related disorder, however, have a low 
prevalence in 22q11.2DS. There is evidence for a strong bidirectional association between 
22q11.2DS and schizophrenia, ID and mood disorder but less so for other psychiatric features of 
22q11.2DS. The nature of schizophrenia in 22q11.2DS is similar to clinical presentation in the general 
population, but there is uncertainty whether this is true for other features of the neuropsychiatric 
phenotype such as ASD, ADHD and ODD. The neuropsychiatric phenotype of 22q11.2DS is complex. 
However, there are apparent themes which transcend diagnostic categories and cognitive domains 
such as social impairments, attention difficulties and affective dysregulation. This chapter has 
described the features of 22q11.2DS in depth, next I will discuss the insights that researching 
neuropsychiatric development in 22q11.2DS can provide.  
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2. Introduction: Insights that can be gained from examining 
neuropsychiatric development in 22q11.2DS 
2.1 Understanding schizophrenia risk trajectories 
2.1.1 22q11.2DS as a high risk condition for schizophrenia 
It has been discussed in Chapter 1 that 22q11.2DS is a high risk condition for schizophrenia. 30-40% 
of adults develop psychotic disorder and 20-30% of adults are diagnosed with schizophrenia 
(Murphy, Jones et al. 1999, Monks, Niarchou et al. 2014, Schneider, Debbané et al. 2014). Thus, 
following child patients over time provides a rare opportunity for prospective examination of the 
development of schizophrenia.  
Studies based on retrospective accounts by patients with idiopathic schizophrenia often lack 
relevant standardized records. Population cohort studies on the other hand may have low power, 
because only a very small proportion of participants will transition to schizophrenia, while 
furthermore at risk individuals may also be more likely to drop out of the study. High risk studies 
represent an effective methodology, particularly if a high proportion of young people will develop 
psychotic disorder. 
The transition rate to psychosis in 22q11.2DS is much higher than that observed in the Edinburgh 
High Risk Study (clinical risk of 12% (McIntosh, Owens et al. 2011)) and the New York High-Risk 
Project (familial risk of 23.8% (Erlenmeyer-Kimling, Adamo et al. 1997)). Only one genetic condition 
has been reported to confer even higher risk of psychosis of 60-100%, the maternal uniparental 
disomy (mUPD) genetic subtype of Prader-Willi syndrome (PWS), where individuals inherit two 
maternal copies of chromosome 15 (Larson, Whittington et al. 2014). 22q11.2DS individuals are 
generally diagnosed early in development and are not ascertained on the basis of psychotic 
phenomenology. 22q11.2DS offers a unique window into psychosis development without bias 
introduced by use of antipsychotic medication (as is the case in clinical high risk studies) and 
provides a means to explore the neurodevelopmental hypothesis of schizophrenia. 
However, it should be highlighted that it is difficult to achieve large cohorts of 22q11.2DS individuals 
because of the rarity of the syndrome.  Also, the range of difficulties experienced by children with 
22q11.2DS can complicate longitudinal follow-up.  
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2.1.2 Neurodevelopmental hypothesis of schizophrenia 
First formulated by Weinberger (Weinberger 1986), and Murray and Lewis (Murray and Lewis 1987) 
the ‘neurodevelopmental hypothesis of schizophrenia', posits that, although schizophrenia generally 
manifests in adulthood, diagnosis is the endpoint of an extended period of perturbed developmental 
processes (Seidman 1990, Owen, O'Donovan et al. 2011, Rapoport, Giedd et al. 2012). Below I 
summarise the main sources of evidence for this hypothesis.  
1. Longitudinal epidemiology  
Retrospective and population cohort studies find significant neurodevelopmental deviance pre-
existing to the diagnosis of idiopathic schizophrenia. Individuals who develop schizophrenia 
exhibit childhood deficits in cognition, language, social skills and motor development (Clegg, 
Hollis et al. 2005, Rutter, Kim‐Cohen et al. 2006, Woodberry, Giuliano et al. 2008, Dickson, 
Laurens et al. 2012). One study finds impairments are evident from as early as age one (Isohanni, 
Murray et al. 2004). The pattern of premorbid cognitive deficits is specific to schizophrenia 
rather than being non-specific to adult psychiatric disorder (Reichenberg, Caspi et al. 2010). Also 
subclinical psychotic experiences can be present in childhood and have a prevalence of 5% (van 
Os, Linscott et al. 2009) and are predictive of later psychotic disorder (Chapman, Chapman et al. 
1994, Poulton, Caspi et al. 2000, Hanssen, Bak et al. 2005, Zammit, Kounali et al. 2013). 
2. Prenatal risk 
Prenatal infection, famine and obstetric complications have been highlighted as risk factors for 
schizophrenia (Brown and Derkits 2010, Rapoport, Giedd et al. 2012). Toxoplasma gondii is a 
specific infection which has been consistently associated (Mortensen, Nørgaard-Pedersen et al. 
2007, Pedersen, Stevens et al. 2011) and the immune system has been further implicated with a 
recent finding that many genes associated with schizophrenia are involved in immune pathways 
(O'Dushlaine, Rossin et al. 2015). Retrospective studies of the Dutch Hunger Winter and Chinese 
Cultural Revolution find in utero exposure to famine increases risk for later schizophrenia 
development (Susser and Lin 1992, St Clair, Xu et al. 2005, Xu, Sun et al. 2009). Although there is 
an association between obstetrical complications and schizophrenia (Rapoport, Addington et al. 
2005), the link may not be causal, rather obstetrical events may be markers of abnormal foetal 
development (Rapoport, Giedd et al. 2012). Overall it is evident that processes related to 
schizophrenia risk manifest very early on in development. 
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3. Adverse postnatal early environment 
Minority group position is associated with psychotic phenomena with effects being mediated by 
social adversity (Bourque, Van der Ven et al. 2011). Migration into a country where the 
individual becomes part of the minority particularly impacts on psychosis risk when the 
individual is between ages 0-4, again highlighting that early development is crucial in the 
aetiology of schizophrenia (Veling, Hoek et al. 2011). Childhood trauma has been linked to 
psychosis, however the small sample size of studies and methodological issues means the causal 
nature of this relationship remains uncertain (Morgan and Fisher 2007). 
4. Structural brain differences 
The developmental origin of structural brain abnormalities in schizophrenia patients has been 
inferred from the observation that post-mortem brain studies find an absence of evidence for 
neurodegeneration (Owen, O'Donovan et al. 2011). There is also direct evidence from imaging 
studies of individuals identified as clinically ultra-high-risk with reports that those who develop 
psychosis have reductions in white matter volume in the left fronto-occipital fasciculus 
(Walterfang, McGuire et al. 2008) and white matter abnormalities in the medial frontal cortex 
(Bloemen, De Koning et al. 2010). 
2.1.3 Evidence from 22q11.2DS 
The phenotype of 22q11.2DS supports ‘the neurodevelopmental hypothesis of schizophrenia’ as in 
addition to schizophrenia 22q11.2DS is associated with a wide range of early onset 
neurodevelopmental problems (as discussed in Chapter 1). The hypothesis can be explored further 
as studies of 22q11.2DS provide a rare opportunity to uncover the childhood antecedents of 
schizophrenia.  
2.1.4 Antecedents of psychotic disorder in 22q11.2DS 
There are few 22q11.2DS studies which are able to test for associations between early behaviour 
and later psychotic disorder. The majority of longitudinal studies following child cohorts over time 
are yet to reach the adulthood phase. However, studies have highlighted potential risk factors. 
1. Cognitive development 
Decline in intelligence particularly in the verbal domain has been implicated. Emergence of 
psychotic disorder has been reported to be predicted by baseline IQ (Gothelf, Feinstein et al. 
2007) as well as decline in Verbal IQ (VIQ) (Gothelf, Penniman et al. 2007, Gothelf, Schneider et 
al. 2013). A recent longitudinal study of 411 22q11.2DS individuals, the largest to date, 
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replicated these findings. They also reported that the VIQ trajectories of the group who 
subsequently developed psychotic disorder began to differ from age 11 (Vorstman, Breetvelt et 
al. 2015). It should be noted that such a large sample size was achieved from combining 
22q11.2DS cohorts from different countries. Assessment protocols differed across sites and 
psychotic disorder was not necessarily assessed concurrently with cognition so the question 
whether decline precedes onset or is due to onset of psychotic disorder remains open.  
2. Anxiety and Mood 
Two longitudinal studies report that diagnosis of an anxiety disorder predicts later emergence of 
psychotic disorder (Gothelf, Feinstein et al. 2007, Gothelf, Schneider et al. 2013). Anxiety is also 
predictive when it is measured dimensionally (Gothelf, Feinstein et al. 2007, Schonherz, Davidov 
et al. 2014). Findings are inconsistent with regards to the predictive nature of mood (Gothelf, 
Feinstein et al. 2007, Gothelf, Schneider et al. 2013, Schonherz, Davidov et al. 2014).  
3. Prepsychotic phenomena 
Subthreshold psychotic symptoms in 22q11.2DS are found to be predictive of later psychotic 
disorder (Gothelf, Feinstein et al. 2007). A retrospective study of 22q11.2DS adults with and 
without schizophrenia examined premorbid adjustment and reported deterioration in social and 
academic skills from childhood to adolescence in those who later developed schizophrenia 
(Yuen, Chow et al. 2013). 
4. No evidence for differences in brain morphology 
Two studies report no brain morphology differences in those who subsequently developed 
psychotic disorder, however sample sizes were small (psychotic disorder n/total n; 7/19, 9/28) 
(Gothelf, Feinstein et al. 2007, Gothelf, Penniman et al. 2007).  
2.1.5 Antecedents of psychotic symptoms in 22q11.2DS 
Studies have also assessed the factors preceding emergence of psychotic and prodromal symptoms, 
rather than frank psychotic disorder, in 22q11.2DS.  
1.  Cognitive development 
VIQ decline has been implicated in emergence of psychotic symptoms (Gothelf, Eliez et al. 2005, 
Kates, Antshel et al. 2011) but not by all studies (Antshel, Shprintzen et al. 2010, Hooper, Curtiss 
et al. 2013). Baseline IQ is also reported to be a risk factor (Hooper, Curtiss et al. 2013, 
Schneider, Schaer et al. 2014). Many other neurocognitive domains have been investigated and 
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there is strong evidence for a link with worse baseline cognitive performance across several 
domains (Antshel, Shprintzen et al. 2010, Hooper, Curtiss et al. 2013, Kates, Russo et al. 2014, 
Schneider, Schaer et al. 2014). Change in these non-IQ neurocognitive domains has not been 
implicated (Schneider, Schaer et al. 2014), however studies have not always examined change in 
relation to psychotic symptoms (Antshel, Shprintzen et al. 2010, Hooper, Curtiss et al. 2013).  
2. Psychopathology 
Anxiety is a predictor of prodromal symptoms (Antshel, Shprintzen et al. 2010). There is 
evidence that this relationship may be moderated by verbal learning ability, that is good verbal 
learning ability is protective of psychotic symptoms in 22q11.2DS individuals with high anxiety 
(Kates, Russo et al. 2014). Other childhood behaviours, such as externalizing, odd eccentric and 
problem social behaviours have also been implicated (Hooper, Curtiss et al. 2013).  
3. Family Environment 
Family dis-organization has been found to amplify the relationship between childhood mood 
dysregulation and later emergence of prodromal symptoms (Kates, Russo et al. 2014), however 
it remains unclear to what extent family background factors antecede occurrence of children’s 
mental health problems.   
4. Brain morphology 
Differences in brain morphology have been associated with development of psychotic 
symptoms, but a consistent pattern is not yet emerging. The following differences have been 
reported; reduction in grey matter volume in the left dorsal prefrontal cortex (Gothelf, Hoeft et 
al. 2011), decreased temporal lobe grey matter volume (Kates, Antshel et al. 2011), change in 
cortical gyrification in the left occipital lobe (Kunwar, Ramanathan et al. 2012) and larger 
baseline hippocampal volume (Flahault, Schaer et al. 2012).  One study has claimed to be able to 
predict risk for psychotic symptoms with >94% accuracy using multivariate pattern analysis 
(Gothelf, Hoeft et al. 2011), but sample size was small so this result could be an artefact of 
having too many predictor variables. 
2.1.6 Discussion 
Development in 22q11.2DS provides many clues to the neurodevelopmental processes that precede 
psychosis, particularly highlighting childhood cognitive development, anxiety, subclinical psychotic 
phenomena and brain morphology. However many findings are inconsistent and/or need 
replication. There is an overlap in the risk factors for psychotic disorder and symptoms but there are 
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differences, which is consistent with the idiopathic literature (van Os, Linscott et al. 2009, Zammit, 
Hamshere et al. 2014).  
Examining development in 22q11.2DS could uncover risk factors for psychiatric disorders other than 
schizophrenia. Depression has been examined in one study but no cognitive risk factors were 
identified (Antshel, Shprintzen et al. 2010). There is potential for risk trajectories for ASD and ADHD 
to be investigated, but current 22q11.2DS studies do not capture ages at the extremities of the life 
span.  
2.2 Understand genetic risk for psychiatric disorder 
2.2.1 CNVs confer risk for psychiatric disorder 
22q11.2DS offers the opportunity to explore how genetic risk contributes to psychiatric disorder. As 
mentioned briefly in Chapter 1 22q11.2DS is a CNV. CNVs represent an important source of genetic 
variation, and unlike 22q11.2DS, many can be benign and present in healthy individuals (Kirov, Rees 
et al. 2015). A number of pathogenic CNVs have been identified (Girirajan, Rosenfeld et al. 2012, 
Vissers and Stankiewicz 2012) and there is consensus that multiple CNVs confer risk for 
neuropsychiatric disorder (Cook and Scherer 2008), including 22q11.2DS. I will now discuss what has 
been learnt from psychiatric-risk CNVs in relation to findings with 22q11.2DS. 
1. CNVs are rare but penetrant 
Initial evidence for a genetic contribution to psychiatric illness came from twin studies, which 
consistently indicate that neuropsychiatric disorders are highly heritable (Bailey, Le Couteur et 
al. 1995, Kendler 2001, Faraone, Perlis et al. 2005). Molecular genetic studies suggest that the 
genetic architecture of psychiatric disorder is complex with combined effects of many common 
variants of small effect, as well as rare variants of large effect (Gratten, Wray et al. 2014). In 
schizophrenia research, odd ratios (ORs) ranging from 2 to <50 have been reported for CNVs 
(Kirov, Rees et al. 2015). Large variants such as CNVs may provide a starting point for 
investigation into the biological mechanisms of neuropsychiatric dysfunction (Stefansson, 
Meyer-Lindenberg et al. 2014). As mentioned in Chapter 1, 22q11.2DS is both rare (1 in 4000 live 
births) and penetrant for schizophrenia (20-30% prevalence). 
2. The same CNVs confer risk for multiple neuropsychiatric disorders 
CNVs are not specific risk factors for particular psychiatric disorders. Like 22q11.2DS, many CNVs 
that confer risk for schizophrenia also increase risk for early developmental disorders such as 
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ASD, ADHD and ID. These findings suggest that there may be a general overlap in genetic risk 
amongst early developmental disorder and schizophrenia, a proposition that challenges 
nosological views in psychiatry (Owen, O'Donovan et al. 2011, Kirov, Rees et al. 2015). 
3. CNVs contribute to severe cases of neuropsychiatric disorder 
There is evidence to suggest CNVs are more enriched in extreme populations and have a more 
severe phenotype in contrast to idiopathic psychiatric cases. CNVs are more frequent in child-
onset schizophrenia (Walsh, McClellan et al. 2008, Lee, Mattai et al. 2012), indeed 22q11.2DS 
occurs at a rate of 4.0% in child-onset cases vs 0.3-1.0% of adult cases (Ahn, Gotay et al. 2014). 
Psychosis in the mUPD subtype of Prader-Willi syndrome is severe, showing a cycloid PWS 
specific pattern (Soni, Whittington et al. 2007, Soni, Whittington et al. 2008). In an ADHD cohort 
it was reported that the rate of comorbid ID was elevated in children with CNVs (Langley, Martin 
et al. 2011), although the nature and severity of ADHD in CNV carriers did not differ from 
idiopathic ADHD.  
4. The phenotype of CNVs provides insight into potential models of psychiatric disorder 
Crespi and Badcock propose that autism and psychosis are reciprocal disorders of the social 
brain. They have highlighted physiological, neurological, and psychological evidence as well as 
studies from psychiatric risk CNVs as supporting this hypothesis. They comment that deletions 
and duplications at the same loci confer opposing risk for autism and psychosis (Crespi and 
Badcock 2008, Crespi, Summers et al. 2009). The recent finding described in Chapter 1 (1.2.2) 
that 22q11.2 duplications are protective of schizophrenia in contrast to the deletion supports 
this view (Rees, Kirov et al. 2014). However both ASD and schizophrenia are elevated in 
22q11.2DS which would appear to go against the hypothesis, though Crespi has cited the 
argument discussed in Chapter 1 (1.2.3) that ASD is misdiagnosed in 22q11.2DS and is in fact 
prepsychotic phenomena (Crespi and Crofts 2012). This ongoing debate highlights the 
importance of critically examining the phenotype of CNVs and the implications this has for wider 
aetiological understanding of psychiatric disorder. 
5. CNVs can help identify endophenotypes 
Endophenotypes are intermediary phenotypes which fall on the causal pathway between genes 
and disease (Gottesman and Gould 2003, Walters and Owen 2007). They are useful for studying 
the functional consequences of genetic risk variants and will hopefully provide a window onto 
the biological mechanisms underlying neuropsychiatric disorder. Neuropsychiatric risk CNVs are 
variants of large effect and thus provide an opportunity to uncover endophenotypes. 
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A study conducted using the Icelandic DeCODE genetic population cohort (n=101,655) 
demonstrates the utility of this approach (Stefansson, Meyer-Lindenberg et al. 2014). They 
identified neuropsychiatric risk CNV carriers from their cohort and examined their cognition and 
brain structure. They found that carriers who had not been diagnosed with ASD, ID or 
schizophrenia still exhibited intermediary endophenotypes in cognition and brain structure that 
are consistent with that observed in first-episode psychosis, thus affirming the role of genetic 
risk variants, as well as cognition and brain development in the pathogenesis of schizophrenia. 
However this study could not give much insight into 22q11.2DS as only 18 individuals had 
22q11.2DS of which just 3 agreed to take part in the cognitive assessment and structural brain 
scanning. This illustrates that although large population cohorts can identify 22q11.2DS 
individuals who have not necessarily been identified by medical genetic services and therefore 
reflect the wider range of manifestations associated with the 22q11.2DS phenotype, they are 
unlikely to provide sample sizes as large as current clinically ascertained cohorts. 
2.2.2 Endophenotypes in 22q11.2DS 
Here I discuss some of the endophenotypes identified in 22q11.2DS. Mouse models of 22q11.2DS 
have been particularly useful in identifying endophenotypes. The human 22q11.2 region is syntenic 
with a region of chromosome 16 in mice, therefore allowing recapitulation of human 22q11.2DS 
(Drew, Crabtree et al. 2011). 
1. Cognition 
A study of 22q11.2DS children reported decline in IQ between the ages of 5.5 and 9.5, 
demonstrating that decline is occurring very early on and before the period of schizophrenia risk 
(Duijff, Klaassen et al. 2012). However there was no comparison group to control for 
methodological artefacts (more detail in Chapter 5).  
Sensorimotor gating deficits, as indexed by prepulse inhibition (PPI), is consistently identified as 
an endophenotype of ASD and schizophrenia (Baker, Adler et al. 1987). PPI is reduced both in 
children with 22q11.2DS (Sobin, Kiley-Brabeck et al. 2005) and in mouse models (Paylor, Glaser 
et al. 2006). 
2. Brain Structure  
Human studies report whole brain volumetric reduction in 22q11.2DS (Jonas, Montojo et al. 
2014) which is consistent with findings in schizophrenia patients (Ward, Friedman et al. 1996). 
Reduction occurs in the parietal lobes and there is thinning of midline brain regions. Studies in 
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mice suggest this is due to abnormal cortical neurogenesis (Stark, Xu et al. 2008, Meechan, 
Tucker et al. 2009).   
3. Brain Physiology 
Cortical dysconnectivity as measured by resting state functional magnetic resonance imaging is 
consistently implicated in idiopathic neuropsychiatric disorder (Broyd, Demanuele et al. 2009). 
Reduced synchronicity in long distance connectivity is observed in 22q11.2DS adolescents and 
may act as an intermediary endophenotype for schizophrenia risk (Debbané, Lazouret et al. 
2012). Findings from a mouse model of 22q11.2DS suggest the neuronal basis for this lies in 
reduced hippocampal-prefrontal functional connectivity (Jonas, Montojo et al. 2014). With the 
advent of induced pluripotent stem cell (iPSC) technology it will be possible for 22q11.2DS 
patient derived neurons to be grown and physiologically interrogated for possible 
endophenotypes (Drew, Crabtree et al. 2011). 
2.2.3 Reconceptualising the neuropsychiatric phenotype in 22q11.2DS  
22q11.2DS offers a genetic starting point for exploring development of psychiatric disorder. It is 
clear the phenotype transcends multiple diagnostic boundaries and cognitive domains and it is 
questioned whether current nosology adequately captures the phenotype of 22q11.2DS. I will 
discuss potential models and approaches for reconceptualising the neuropsychiatric phenotype.  
1. Symptom-cognitive domains 
Baker and Vorstman propose that a core neuropsychiatric phenotype underlies disruptions 
across multiple symptom domains in 22q11.2DS and would have the potential to predict later 
psychiatric morbidity (Baker and Vorstman 2012). This core phenotype can be characterized by 
four symptom-cognitive domains which cross-cut traditional classifications; attention-executive 
deficits, social-cognitive deficits, anxiety-affective dysregulation and psychosis. However this 
hypothesis currently lacks empirical evidence. 
2. Developmental Brain Dysfunction 
It has been proposed that developmental brain dysfunction underlies the variable phenotype of 
psychiatric risk in CNV carriers and that if brain dysfunction is measured quantitatively there is 
100% penetrance in carriers (Moreno-De-Luca, Myers et al. 2013). Quantitative measurement of 
different aspects of brain dysfunction in 22q11.2DS could help delineate a neurodevelopmental 
profile of strengths and weaknesses in 22q11.2DS. IQ is normally distributed in 22q11.2DS, but is 
two standard deviations below the general population (Moss, Batshaw et al. 1999, Niarchou, 
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Zammit et al. 2014), but other aspects of the 22q11.2DS profile such as behavioural, emotional 
and social deficits are yet to be explored quantitatively. 
3. Research Domain Criteria 
There is a growing consensus that psychiatry needs to move away from using traditional 
diagnostic measures to quantitative dimensional measures (Craddock and Owen 2010, Owen 
2012, Moreno-De-Luca, Myers et al. 2013). The National Institute of Mental Health (NIMH) have 
developed one such dimensional system, research domain criteria (RDoC) (Cuthbert and Insel 
2013). This approach could be applied to 22q11.2DS to better understand how it confers risk for 
neuropsychiatric disorder and how it impacts cognitive and neural systems (Doherty and Owen 
2014).  
2.3   Understanding the factors that modulate psychiatric risk 
It has been discussed that there is great variability in the neuropsychiatric phenotype of 22q11.2DS. 
Here I discuss some of the factors that may underlie this variation.   
2.3.1 Genetic factors 
1. Deletion size 
As previously mentioned deletion size is variable, 87% of deletions are 3 Mb region and the rest 
are smaller nested regions (Shaikh, Kurahashi et al. 2000). This could contribute to phenotypic 
variability. One study reports schizophrenia and ASD not being present in smaller deletion cases, 
the though authors emphasise that this may reflect the small sample size of their study 
(Michaelovsky, Frisch et al. 2012). Smaller deletions have been reported in cohorts of 
schizophrenia and ASD patients but also in control samples (Hiroi, Takahashi et al. 2013), so it 
remains unclear to what extent deletion size is associated with neuropsychiatric outcomes. 
2. Two-hit hypothesis 
Other genetic variants may contribute to variability. Risk for neuropsychiatric features could be 
conferred by the combination of 22q11.2DS and a second variant, a two-hit hypothesis. 
i. Modifier genes 
 
The 22q11.2 deletion could be unmasking a deleterious allele within the remaining 
22q11.2 region. The combination of a CNV occurring in combination with an inherited 
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gene variant has been reported in autism (Vorstman, van Daalen et al. 2011). COMT has 
received a lot of attention as an initial report suggested common variation of this gene 
predicts longitudinal change in cognition, prefrontal cortical volume and psychotic 
symptoms in 22q11.2DS (Gothelf, Eliez et al. 2005). Two other studies report that 
variation in COMT genotype predicts psychotic phenomena (Gothelf, Feinstein et al. 
2007, Boot, Booij et al. 2011) but there are many studies which have found no 
association with psychotic phenomena, depression or anxiety (Murphy, Jones et al. 
1999, Bassett, Caluseriu et al. 2007, van Amelsvoort, Zinkstok et al. 2008, Antshel, 
Shprintzen et al. 2010, de Koning, Boot et al. 2012, Gothelf, Schneider et al. 2013). 
However, there is evidence that COMT genotype influences frontal lobe volume and 
functioning in 22q11.2DS (Bassett, Caluseriu et al. 2007, van Amelsvoort, Zinkstok et al. 
2008, de Koning, Boot et al. 2012). Another gene in the 22q11.2 region, PIK4CA, has 
been investigated but genotype did not predict psychosis (Ikeda, Williams et al. 2010). 
For background information on COMT and PIK4CA see section 1.2.1. 
 
ii. Second hit CNVs 
 
It could be that a second CNV outside the 22q11.2DS region explains phenotypic 
variability. One study suggests second-hit CNVs may be enriched in 22q11.2DS 
individuals with psychosis, however the sample size is small and findings need 
replicating (Williams, Monks et al. 2013).  
3. Polygenic risk 
Variability may be explained by the summation of risk from multiple genes outside the 22q11.2 
region. Risk alleles have been identified for many psychiatric disorders (Collins and Sullivan 
2013). There is evidence that CNV carriers with psychiatric disorder have a lower polygenic risk 
than non-carriers with psychiatric disorder, suggesting CNVs lower the threshold for polygenic 
risk (Ripke, Neale et al. 2014, Martin, O'Donovan et al. 2015). The role of polygenic risk in the 
22q11.2DS phenotype has not been investigated. 
2.3.2 Family factors 
Neuropsychiatric traits in children with ‘de novo’ 22q11.2DS may be predicted by the presence of 
similar traits in their parents. The intellectual functioning of parents has been found to be predictive 
of childhood intelligence in 22q11.2DS (Klaassen, Duijff et al. 2014, Olszewski, Radoeva et al. 2014). 
Also familial ADHD is predictive of persistence of ADHD into adolescence in 22q11.2DS (Antshel, 
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Hendricks et al. 2013). The mechanisms are uncertain but it could reflect a combination of inherited 
polygenic risk from the parent but also shared family environment. It is also possible that gene-
environment covariation is occurring, in that exposure to an environment is influenced by genotype 
(Mackintosh 2011). 
2.3.3 Environmental factors 
This is an understudied area in 22q11.2DS research. It has been suggested that 22q11.2DS confers 
susceptibility to stress, thus providing a sensitised background for exploring environmental risk 
factors for psychiatric disorder (Beaton and Simon 2011, Jonas, Montojo et al. 2014). As mentioned 
previously, family environment has been found to amplify the relationship between childhood mood 
dysregulation and later emergence of prodromal symptoms (Kates, Russo et al. 2014). Identification 
of protective environmental factors will be useful for informing interventions. 
2.4 Potential impact 
Research into the neuropsychiatric phenotype is needed to help 22q11.2DS individuals and their 
families. 22q11.2DS is one of the strongest risk factors for schizophrenia, yet no effective 
intervention is available. Parents report anxiety in response to behavioural difficulties in their child 
and they worry about the development of psychosis (Briegel, Schneider et al. 2007, Hercher and 
Bruenner 2008). Understanding the pathways to psychiatric disorder in 22q11.2DS will hopefully 
inform potential treatments and interventions. Preliminary trials of cognitive remediation and social 
cognitive training interventions have been conducted and show some positive benefits but their long 
term efficacy on psychosis risk remains unknown (Harrell, Eack et al. 2013, Shashi, Harrell et al. 
2015).  
Investigation into neuropsychiatric development in 22q11.2DS will give insights which can be 
expected to be applicable to general psychiatry. Understanding development and prevention of 
neuropsychiatric disorder in high risk conditions, such as 22q11.2DS, is arguably an important step 
before understanding how complex multifactorial risk for psychiatric disorder manifests. 
2.5 Summary 
22q11.2DS provides a rare opportunity to examine the developmental pathways of neuropsychiatric 
disorders. Potential causal pathways to psychotic phenomena have been identified involving 
prodromal features, anxiety, cognition, brain morphological changes and family environment. 
However there are many inconsistencies in findings, difficulties in interpreting causality and a need 
for replication. 22q11.2DS represents a genetic starting point to explore how risk for 
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neuropsychiatric disorder manifests and allows investigation into endophenotypes. Heightened 
psychiatric risk in 22q11.2DS allows the genetic and environmental factors that modulate psychiatric 
risk to be explored.  
The following chapters summarise the work I have undertaken on neuropsychiatric development in 
22q11.2DS. I report findings from a longitudinal cohort of children with 22q11.2DS. My aims are to: 
1. Characterise development of psychopathology in 22q11.2DS 
2. Examine cognitive development in 22q11.2DS 
3. Explore the relationship between psychopathology and cognitive development in 22q11.2DS 
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3. The ECHO study 22q11.2DS cohort 
The Cardiff University ECHO study (Experiences of CHildren with cOpy number variants) started in 
2010, led by principal investigators Professor Marianne van den Bree and Professor Sir Michael 
Owen. The study assesses children with CNVs associated with increased risk of intellectual disability 
and psychiatric problems, including 22q11.2DS. In 2013 a second wave of assessment was initiated.  
3.1 Recruitment  
3.1.1 Wave 1 assessment 
Currently 121 children with 22q11.2DS have been assessed. Children are recruited from NHS medical 
genetics clinics, UK support groups Max Appeal!, 22crew and Unique, and the ECHO study website. 
Children have been assessed from Wales, England, Scotland and Northern Ireland. The closest 
unaffected sibling in age to the child with 22q11.2DS is recruited as a control. 22q11.2DS is 
confirmed by medical genetics clinics, medical reports from the primary carer and also by the 
Institute of Psychological Medicine and Clinical Neurosciences laboratory.  
3.1.2 Wave 2 assessment 
The target time gap between assessments was 2.5 years. At the time of writing of the 121 children 
who were initially assessed 102 were eligible to be re-contacted, in that 2.5 years had passed since 
initial assessment. Of these, 70 children have been assessed for a second time. This represents a 
participation rate of 69%, which is consistent with other longitudinal 22q11.2DS studies (Antshel, 
Shprintzen et al. 2010, Gothelf, Schneider et al. 2013). 29 controls (unaffected siblings) have also 
been assessed longitudinally.  
3.1.3 Ethics 
Informed written consent was obtained at both waves of assessment from the primary carer of the 
participant and directly from the participant if aged 16 and above. Protocols were approved by 
National Health Service (NHS) South East Wales Research Ethics and Research and Development 
committees of individual NHS Trusts.  
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3.2 Measures 
3.2.1 Psychiatric 
1. Psychopathology: CAPA 
Psychopathology, during the last 3 months and including psychotic experiences, was assessed at 
both waves using the Child and Adolescent Psychiatric Assessment (CAPA) (Angold, Prendergast et 
al. 1995) by means of semi-structured interview (parent CAPA) with the primary carer. Criteria were 
applied to establish DSM-IV-TR (Diagnostic Statistical Manual of mental disorders, Fourth edition, 
Text Revision) (American Psychiatric Association 2000) diagnosis. Rules regarding mutually exclusive 
diagnoses were not applied. Presence of the following psychiatric disorders were established 
(numbers referring to DSM-IV-TR code): 
i. Psychotic Disorder 
Schizophrenia 295.10/295.20/295.30/295.90 
Schizophreniform Disorder 295.40 
Schizoaffective Disorder 295.70 
Delusional Disorder 297.10 
Brief Psychotic Disorder 298.8 
 
ii. Mood Disorder 
Bipolar I Disorder – Single Manic Episode 296.0 
Major Depressive Disorder – Single Episode 296.2 
Major Depressive Disorder – Recurrent 296.3 
Bipolar II Disorder – Recurrent Major Depressive Episodes with Hypomanic Episodes 296.89 
Dysthymic Disorder 300.4 
 
iii. Anxiety Disorder 
Generalised Anxiety Disorder 300.02 
Panic Disorder without Agoraphobia 300.1 
Panic Disorder with Agoraphobia 300.21 
Agoraphobia without history of Panic Disorder 300.22 
Social Phobia 300.23 
Specific Phobia 300.29 
Obsessive Compulsive Disorder 300.3 
Separation Anxiety   309.21 
Selective Mutism 313.23  
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iv. Tic Disorders – Chronic Motor or Vocal Tic Disorder 307.2 
v. Trichotillomania 312.39 
vi. Conduct Disorder 312.81/312.82/312.89 
vii. Oppositional Defiant Disorder 313.81 
viii. Attention Deficit Hyperactivity Disorder 314.00/314.01 
In addition, psychotic experiences were assessed through child-report using the psychosis section of 
the child CAPA at both waves. In this section, initial screening questions probed for any evidence of 
perceptual disorders or hallucinations, delusions or psychotic abnormalities of thought processes. If 
participants scored on the screening questions, the interviewer continued with more detailed 
probing about the nature of possible experiences. Questions were asked about the content and 
location of auditory, olfactory and tactile hallucinations, thought insertion and broadcast, thought 
echo and withdrawal and delusional thinking. Phenomena not coded as psychotic experiences 
included hypnagogic/pompic hallucinations, eidetic imagery, elaborated fantasies, imaginary 
companions, illusions, hallucinations occurring as part of a seizure or clouded sensorium, 
spots/stripes before the eyes and sensory changes associated with headaches. Psychotic experiences 
were counted as present if reported by either the primary carer or child. 
 All interviews were conducted by trained researchers, who were supervised by a consultant child 
and adolescent psychiatrist. Interviews were audio-taped for monitoring purposes. 
2. ASD traits: SCQ 
ASD traits were assessed using the Social Communication Questionnaire (SCQ) (Rutter, Bailey et al. 
2003), which was completed by the primary carer at both waves of assessment. Total scores can 
range from 0 to 39. Questions cover three domains; reciprocal social interaction, language and 
communication, repetitive and stereotyped patterns of behaviour. Behaviour both current and 
during the ages 4 to 5 are assessed. A score of 15 or higher is suggestive of ASD and a score of 22 or 
higher is suggestive of autism (Berument, Rutter et al. 1999).   
3. ASD diagnosis: ADI-R 
The SCQ does not provide a formal research diagnosis. At wave 1 of the ECHO study, 26.0% of 
participants with 22q11.2DS had SCQ scores which were suggestive of ASD in comparison to 5.3% of 
control siblings (Niarchou, Zammit et al. 2014). In light of this it was decided at wave 2 to administer 
the Autism Diagnostic Interview-Revised (ADI-R) (Rutter, Le Couteur et al. 2003), a semi-structured 
interview with the primary carer, to assess autism. The ADI-R was conducted over the telephone due 
to time restraints during the home visit. This method of administration has been validated  for the 
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ADI-R (Ward-King, Cohen et al. 2010) and used by another 22q11.2DS study (Kates, Antshel et al. 
2007). All interviews were conducted by trained researchers. Interviews were audio-taped for 
consensus coding and monitoring purposes.  
The ADI-R assesses autism symptomatology across three domains and whether abnormality in 
development is evident before age 3. The interview focuses on current behaviour and 
developmental history, particularly between ages 4 to 5. It should be noted that the SCQ was 
developed from the ADI-R so the domains of each measure are analogous. Algorithms are applied 
for ASD diagnosis. Below is a list of the domains and subdomains for the ADI-R with the cut-offs used 
for diagnosis.  
A: Qualitative Abnormalities in Reciprocal Social Interaction 
Diagnostic cut-off = 10  
A1: Failure to use nonverbal behaviours to regulate social interaction 
A2: Failure to develop peer relationships 
A3: Lack of shared enjoyment 
A4: Lack of socioemotional reciprocity 
 
B: Qualitative Abnormalities in Communication 
Diagnostic cut-off = 8 (7 if non-verbal) 
B1: Lack of, or delay in, spoken language and failure to compensate through gesture 
B2: Relative failure to initiate or sustain conversational interchange 
B3: Stereotyped, repetitive, or idiosyncratic speech 
B4: Lack of varied spontaneous make-believe or social imitative play 
 
C: Restricted, Repetitive, and Stereotyped Patterns of Behaviour 
Diagnostic cut-off = 3 
C1: Encompassing preoccupation or circumscribed pattern of interest 
C2: Apparently compulsive adherence to non-functional routines or rituals 
C3: Stereotyped and repetitive motor mannerisms 
C4: Preoccupation with parts of objects or non-functional elements of material 
 
D: Abnormality of Development Evident at or Before 36 Months 
Diagnostic cut-off = 1 
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3.2.2 Cognitive Assessment 
1. Global cognitive ability 
General intelligence was assessed using the Wechsler Abbreviated Scale of Intelligence 
(WASI)(Wechsler 1999) at both waves of assessment. It is comprised of four subtests; two verbal 
tasks, vocabulary and similarities, and two non-verbal tasks, block design and matrix reasoning from 
which Verbal IQ (VIQ), Performance IQ (PIQ) and Full Scale IQ (FSIQ) can be derived. Rater drift was 
avoided by double-rating and anonymising transcripts so raters were blind to deletion status and 
wave. There was a high correlation between ratings (22q11.2DS r=0.989, Control r=0.970). Below is a 
fuller description of each subtest adapted from the manual (Wechsler 1999). 
Verbal IQ subtests 
VIQ is a measure of verbal ability but can also be conceptualised as acquired, crystallized 
intelligence.  
Vocabulary  
It has 42 items, items 1-4 require the participant to name pictures and items 5-42 involves orally and 
visually presented words that the participant orally defines.  
The subtest is a measure of expressive vocabulary and verbal knowledge. As well as being 
considered a good measure of crystallized intelligence it also taps other abilities such as memory, 
learning ability, and concept and language development.  
Similarities 
It has 26 items, items 1-4 are picture items and 5-26 are verbal items. For each picture item the 
participant is shown a picture of three common objects on the top row and four response options on 
the bottom row. The participant has to pick the response option that best matches the pictures on 
the top tow. For the verbal items, a pair of words is presented orally and the participant has to 
explain the similarity between the objects or concepts that the words represent. 
The subtest is a measure of verbal concept formation and abstract verbal reasoning. 
Performance IQ 
PIQ is a measure of nonverbal ability and perceptual organisation and can be conceptualised as fluid 
intelligence. 
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Block design 
It has 13 items where the participant has to replicate a geometric pattern within a time limit using 
two-colour cubes. 
The subtest taps spatial visualisation, visual-motor coordination, abstract conceptualisation and 
perceptual organisation. 
Matrix reasoning 
It has 35 items of incomplete gridded patterns which the participant completes by choosing a 
response from five possible choices.  
It is a measure of nonverbal fluid reasoning. 
2. Specific neurocognitive functions 
Neurocognitive domains were assessed using the Wisconsin Card Sorting Test (WCST) (Heaton, 
Chelune et al. 1993) which measures set-shifting ability and the CANTAB (Cambridge 
Neuropsychological Test Automated Battery) (CANTAB 2006) computerised touch screen platform 
where the following tests were administered: spatial working memory, stockings of Cambridge, five 
choice reaction time, match to sample and rapid visual information processing. Below is a 
description of the neurocognitive domains they assess and their administration based upon details in 
the test manuals (Heaton, Chelune et al. 1993, CANTAB 2006). 
Wisconsin Card Sorting Test 
The WCST consists of four stimulus cards and sixty-four response cards that depict figures of varying 
form, colour, and numbers of figures. The participant has to match each response card to a stimulus 
card. They are told whether the response was right or wrong but are never explicitly told the correct 
matching principle. Once the participant makes ten consecutive correct matches the matching 
principle is changed without warning. 
When a participant persists in responding to a stimulus characteristic that is incorrect this is scored 
as a perseverative error. The total number of perseverative errors is used as the outcome measure 
in this thesis. 
Performance on the WCST measures set-shifting aspect of executive function and requires, strategic 
planning, organised searching, utilising feedback to shift cognitive sets, goal directing behaviour, and 
modulation of impulsive responding.  
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Cambridge Neuropsychological Test Automated Battery (CANTAB) 
Spatial working memory (SWM) 
The SWM task measures the spatial working memory aspect of executive function. 
The SWM task begins with a number of coloured boxes being shown on the screen. The aim is for 
the participant to find which box the blue token is hidden in. Once it has been found behind one box 
it will not appear in that that location on the next round.  
The outcome measure is “SWM between errors” which is defined as the number of times the subject 
revisits a box in which a token has previously been found. A lower score is better. 
Stockings of Cambridge (SOC) 
The SOC task measures spatial planning, which is an aspect of executive function.  
The participant is shown two displays containing three coloured balls which are stacked in stockings 
suspended from a beam and they must use the balls in the lower display to copy the pattern of the 
upper display. The balls can only be moved one at a time and balls at the bottom of a stack cannot 
be moved until ones higher up in the stack have been moved.  
The outcome measure used was “SOC Problems solved in minimum moves” which is the number of 
occasions the participant completed the test problem in the minimum possible number of moves. A 
higher score is better. 
Five Choice Reaction Time (RTI) 
RTI is a measure of processing speed 
The participant holds down a press pad button. When a yellow spot appears on the screen in one of 
five possible locations the participant has to respond and tap it as quickly as possible. Child mode 
was administered. 
The outcome measure is the time it takes to release the press pad button in response to the yellow 
spot. Quicker is better. 
Match to Sample Visual Search (MTS) 
MTS is a measure of visual attention. 
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The participant is presented an abstract patterned stimulus in the middle of the screen. Then a 
number of similar patterns are shown in a circle of boxes around the edge of the screen. The 
participant must tap the pattern which matches. 
The outcome measure is the number of correct responses out of a possible 48 trials. A higher score 
is better. 
Rapid Visual Processing (RVP) 
RVP is a measure of visual sustained attention. 
Digits from 2 to 9 are presented in a pseudo-random order on the screen. Participants have to tap 
the press pad button when 3, 5, 7 appear in a row. Child mode was administered. 
The outcome measure is RVP A prime which is the signal detection measure of sensitivity to the 
target sequence (3,5,7) and ranges from 0 to 1 (bad to good).  
3.2.3 Consistency across assessments 
Effort was made to keep the testing environment and testing procedures as consistent as possible. 
Cognitive measures were always administered in the following order: IQ, WCST, SWM, SOC, RTI, MTS 
and RVP. The majority of participants were assessed at the same time of day, in the afternoon and 
were assessed at home, though it should be noted that 10% were tested at the Institute of 
Psychological Medicine and Clinical Neurosciences in Cardiff when they were visiting to take part in 
the ECHO study’s brain imaging project. 
3.3 Sample characteristics 
3.3.1 Age and gender 
Table 1 gives the age characteristics of the longitudinal sample. Age distribution did not differ 
between 22q11.2DS children and controls. Gender distribution did not differ between groups 
(22q11.2DS: 41M 29F, controls: 16M 13F, χ2 p=0.825). 
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Table 1: Assessment ages 
 
3.3.2 Representativeness of longitudinal cohort 
Table 2 displays the wave 1 characteristics of 22q11.2DS individuals in the longitudinal cohort and 
compares this to 22q11.2DS individuals who were eligible to take part in terms of 2.5 years passing 
since wave 1 but have not taken part in wave 2 assessments. The longitudinal cohort is 
representative in terms of age, gender, deletion origin, psychiatric disorder, ASD traits (SCQ), 
ethnicity, maternal education and family income. However the longitudinal cohort underrepresents 
those who reported psychotic experiences at wave 1 (p=0.011) and on average individuals have a 
lower wave 1 FSIQ than those who did not take part again (-5.8 FSIQ points, p=0.035). This may 
suggest that the longitudinal cohort has greater cognitive deficits but lower proneness to psychotic 
phenomena. These issues will be considered when interpreting findings in later chapters. 
Age at wave 1 Age at wave 2 Time gap
N years (SD) years (SD) years (SD)
22q11.2DS 70 10.0(2.3) 12.5(2.2) 2.5(0.4)
Controls 29 10.7(2.0) 13.4(2.1) 2.7(0.4)
T-test p-value - 0.166 0.090 0.137
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Table 2: Characteristics of longitudinal cohort compared to those not revisited 
 
# (χ2 for categorical, t-test for continuous data) 
3.3.3 Representativeness of the ECHO study cohort 
This section will briefly discuss to what extent the ECHO study 22q11.2DS cohort represents all 
22q11.2DS children. There is likely to be ascertainment bias for several reasons. Not all individuals 
with 22q11.2DS will receive a diagnosis in childhood and it is likely there are many individuals who 
go throughout life without a diagnosis particularly if they have a mild phenotype. There is evidence 
that those diagnosed later in life differ in symptom profile so child cohorts may not be fully 
representative of the full age range (Vogels, Schevenels et al. 2014). The ECHO study recruits from 
the UK so findings may not be internationally representative, though previous cross-sectional 
findings from the ECHO study (Niarchou, Zammit et al. 2014) are consistent with a recent 
international study (Schneider, Debbané et al. 2014). However, it should be noted that the ECHO 
Longitudinal Not revisted p-value# 
N 70 32
Mean age in years (SD) 10.0 (2.3) 10.0(2.2) 0.949
Gender (% male) 58.6% 43.8% 0.201
Inherited 22q11.2DS 10.0 % 3.0% 0.430
Mean FSIQ (SD) n(62,29)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         74.4 (11.1) 80.2 (14.3) 0.035
Any DSM IV Psychiatric disorder prevalence 55.7 % 56.3 % 0.999
Psychotic experience prevalence 2.9 % 18.8 % 0.011
Mean SCQ score (SD) 12.8 (7.1) 11.7 (7.0) 0.488
Family ethnic background 0.167
European 92.9 % 88.8 %
Non-European 1.4 % 3.1 %
Mixed 5.7 % 3.1 %
Unknown 0.0 % 6.3 %
Highest maternal educational qualification 0.480
Low: O-levels or GCSEs 21.4 % 21.9 %
Middle: A-levels/highers or vocational training 42.9 % 28.1 %
High: university degree and/or other higher 
postgraduate qualification
22.9 % 34.4%
Unknown 12.9 % 15.6 %
Family income, £ 0.142
≤19,999 24.3 % 9.4 %
20,000-39,999 27.1 % 25.0%
40,000-59,999 20.0 % 12.5%
≥60,000 18.6 % 34.4 %
Unknown 10.0 % 18.8 %
40 
 
study was a major contributor to this study. Research participation is voluntary so families who take 
part in research may differ from those who do not.  
An advantage of recruiting via medical genetics clinics and support groups is that individuals are not 
directly ascertained on the basis of neuropsychiatric disorder. However it is likely the presence of ID 
increases chance of referral to medical genetic clinics and perhaps there is perhaps a bias in families 
who join support groups and volunteer for research. 
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4. Longitudinal psychopathology in 22q11.2DS 
This chapter will examine how psychopathology develops in 22q11.2DS. I will introduce the insights 
that can be gained from such work and highlight longitudinal trends previously reported in 
22q11.2DS. There will also be a focus on the nature of autism spectrum disorder in 22q11.2DS. I will 
present findings on psychopathology from the longitudinal 22q11.2DS ECHO cohort. 
4.1 Potential insights from longitudinal studies of 22q11.2DS  
4.1.1 Characterise  psychiatric morbidity developmentally 
CNVs are not specific risk factors for particular psychiatric disorders (see 2.2.1) and 22q11.2DS is no 
exception, conferring risk for multiple conditions (see 1.2). There are different possible underlying 
explanations for non-specific risk. One explanation could be cross-sectional comorbidity where a 
proportion of individuals meet criteria for multiple psychiatric disorders. Another possibility is that 
heterogeneity may be present such that different psychiatric disorders may affect different 
individuals. There could also be sequential comorbidity in that psychiatric disorder at one point in 
the life course is associated with psychiatric disorder later in the life. This latter issue can only be 
clarified using a longitudinal design. There has been a concerted research effort to examine whether 
early psychopathology in 22q11.2DS predicts development of psychotic phenomenology (see 2.1.4, 
2.1.5). Longitudinal studies can also examine the stability and persistence of psychiatric disorder 
over time. Characterising cross-sectional and sequential comorbidity will help understand the extent 
to which psychiatric disorders across the life course have shared aetiology.  
4.1.2 Examine early psychopathology associated with schizophrenia risk 
22q11.2DS provides a rare opportunity to explore childhood development associated with 
schizophrenia (see 2.1.2, 2.1.3). Longitudinal studies of idiopathic cohorts have identified several 
factors. 
1. ADHD and ASD symptomatology 
Symptoms of ADHD and attentional deficits have been reported in those who later develop 
schizophrenia (Cornblatt, Obuchowski et al. 1999, Pine and Fox 2015). Attentional impairment 
has been suggested as an endophenotype for uncovering risk genes for schizophrenia (Cornblatt 
and Malhotra 2001). Also there is evidence that polygenic risk for ADHD overlaps with that for 
schizophrenia (Hamshere, Stergiakouli et al. 2013).  
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Historically autism was described as childhood onset schizophrenia (American Psychiatric 
Association 1975). It was not until the third edition that DSM considered autism/pervasive 
developmental disorder to be a separate category (American Psychiatric Association 1987). In 
modern clinical practice the disorders are rarely diagnosed in the same individual (Rapoport, 
Chavez et al. 2009), partly because some clinicians consider them mutually exclusive and 
classification in DSM-5 has specific extra requirements for diagnosing schizophrenia in those 
with a history of ASD (American Psychiatric Association 2013). There are a few studies that 
report children with ASD are at increased risk of developing schizophrenia in adulthood 
(Stahlberg, Soderstrom et al. 2004, Mouridsen, Rich et al. 2007, Sprong, Becker et al. 2008). This 
relationship is stronger when ASD is considered more broadly in terms of impairments in ASD 
related domains such as language and social ability. Impairment in receptive language has been 
identified as a precursor for schizophrenia (Rutter, Kim‐Cohen et al. 2006) and adults with a 
childhood diagnosis of developmental language disorder show increased schizotypal traits and 
prevalence of schizophrenia (Clegg, Hollis et al. 2005). Social deficits are a well-documented 
feature of the premorbid phase of psychosis (Häfner, Nowotny et al. 1995), though it should be 
noted that social deficits are not synonymous with ASD. 
2. Affective symptomatology 
Children who later develop schizophrenia are more likely than typically developing children to 
exhibit social, emotional and behavioural problems (Rutter and Garmezy 1983). Childhood 
anxiety and stressful life events are also associated with the development of schizophrenia 
(McReynolds 1960, Walker and Diforio 1997, Rapoport, Giedd et al. 2012). 
3. Subclinical psychotic experiences 
Psychotic experiences are predictive of later psychotic disorder (Chapman, Chapman et al. 1994, 
Poulton, Caspi et al. 2000, Hanssen, Bak et al. 2005, Zammit, Kounali et al. 2013), varying from 
5.5% to 25% increased risk depending on criteria of establishing such experiences. Findings from 
the Avon Longitudinal Study of Parents and Children (ALSPAC) suggest psychotic experiences and 
schizophrenia have shared aetiology as they share some of the same risk factors, including 
childhood cognitive deficits, adverse pre-natal exposures, childhood infection, and stress and 
cannabis use (Niarchou, Zammit et al. 2015). There is however no strong evidence from the 
ALSPAC cohort for shared genetic aetiology for psychotic experiences and schizophrenia 
(Zammit, Hamshere et al. 2014). 
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4.2 Childhood psychopathology in 22q11.2DS 
There is a high burden of childhood psychopathology in 22q11.2DS including a high prevalence of 
ADHD, ASD, anxiety, mood disorder and ODD (see 1.2). There is evidence that childhood 
psychopathology associated with 22q11.2DS cannot be fully attributed to cognitive impairment 
(Niarchou, Zammit et al. 2014). 
4.2.1 Nature of psychotic experiences in 22q11.2DS 
The prevalence of subthreshold psychotic symptoms varies from 10% to 83% depending on the 
measure used, study age range and relative representation of children versus adults (Feinstein, Eliez 
et al. 2002, Baker and Skuse 2005, Niarchou, Zammit et al. 2014, Schneider, Schaer et al. 2014, Tang, 
Yi et al. 2014). As seen in idiopathic schizophrenia, subthreshold symptoms are predictive of later 
disorder (Gothelf, Feinstein et al. 2007). Prevalence in one study that used the CAPA, as was used in 
the ECHO cohort that this thesis is based on, was 48% (mean age = 16.4 , age range = 13 - 25) (Baker 
and Skuse 2005). Phenomena reported were diverse and included delusional thinking, auditory and 
visual hallucinations, depersonalisation and thought broadcast, but they were generally of short 
duration and were not perceived to be highly distressing or intrusive.  It should be mentioned that 
the findings from these cohorts are not necessarily fully comparable to what may be found in the 
ECHO sample as they had an older age range.  
4.2.2 Longitudinal trends reported in 22q11.2DS 
Longitudinal findings in 22q11.2DS have been discussed in the introductory chapters, albeit in 
separate sections. Here I briefly summarise and bring together different aspects. 
1. ADHD prevalence declines with age at a similar rate to idiopathic ADHD (see 1.2.4). 
2. Mood disorder prevalence increases with age (Antshel, Shprintzen et al. 2010) (also see 1.2.7) 
3. Differential prevalence change  for different anxiety disorders  
Prevalence for presence of any anxiety disorder remains relatively stable from childhood to 
adolescence (Schneider, Debbané et al. 2014). However, there is evidence that phobia 
prevalence decreases whereas generalised anxiety disorder prevalence increases from childhood 
to adolescence (Antshel, Shprintzen et al. 2010). 
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4. Prevalence of psychotic phenomena increases with age 
The prevalence of psychotic disorder and subthreshold symptoms increases with age (Gothelf, 
Feinstein et al. 2007, Gothelf, Schneider et al. 2013, Hooper, Curtiss et al. 2013, Schneider, 
Debbané et al. 2014, Schneider, Schaer et al. 2014).  
5. Anxiety and mood disorder/symptomatology predict later psychotic phenomena (see 2.1.4 and 
2.1.5) 
6. Childhood ASD does not predict later psychotic phenomena (see 1.2.3)  
4.2.3 Limitations of 22q11.2DS longitudinal psychopathology studies 
1. Subthreshold psychotic symptoms not always examined at every time points 
Some studies have only assessed subthreshold psychotic symptoms at the final time point 
(Antshel, Shprintzen et al. 2010, Kates, Russo et al. 2014). This makes it difficult to distinguish 
whether psychotic phenomenology is preceded by other psychopathology or whether psychotic 
phenomenology covaries with other psychopathology. 
2. Few studies have considered stability and individual change in diagnosis 
Although studies report prevalence and statistically test for change, few have examined stability. 
At a group level prevalence may not change but this could mask significant change at the level of 
the individual. Change in prevalence provides no indication of whether the same individuals are 
affected at both time points and whether individuals vary in developmental course. One study 
that considered this when examining the longitudinal course of ADHD found 15% of 22q11.2DS 
children without ADHD at time 1 had ADHD by time 2 (Antshel, Hendricks et al. 2013), though 
overall ADHD prevalence decreased between time points. This could represent measurement 
error. Alternatively, it could suggest that in some 22q11.2DS individuals ADHD traits may be 
present early but do not impact enough to reach diagnostic threshold until they are older. 
Important insights and variability in development may be missed by not examining individual 
change in diagnosis.  
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4.3 The nature of autism spectrum disorder in 22q11.2DS 
There is great uncertainty in the 22q11.2DS literature whether difficulties in social behaviour and 
language development can be considered ASD (see 1.2.3). This issue is important to clarify in terms 
of informing treatment and care provision for individuals with 22q11.2DS and in terms of 
understanding whether 22q11.2DS, as a genetic risk variant for schizophrenia, also confers risk for 
ASD. This has implications for Crespi and Badcock’s hypothesis that ASD and psychosis are reciprocal 
disorders of the social brain (see section 2.2.1.4). Before exploring this issue empirically using the 
ECHO cohort, this section will discuss ASD diagnosis, ASD assessment instruments and current issues 
in the 22q11.2DS ASD literature. 
4.3.1 ASD criteria 
Diagnostic classification has changed between DSM-IV and DSM-5. DSM-IV had a section on 
disorders usually first diagnosed in infancy, childhood, or adolescence which included a subsection 
on Pervasive Developmental Disorders which included Autistic Disorder, Rett’s Disorder, Childhood 
Disintegrative Disorder and Asperger’s Disorder (American Psychiatric Association 2000). A diagnosis 
of Autistic Disorder was on the basis of impairments in three domains which included deficits in 
communication, deficits in social interaction and finally the presence of restricted, repetitive 
patterns of behaviour, interests or activities. The classification Pervasive Developmental Disorder 
Not Otherwise Specified (PDD-NOS) was applied to individuals who only showed impairment in some 
domains. Symptoms from these domains have to be present in the early developmental period and 
cause clinical impairment. Diagnostic classification was restructured in DSM-5 and the different 
Pervasive Developmental Disorders were replaced by one disorder, Autism Spectrum Disorder (ASD) 
which is placed within the category of Neurodevelopmental Disorders (American Psychiatric 
Association 2013). DSM-5 criteria of ASD is different to DSM-IV Autistic Disorder with only two 
domains, the domains of communication and social interaction were combined. 
22q11.2DS research studies are yet to transition to DSM-5 criteria, including the ECHO study. The 
term autism in 22q11.2DS studies generally refers to the DSM-IV criteria of impairments in all three 
domains. However when the term ASD is used in studies it has not referred to DSM-5 ASD criteria, 
rather it has referred to the presence of impairments in only some domains. This can be seen to be 
analogous to DSM-IV PDD-NOS criteria. There is also a habit in studies that use trait measures of 
ASD, to use the term autism to indicate greater severity than ASD. In this chapter I have followed 
suit of previous 22q11.2DS studies and so have not used DSM-5 criteria. Below I specify exactly how 
the terms ASD and autism have been applied to measures used.  
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4.3.2 ASD assessment instruments 
Ideally, clinical diagnosis of ASD requires both parent-report of the child’s developmental history as 
well as the observation of the child’s behaviour (Charman and Baird 2002, Johnson and Myers 2007). 
A range of parent-report, self-report and observational measures of ASD have been developed for 
clinical and research purposes (Volkmar 2013). The ECHO study uses the Social Communication 
Questionnaire (SCQ) and the Autism Diagnostic Interview-Revised (ADI-R), which have already been 
described in the Chapter 3.  Here I will discuss their psychometric properties as well as findings from 
previous research studies.  I will also discuss the Autism Diagnostic Observation Schedule (ADOS) as 
this has been used in other studies of 22q11.2DS. 
1. ADI-R  
The ADI-R is a standardised, semi-structured, investigator led interview administered to parents 
or caregivers to assess the presence of ASD in an individual (Lord, Rutter et al. 1994, Rutter, Le 
Couteur et al. 2003). It provides a useful structure for obtaining the developmental history and 
caregiver’s perspective of their child’s ASD symptomatology, with a particular focus on ages 4 to 
5. It requires substantial training and practice to administer reliably and takes approximately two 
to three hours to complete. 
The ADI-R assesses three domains of functioning: communication, reciprocal social interaction, 
and restricted, repetitive, and stereotyped patterns of behaviour. There is also a fourth domain, 
abnormality of development evident at or before 36 months, which indicates whether 
symptomatology is present early in development. For an ADI-R classification of autism an 
individual must meet or exceed cut-offs in all three domains plus meet the criteria of the fourth 
domain. Algorithms for the broader classification of ASD can also be applied to ADI-R items 
(Dawson, Webb et al. 2004, Lainhart, Bigler et al. 2006).  
One of the strengths of the ADI-R is its ability to distinguish ASD from ID, which is pertinent to 
the assessment of children with 22q11.2DS, given the syndrome’s association with ID. The ADI-R 
algorithm for autism shows high sensitivity and specificity (both over 0.90) when differentiating 
children with autism from those with ID (Lord, Rutter et al. 1994). Also the majority of ADI-R 
items demonstrate good discriminative ability between children with autism and children with 
ID. 
Researchers have used individual domain scores and the overall total of the three functional 
domains to estimate autistic symptom severity (Volkmar 2013). However, the validity of this 
approach has not been directly investigated. 
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An important caveat to recognise is that diagnostic classification based on ADI-R algorithms and 
true clinical diagnosis is not the same thing. Clinical diagnosis is based on multiples sources of 
information (Le Couteur, Haden et al. 2008).  
2. SCQ 
The SCQ when first developed was originally called the Autism Screening Questionnaire (ASQ) 
(Berument, Rutter et al. 1999). It consists of 40 questions derived from the ADI-R which have 
been modified into a form understandable by parents and can be completed as a written 
questionnaire rather than a semi-structured interview. Questions were selected to focus on 
behaviours that can be identified by non-professionals.  
Questions assess both current behaviour and developmental history. A cut-off of 15 suggests 
ASD and a cut-off of 22 is used to distinguish autism from other disorders on the spectrum 
(Berument, Rutter et al. 1999). The ASD cut-off has a high sensitivity and specificity when 
comparing those with autism to typically developing children, 0.96 and 0.80 respectively. The 
ASD cut-off is not as effective in discriminating ASD from ID, specificity is lower (0.67). The higher 
cut-off of 22 discriminates children with autism from other spectrum disorders with a sensitivity 
of 0.75 and specificity of 0.60. 
3. Comparing the SCQ and ADI-R  
As the SCQ is administered as a written questionnaire rather than a semi-structured interview it 
takes much less time to complete and is therefore often chosen over the ADI-R for inclusion in 
research protocols (Charman and Baird 2002). SCQ score correlates highly with ADI-R total score 
(0.71). The SCQ is as effective as the ADI-R in discriminating children with autism from typically 
developing children, but the ADI-R is better at discriminating autism from ID (Berument, Rutter 
et al. 1999). Therefore the ADI-R, although lengthy, may be a better measure for assessing ASD 
in 22q11.2DS given that ID is associated with the syndrome. Also in general the researchers who 
developed both the SCQ and ADI-R consider the SCQ as a good screening instrument but 
inappropriate for making a diagnosis at the level of the individual, for which the ADI-R is better 
suited (Berument, Rutter et al. 1999).  
4. ADOS 
The ADOS is one of the most widely used observational measures of autism (Lord, Rutter et al. 
2008). It is a semi-structured assessment of social interaction, play and imagination 
administered directly with the individual. It is one of the few diagnostic measures that involves 
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direct observation of the individual’s interactions and that takes account of age and 
developmental level. Similar to the ADI-R it requires substantial training to administer reliably, 
though administration is much shorter than the ADI-R at 30 to 45 minutes.  
ADOS classifications are based on specific coded behaviours from which communication, 
reciprocal social interaction and total scores can be derived. Thresholds for autism and ASD can 
be applied to overall scores. Findings from the ADOS validity sample report high sensitivity and 
specificity (both over 0.80) (Lord, Rutter et al. 2008) and that it is very effective in discriminating 
individuals with ASD from those with non-spectrum disorders. However a more recent study 
suggests that the ADOS has difficulty discriminating children with ASD from children with other 
developmental and behavioural disorders (Molloy, Murray et al. 2011). This suggests that the 
ADOS may not be appropriate for assessing children with 22q11.2DS given the range of 
developmental and behavioural disorders associated with the syndrome. In general it is 
recommended that the ADOS outcome is used alongside other sources of information.  
5. ADI-R and ADOS 
Combined, the ADI-R and ADOS are considered the gold standard in assessing autism. The ADI-R 
provides developmental history ascertained through semi-structured interview and the ADOS 
provides an observational measure.  Combined usage provides better diagnostic accuracy than 
the use of either alone (Zander, Sturm et al. 2014).   
Although the combined ADI-R and ADOS diagnostic procedure is comprehensive, it does have 
drawbacks. It is very time consuming, and in clinical samples of ‘diagnostically challenging’ 
children there is not strong agreement between the ADI-R and ADOS (Bishop and Norbury 2002).  
Another criticism is that in development of the ADI-R and ADOS the selection of items was based 
on clinical judgment rather than a statistical approach such as discriminant function analysis. The 
latter could improve diagnostic accuracy and potentially remove non-discriminatory items.  
4.3.3 The extent to which autism measures index other psychopathology 
There is increasing evidence that psychiatric disorders, including ASD, overlap in symptomatology 
and share aetiology (Owen 2014). A study that assessed psychiatric comorbidity in children with ASD 
found 70% had at least one comorbid disorder, with the most common diagnoses being anxiety 
disorder (42%), ADHD (28%) and ODD (28%) (Simonoff, Pickles et al. 2008). This study assessed 
psychiatric comorbidity using the CAPA, as is used in the ECHO study, presenting optimal 
opportunities for comparison with findings in this chapter.   
49 
 
ASD may be associated with high levels of psychopathology but there is also the possibility that 
measures of ASD misdiagnose ASD when other psychopathology is present. This is an important 
issue to consider given the high level of psychopathology and comorbidity in 22q11.2DS. Here I 
discuss what other psychopathology is indexed by ASD measures and present evidence of clinical 
presentations where ASD measures have a tendency to misdiagnosis.  
The ADI-R and ADOS diagnostic systems have been highlighted to being prone to identifying 
individuals with ID as having autism (Fombonne 1992).  Though as mentioned before, the ADI-R can 
discriminate ASD from ID better than the SCQ can. In children with ADHD the SCQ has been reported 
to index ADHD clinical severity and cognitive impairment (Cooper, Martin et al. 2014). One study 
reports that the ADI-R and ADOS misdiagnose ASD in children with childhood-onset schizophrenia 
(Reaven, Hepburn et al. 2008). However this may not necessarily represent an issue with the ADI-R 
and ADOS specifically, as there is a debate whether child-onset schizophrenia and ASD 
symptomatology overlap (Sporn, Addington et al. 2004). It has been found that whilst ASD domains 
of communication and reciprocal social interaction discriminate ASD rather well from ADHD and 
anxiety disorder, the repetitive and stereotyped behaviour domain did not (Hartley and Sikora 
2009).  
4.3.4 Studies that have assessed ASD in 22q11.2DS 
First I will recap what was discussed about ASD and 22q11.2DS in Chapter 1 (1.2.3),  
 Reported prevalence of ASD in 22q11.2DS varies considerably (10%-50%)  
 One study that used both an observational measure (ADOS) and a measure of clinical history 
(SCQ) found no individuals met cut-offs for both (Angkustsiri, Goodlin-Jones et al. 2014) 
 One study (which used the ADI-R) reported that the clinical presentation of ASD in 
22q11.2DS is less severe than in children with idiopathic ASD (Kates, Antshel et al. 2007) 
 The well documented male preponderance for ASD is not observed in 22q11.2DS 
 It is argued that prepsychotic phenomena and anxiety are misdiagnosed as ASD in 
22q11.2DS 
There are several noteworthy issues regarding the investigation of ASD in the 22q11.2DS literature. 
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1. Not all studies of psychopathology assess ASD 
Compared to other psychopathology, ASD has been investigated less so in the 22q11.2DS 
literature. In the IBBC study fifteen sites contributed psychopathology data, of which only seven 
assessed ASD. ASD was one of the least investigated disorders in children and adolescents in the 
IBBC study (Schneider, Debbané et al. 2014).  
2. Inconsistency in ASD measures used  
Within the IBBC study, sites administered different measures; the ADI-R and/or ADOS and the 
Mini Psychiatric Assessment Schedules for Adults with Developmental Disabilities (Mini PAS-
ADD) (Schneider, Debbané et al. 2014). One site used the Mini PAS-ADD and reported an 
unusually high prevalence of 80%. Only three sites used the gold-standard combination of ADI-R 
and ADOS.  
Studies based on single cohorts have assessed ASD using the ADI-R (Vorstman, Morcus et al. 
2006, Antshel, Aneja et al. 2007) and the SCQ (Vorstman, Breetvelt et al. 2013, Angkustsiri, 
Goodlin-Jones et al. 2014, Niarchou, Zammit et al. 2014), with one study using the SCQ in 
combination with the ADOS (Angkustsiri, Goodlin-Jones et al. 2014). One study has used the SCQ 
as a screening measure and then the ADI-R for those who screen positively (Fine, Weissman et 
al. 2005). 
3. Ascertainment bias 
Reported prevalence varies even amongst studies that have administered the same measure 
suggesting that ascertainment bias plays a part. See Table 3 for reported using the ADI-R. 
Table 3: ASD and autism prevalence using the ADI-R from previous 22q11.2DS studies 
 
Note Fine, Weissman et al. 2005 used the SCQ as a screener to identify individuals for ADI-R 
assessment.  
Reported prevalence3 is variable for the SCQ. The percentage of 22q11.2DS individuals who 
meet the ASD cut-off of 15 has been reported to be 7% (Angkustsiri, Goodlin-Jones et al. 2014), 
17% (Vorstman, Breetvelt et al. 2013) and 26% (Niarchou, Zammit et al. 2014). As the SCQ is a 
Study ASD Autism
Fine, Weissman et al. 2005 14.3% 11.2%
Vorstman, Morcus et al. 2006 50.0% 33.3%
Antshel, Aneja et al. 2007 41.5% 19.5%
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questionnaire filled in by the parent, differences cannot be attributable to differences in 
interviewer style. The study with the lower prevalence mainly recruits participants by self-
referral via their website whereas the other two recruit mainly via medical genetics clinics.  
4. Issues in interpreting findings 
Studies that have reported very low or very high prevalence have not always been critical in 
their interpretation. The previously mentioned study (Angkustsiri, Goodlin-Jones et al. 2014) that 
reports that no individuals meet criteria for ASD when using both the SCQ and the ADOS makes a 
strong conclusion that ASD is not as common as once thought in 22q11.2DS. However, as 
mentioned in 7.2.3, prevalence of those who meet criteria on the SCQ is lower than in other 
studies suggesting ascertainment bias.  
Another study reported a high ASD prevalence of 50%, however they used relatively relaxed 
criteria for interpreting ADI-R scores by including individuals who met cut-offs on any two 
functional domains (Vorstman, Morcus et al. 2006). The ADI-R has an official algorithm for 
autism that is based on meeting specific cut-offs across all three functional domains (Lord, 
Rutter et al. 1994). There is no official ADI-R algorithm for ASD, however studies which have 
developed ASD criteria have applied stricter criteria compared to Vorstman, Morcus et al, 2006 
(Dawson, Webb et al. 2004, Kaufmann, Cortell et al. 2004, Lainhart, Bigler et al. 2006).  
5. Previous studies have not examined gender difference in ASD rigorously 
Although studies do not report a gender difference in ASD in 22q11.2DS (1.2.3), detailed 
summary statistics are not always provided. Often the p-value is reported but not the male-to-
female ratios (Vorstman, Morcus et al. 2006, Schneider, Debbané et al. 2014), so it is not 
possible to identify if gender has a large effect size, albeit non-significant. There are studies that 
have not formally tested for a gender difference in ASD but inspection of their sample 
demographics indicates male preponderance for ASD (Fine, Weissman et al. 2005, Antshel, Aneja 
et al. 2007). 
No study has examined whether there is a gender difference in ASD symptomatology in 
22q11.2DS. A previous 22q11.2DS study that investigated gender differences in 
psychopathology, which did not focus on ASD, found marked differences on dimensional 
measures which were not reflected by differences in categorical diagnoses (Sobin, Kiley-Brabeck 
et al. 2009). 
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6. Not all studies have investigated comorbidity of ASD with psychopathology 
It has been strongly argued that ASD in 22q11.2DS represents a misdiagnosis of anxiety or 
prepsychotic phenomena, even when measures such as the ADI-R which examine 
developmental history have been used (Eliez 2007).  There is a danger that no matter what ASD 
instrument is used such arguments will continue to be made.  A different perspective that may 
give insight into the debate is to investigate to what extent such psychopathology overlaps and 
whether variation in ASD severity is associated with presence of other psychopathology. One 
study found that ASD symptomatology (as measured by the SCQ) and psychotic symptomatology 
were distinct phenotypic manifestations in 22q11.2DS (Vorstman, Breetvelt et al. 2013). 
An alternative perspective is that ASD rather than being misidentified may be a core feature of 
the neuropsychiatric phenotype in 22q11.2DS. Indeed one study reports that 94% of children 
with 22q11.2DS and ASD had a co-occurring psychiatric disorder, which is higher than the overall 
prevalence of psychiatric disorder in their sample (60%) (Antshel, Aneja et al. 2007). 
The largest study of psychopathology in 22q11.2DS to date, based on the IBBC data, did not 
examine comorbidity of ASD with other psychopathology (Schneider, Debbané et al. 2014). This 
has been previously examined in the cross-sectional ECHO cohort using the SCQ, and ASD 
showed comorbidity with ADHD (41.2%), anxiety (52.4%) and ODD (30.0%) (Niarchou, Zammit et 
al. 2014). However the SCQ is known to index other psychopathology (see section 7.1.3) so it is 
important to confirm these findings using the ADI-R in the ECHO cohort. 
7. ASD prevalence not examined longitudinally 
No longitudinal study of psychopathology in 22q11.2DS has examined ASD symptomatology 
(Gothelf, Eliez et al. 2005, Antshel, Shprintzen et al. 2010, Gothelf, Schneider et al. 2013, Hooper, 
Curtiss et al. 2013). This may be because many semi-structured interviews of psychopathology 
often do not include ASD and therefore ASD assessment requires additional time-consuming 
measures. Also as ASD is a neurodevelopmental disorder it is diagnosed on the basis of 
developmental history, so in a sense once a diagnosis has been made, it is present for life. 
However it is of interest to what extent symptoms continue to present and impact throughout 
the life course. The IBBC study reports ASD prevalence to peak in adolescence perhaps 
suggesting ASD measures are indexing other psychiatric features (Schneider, Debbané et al. 
2014). However, this needs to be explored in longitudinal cohorts. 
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4.4 Aims 
The aims of this chapter are: 
1. Examine the prevalence of psychopathology longitudinally in 22q11.2DS and controls  
2. Describe diagnostic stability and consider diagnostic change at the level of the individual 
3. Examine the prevalence of psychotic experiences longitudinally in 22q11.2DS and controls and 
describe their nature and content 
4. Examine whether psychopathology is associated with psychotic experiences at wave 2 
5. Explore the nature of ASD in 22q11.2DS in depth using the ADI-R 
a) Establish the prevalence of ASD in the ECHO cohort using the ADI-R 
b) Examine inter-method reliability between the SCQ and ADI-R in 22q11.2DS 
c) Examine whether there is a gender difference in the ASD phenotype of 22q11.2DS 
d) Investigate whether ASD indexes comorbidity in 22q11.2DS 
4.5 Methodology 
Sample description and assessment details have been presented in Chapter 3. Psychiatric data was 
available at both time points for 70 children with 22q11.2DS and 29 controls. SCQ data was available 
for 64 children with 22q11.2DS and 26 controls (missing cases due to missing questionnaire data). 
4.5.1 Aim 1: Examine the prevalence of psychopathology longitudinally in 22q11.2DS 
and controls including ASD 
DSM-IV-TR criteria were applied to symptoms elicited from the CAPA. A score of 15 or more on the 
SCQ was used to screen for probable ASD. The category ‘any DSM-IV-TR psychiatric disorder’ did not 
include probable ASD. To investigate whether prevalence of psychiatric disorder changes between 
waves of assessment McNemar’s test (analogous to chi-square but for paired data) was conducted 
separately for 22q11.2DS children and controls. To investigate whether level of comorbidity differs 
across wave of assessment a related-samples Wilcoxon signed rank test was conducted. 
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To further explore longitudinal development of autism domains, change in SCQ total score and 
domain scores were examined. Also items were split into those that assess behaviours at age 4 to 5 
and current behaviour and longitudinal change were examined for these. Correlations were 
calculated for each type of score separately for children with 22q11.2DS and controls. For each tyoe 
of score related samples Wilcoxon signed rank test was conducted to investigate if there was 
significant change over time.  Mann Whitney U test was conducted to investigate whether the 
distribution of change scores differs between children with 22q11.2DS and controls. This analysis 
was conducted for all individuals with an SCQ score at both wave 1 and wave 2. 
It was investigated whether those who met criteria for ‘any DSM-IV-TR psychiatric disorder’ at wave 
1 differed in the following demographics: age using an independent t-test; gender, 22q11.2DS 
inheritance and ethnicity using Fisher’s exact test; household income and maternal education using 
Mann-Whitney U tests. The same analysis was conducted for those who met ASD criteria at wave 1 
on the SCQ, except for gender which will be explored in depth in Aim 5. 
4.5.2 Aim 2: Describe diagnostic stability and consider diagnostic change at the level of 
the individual 
For each diagnosis 22q11.2DS individuals were categorised into the following groups: 
Diagnosis gain - individuals with no diagnosis at wave 1 but a diagnosis at wave 2  
Diagnosis loss - individuals with a diagnosis at wave 1 but not at wave 2 
Diagnosis at both waves - individuals with a diagnosis at wave 1 and wave 2 
No diagnosis at both waves - individuals with no diagnosis at wave 1 and wave 2 
For each diagnosis the following statistics were calculated for children with 22q11.2DS. These 
statistics have been used in idiopathic psychiatric cohorts to examine diagnostic stability (Schwartz, 
Fennig et al. 2000, Baca-Garcia, Perez-Rodriguez et al. 2007).  No 22q11.2DS study has studied 
diagnostic stability using this approach. 
1. Kappa coefficient 
One way of assessing diagnostic stability is by examining agreement between first wave and 
second wave diagnostic status as calculated by the kappa coefficient. This statistic measures 
agreement whilst correcting for the effect of chance. A kappa coefficient ≤0 indicates no 
agreement and a score of 1 indicates perfect agreement. The magnitude of kappa coefficients 
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can be classified, albeit somewhat arbitrarily, with 0.75 as being excellent, 0.40 to 0.75 as fair to 
good, and below 0.40 as poor (Fleiss 1981). 
2. Prospective consistency 
This is the proportion of individuals with a diagnosis at first assessment who had the same 
diagnosis at the second assessment. 
3. Retrospective consistency 
This is the proportion of individuals with a diagnosis at the second assessment who had the 
same diagnosis at the first assessment.  
Prospective and retrospective consistency values can provide insight into the longitudinal course of 
psychiatric disorders. The combination of a high prospective and retrospective consistency indicates 
high stability and low values low stability.  A low prospective consistency indicates low persistence of 
the disorder. A low retrospective consistency indicates emergence of the disorder between waves. 
There are no formal cut-offs for what is low prospective consistency and retrospective consistency, 
however values are relatively intuitive to interpret. A prospective consistency of 50% translates as a 
50% persistence rate and a retrospective consistency of 50% indicates that individuals without 
emerging disorder between assessments account for 50% of those with a diagnosis at second 
assessment.  
4.5.3 Aim 3: Examine the prevalence of psychotic experiences longitudinally in 
22q11.2DS and controls and describe their nature and content 
Vignettes were written for each individual who reported psychotic experiences. McNemar’s test was 
conducted to investigate whether the prevalence of psychotic experience changes across the two 
waves. It was investigated whether those who with psychotic experiences differed in the following 
demographics: age using an independent t-test; gender, 22q11.2DS inheritance and ethnicity using 
Fisher’s exact test; household income and maternal education using Mann-Whitney U tests. 
4.5.4 Aim 4: Examine whether psychopathology is associated with psychotic experiences 
at wave 2 
To investigate whether psychotic experiences were associated with psychopathology at wave 2 
Fisher’s exact test was conducted for each psychiatric disorder. To investigate whether 
psychopathology at wave 1 was associated with the emergence of psychotic experiences at wave 2 
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Fisher’s exact test was conducted and excluded two 22q11.2DS individuals who reported psychotic 
experiences at both waves.  
In addition to the above analyses, the association of psychotic experiences with comorbidity was 
examined using an independent sample Mann-Whitney U test.  
Spearman correlation coefficients were calculated to quantify the magnitude of associations.  
4.5.5 Aim 5: Explore the nature of ASD in 22q11.2DS in depth using the ADI-R 
The ADI-R was completed for 74.3% (52/70) of children with 22q11.2DS and for 69.0% (20/29) of 
controls. Non-participation was due to difficulties scheduling a phone call after the home visit. 
However the participation rate of 74.3% is higher than a previous 22q11.2DS study that also 
telephone administered the ADI-R (45%, 41/87) (Antshel, Aneja et al. 2007). The sub-sample of 
children with 22q11.2DS for which ADI-R data was available is representative of the longitudinal 
cohort in terms of autism symptomatology as the sub-sample did not differ in SCQ score (ADI-R 
present mean SCQ=12.1, ADI-R absent mean SCQ=11.8, independent samples Mann-Whitney U test 
p=0.610). 45.8% (33/72) of ADI-R interviews were double coded. Inter-rater reliability for ADI-R 
subdomain scores was very good (intra-class correlation=0.917). A full description of the autism 
symptomatology assessed by the SCQ and the ADI-R can be found in section 3.2.1. 
4.5.6 Aim 5a: Establish the prevalence of ASD in the ECHO cohort using the ADI-R 
Criteria for autism and ASD were applied to ADI-R scores. The ADI-R manual provides an algorithm 
for autism (described in section 3.2.1); the individual has to meet the cut-off on all three functional 
domains and there has to be evidence of abnormality of development at or before 36 months 
(Rutter, Le Couteur et al. 2003). Official ASD criteria for the ADI-R are not available in the manual, 
but there are recommendations from the literature. The following criteria from a study of ASD in 
children with Fragile X syndrome were used (Kaufmann, Cortell et al. 2004); the individual has to 
meet the cut-off on the reciprocal social interaction domain and at least one other domain, while 
there also has to be evidence of abnormality of development at or before 36 months. ASD and 
autism classifications were not mutually exclusive, in that an individual who met criteria for autism 
also met criteria for ASD. For each individual the frequency of functional domain cut-offs met was 
calculated. Prevalence of autism, ASD and the proportion who met cut-offs for each domain was 
calculated for children with 22q11.2DS and controls. Fisher’s exact test was conducted to investigate 
whether prevalence differed between children with 22q11.2DS and controls. 
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It was investigated whether those who met criteria for ASD on the ADI-R differed in the following 
demographics: age using an independent t-test; 22q11.2DS inheritance and ethnicity using Fisher’s 
exact test; household income and maternal education using Mann-Whitney U tests. 
4.5.7 Aim 5b: Examine inter-method reliability between the SCQ and ADI-R in 22q11.2DS 
Autism and ASD criteria were applied to the SCQ and ADI-R. Prevalence rates were compared using 
Fisher’s exact test. 
Fisher’s exact test was also conducted to investigate whether meeting criteria on the SCQ was 
associated with meeting criteria on the ADI-R. Spearman’s rank correlation was conducted to 
measure the magnitude of association. Sensitivity and specificity values were calculated. Sensitivity 
is the proportion of those who meet criteria on the ADI-R that are correctly identified by the SCQ. 
Specificity is the proportion of those who do not meet criteria on the ADI-R that are correctly 
identified as such by the SCQ.  
Spearman’s rank correlation was conducted between SCQ and ADI-R total scores and domain scores. 
The variance shared between measures was estimated by squaring the rho coefficient.  
SCQ scores from wave 2 were used as the ADI-R was conducted at wave 2. 
4.5.8 Aim 5c: Examine whether there is a gender difference in the ASD phenotype of 
22q11.2DS 
It was investigated whether a gender difference exists in children with 22q11.2DS who met autism 
and ASD criteria on the SCQ and ADI-R. Fisher’s exact test was conducted to test whether meeting 
criteria is associated with gender. Spearman’s rank correlation was conducted to measure the 
magnitude of association. Male-to-female ratios were calculated. 
Gender difference in SCQ and ADI-R total scores was investigated by conducting a Mann Whitney U 
test. 
SCQ scores from wave 2 were used as the ADI-R was conducted at wave 2. Also, so results could be 
compared for the SCQ and ADI-R, analysis was conducted in a subsample which completed both the 
ADI-R and SCQ at wave 2. 
4.5.9 Aim 5d: Investigate whether ASD indexes comorbidity in 22q11.2DS 
Fisher’s exact test was conducted to investigate whether other psychopathology in 22q11.2DS might 
be associated with presence of ASD as measured by SCQ and ADI-R. Spearman’s rank correlation was 
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conducted to measure the magnitude of association. For each type of psychopathology, prevalence 
in those with and without ASD was calculated.  
The level of comorbidity, in terms of number of DSM diagnoses was compared between children 
with 22q11.2DS with and without ASD using a Mann Whitney U test. Also it was investigated 
whether level of comorbidity was correlated with SCQ and ADI-R total score. 
Psychopathology at wave 2 was used in analysis as the ADI-R was conducted at wave 2. Also, so 
results could be compared for the SCQ and ADI-R, analysis was conducted in a subsample which 
completed both the ADI-R and SCQ at wave 2. 
4.6 Results 
4.6.1 Aim 1: Examine the prevalence of psychopathology longitudinally in 22q11.2DS and 
controls including ASD 
At both waves of assessment at least half of children with 22q11.2DS met criteria for one or more 
DSM-IV psychiatric disorders compared to 10% of sibling controls (p<0.001) (Table 4). In relation to 
controls, children with 22q11.2DS exhibited higher rates of ADHD and anxiety disorder, and more 
individuals met the cut-off for probable ASD diagnosis at both waves of assessment. ADHD 
prevalence in children with 22q11.2DS decreased from 38.6% to 21.4% (McNemar’s p=0.004). Within 
anxiety disorders, prevalence of specific (22q11.2DS=18.6%, controls=0.0%, Fisher’s p=0.009) and 
social phobias (22q11.2DS=21.4%, controls=0.0%, Fisher’s p=0.005) were only significantly elevated 
in 22q11.2DS children compared to controls at wave 1 and generalised anxiety disorder 
(22q11.2DS=15.7%, controls=0.0%, Fisher’s p=0.031) only at wave 2. Although to some extent this 
indicates change, significant changes in prevalence were not found for specific and social phobia, 
and generalised anxiety disorder. Significant prevalence change was not found for other psychiatric 
disorders. 
There were three individuals at wave 2 who were receiving psychiatric medication. One individual 
was prescribed diazepam for anxiety and met criteria for specific phobia and GAD at wave 1 and 
wave 2 and social phobia only at wave 1. It is unclear whether medication contributed to this 
change. One individual was prescribed fluoxetine for anxiety and the medication had ameliorated 
their social phobia to the extent they did not meet criteria at wave 2. The parent reported a distinct 
change once the individual was on medication. One individual was on antipsychotic medication to 
control aggressive outbursts. This individual met criteria for ADHD and ODD at both waves of 
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assessment. Medication was not prescribed because of psychotic phenomenology and the individual 
did not report psychotic experiences at either wave of assessment. 
Table 4: DSM-IV-TR psychiatric disorder prevalence in 22q11.2DS and controls 
 
There was a high level of comorbidity (Table 5) and this did not differ across wave of assessment 
(related-samples Wilcoxon signed rank test p=0.065). 
Table 5: Comorbidity in 22q11.2DS and controls 
 
Wave 1 
%(n)
Wave 2 
%(n)
McNemar's 
p-value
Wave 1 
%(n)
Wave 2 
%(n)
McNemar's 
p-value
Wave 1 
Fisher's      
p-value 
Wave 2 
Fisher's     
p-value 
Any DSM-IV-TR Psychiatric Disorder 55.7%(39) 50.0%(35) 0.454 10.3%(3) 10.3%(3) 0.999 <0.001 <0.001
Any Anxiety Disorder 35.7%(25) 27.1%(19) 0.238 0.0%(0) 6.9%(2) 0.500 <0.001 0.030
Agoraphobia 8.6%(6) 10.0%(7) 0.999 0.0%(0) 0.0%(0) - 0.176 0.102
Generalised Anxiety Disorder 8.6%(6) 15.7%(11) 0.125 0.0%(0) 0.0%(0) - 0.176 0.031
OCD 2.9%(2) 0.0%(0) 0.500 0.0%(0) 0.0%(0) - 0.999 -
Panic Disorder 2.9%(2) 2.9%(2) 0.999 0.0%(0) 0.0%(0) - 0.999 0.999
Separation Anxiety Disorder 5.7%(4) 7.1%(5) 0.999 0.0%(0) 0.0%(0) - 0.318 0.318
Specific Phobia 18.6%(13) 10.0%(7) 0.070 0.0%(0) 3.4%(1) 0.999 0.009 0.431
Social Phobia 21.4%(15) 17.1%(12) 0.607 0.0%(0) 3.4%(1) 0.999 0.005 0.101
Any Mood Disorder 2.9%(2) 5.7%(4) 0.625 0.0%(0) 3.4%(1) 0.999 0.999 0.999
Bipolar Disorder 0.0%(0) 0.0%(0) - 0.0%(0) 0.0%(0) - - -
Dysthymic Disorder 2.9%(2) 4.3%(3) 0.999 0.0%(0) 3.4%(1) 0.999 0.999 0.999
Major Depressive Disorder 0.0%(0) 1.4%(1) 0.804 0.0%(0) 0.0%(0) 0.999 - 0.999
ADHD 38.6%(27) 21.4%(15) 0.004 3.4%(1) 3.4%(1) 0.999 <0.001 0.034
Conduct disorder 0.0%(0) 1.4%(1) 0.999 0.0%(0) 0.0%(0) - - 0.999
Oppositional Defiance Disorder 17.1%(12) 14.3%(10) 0.754 3.4%(1) 3.4%(1) 0.999 0.101 0.167
Any Psychotic disorder 0.0%(0) 0.0%(0) - 0.0%(0) 0.0%(0) - - -
Selective Mutism 4.3%(3) 4.3%(3) 0.999 3.4%(1) 0.0%(0) 0.999 0.999 0.553
Tic Disorder 5.7%(4) 2.9%(2) 0.625 0.0%(0) 0.0%(0) 0.999 0.318 0.999
Trichtillomania 0.0%(0) 0.0%(0) - 0.0%(0) 0.0%(0) - - -
ASD screening (SCQ) 29.7%(19) 39.1%(25) 0.070 0.0%(0) 0.0%(0) - <0.001 <0.001
22q11.2DS Controls
Prevalence difference 
22q11.2DS vs Controls
Number of DSM-IV-TR 
Diagnoses
Wave 1 Wave 2 Wave 1 Wave 2
0 44.3%(31) 50.0%(35) 89.7%(26) 89.7%(26)
1 20.0%(14) 18.6%(13) 10.3%(3) 3.4%(1)
2 17.1%(12) 14.3%(10) 0.0%(0) 6.9%(2)
3 4.3%(3) 8.6%(6) 0.0%(0) 0.0%(0)
4 7.1%(5) 4.3%(3) 0.0%(0) 0.0%(0)
≥5 7.1%(5) 4.3%(3) 0.0%(0) 0.0%(0)
22q11.2DS Controls
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The longitudinal development of autism domains was examined using the SCQ. There were strong 
correlations between wave 1 and wave 2 SCQ scores, including individual domain scores (Table 6). 
Children with 22q11.2DS declined in score on Communication (change score=-0.7, p=0.004), 
Restricted, Repetitive and Stereotyped Patterns of Behaviour (change score=-0.4, p=0.018) domains 
and also on items that assess current behaviour. However there was not a significant change in total 
score (change score=-0.8, p=0.311). Controls declined in score on the Repetitive and Stereotyped 
Patterns of Behaviour (change score=-0.4, p=0.025) domain. There was not a significant change in 
22q11.2DS scores relative to controls (see last column Table 6).  
The finding of a stable total score is in contrast to findings in Table 4 where ASD prevalence (using 
the SCQ) shows a slight increase. Scores for these individuals were examined and increases in 
Reciprocal Social Interaction (p=0.001) and Communication (p=0.003) domain scores were observed. 
Also there were score increases for items that assessed current behaviour (p=0.041) and behaviour 
at age 4 to 5 (p<0.001).  
 
61 
 
Table 6: Longitudinal SCQ scores for 22q11.2DS and controls 
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Individuals who met criteria for ‘any DSM-IV-TR psychiatric disorder’ did not differ in terms of age, 
gender, 22q11.2DS inheritance, ethnicity and maternal education but did on average come from 
families with a lower household income. 
Children who met ASD criteria (SCQ) did not differ in terms of age, 22q11.2DS inheritance, ethnicity, 
household income and maternal education.  
No significant gender differences were found for individual psychiatric disorders at either wave of 
assessment.  
 
4.6.2 Aim 2: Describe diagnostic stability and consider diagnostic change at the level of 
the individual 
The stability of psychiatric diagnosis in 22q11.2DS differs amongst disorders (Table 7).  ASD (SCQ) 
had good stability (kappa = 0.726) whereas social phobia (kappa = 0.314) mood disorder (kappa = 
0.307) and tic disorder (kappa = 0.307) had poor stability.  
The presence of any psychiatric disorder had a high prospective consistency, 74.4% of children with 
22q11.2DS with a diagnosis at wave 1 met criteria for a disorder at wave 2. There was also a high 
retrospective consistency, 82.9% of those with a psychiatric disorder at wave 2 met criteria for a 
disorder at wave 1. Overall this indicates high stability.  
Prospective and retrospective consistency values differed across individual disorders. Generalised 
anxiety disorder, selective mutism and ASD had a high prospective consistency indicating high 
persistence across waves. Agoraphobia, panic disorder, separation anxiety disorder, specific and 
social phobias, ADHD, mood disorder, ODD and tic disorder had a prospective consistency of 50% or 
less which indicates relatively low persistence.   
Agoraphobia, generalised anxiety disorder, panic disorder, separation anxiety disorder, social 
phobia, mood disorder and tic disorder had a retrospective consistency of 50% or less indicating that 
emergence of these disorders across waves was contributing to wave 2 prevalence. In contrast 
specific phobia, ADHD, ODD, selective mutism and ASD had a high retrospective consistency 
indicating that the majority of cases at wave 2 met criteria at wave 1 and thus wave 2 rates were not 
mainly due to individuals developing the disorder between waves.  
It is interesting to note the disparity between prospective and retrospective consistency values for 
the presence of any anxiety disorder and the values for individual anxiety disorders.  
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Although the prevalence of any psychiatric disorder remains consistent over time at the level of the 
group in 22q11.2DS (Table 4) there was variation at the level of the individual. 10% of 22q11.2DS 
children did not meet criteria at wave 1 but did at wave 2 and 14.3% did meet criteria at wave 1 but 
did not at wave 2 (Table 7). It is interesting to note that for ADHD and ASD there were individuals 
who gained a diagnosis between waves despite these being neurodevelopmental disorders. These 
individuals did however have high levels of subthreshold symptoms at wave 1, suggesting they just 
failed to meet criteria when they were younger. Two individuals gained an ADHD diagnosis and they 
were both one symptom below the DSM-IV-TR threshold at wave 1. The seven individuals who met 
the ASD cut-off at wave 2 but not wave 1 all had a score between 10 and 14. Of the psychopathology 
assessed, ASD had the highest number of individuals who exhibited a gain between waves of 
assessment.  
Table 7: Diagnostic stability and variability across waves of assessment in 22q11.2DS 
 
 
Kappa 
value
Kappa 
p-value 
Prospective 
consistency
Retrospective 
consistency
Diagnosis at 
both waves 
%(n) 
Diagnosis 
gain    
%(n)
Diagnosis 
loss     
%(n)
No diagnosis 
at both waves 
%(n)
Any DSM-IV-TR Psychiatric Disorder 0.543 <0.001 74.4% 82.9% 41.4%(29) 8.6%(6) 14.3%(10) 35.7%(25)
Any Anxiety Disorder 0.408 <0.001 52.0% 68.4% 18.6%(13) 8.6%(6) 17.1%(12) 55.7%(39)
Agoraphobia 0.407 0.001 50.0% 42.9% 4.3%(3) 5.7%(4) 4.3%(3) 85.7%(60)
Generalised Anxiety Disorder 0.537 <0.001 83.3% 45.5% 7.1%(5) 8.6%(6) 1.4%(1) 82.9%(58)
OCD - - - - 0.0%(0) 0.0%(0) 2.9%(2) 97.1%(68)
Panic Disorder 0.485 <0.001 50.0% 50.0% 1.4%(1) 1.4%(1) 1.4%(1) 95.7%(67)
Separation Anxiety Disorder 0.407 0.001 50.0% 40.0% 2.9%(2) 4.3%(3) 2.9%(2) 90.0%(63)
Specific Phobia 0.540 <0.001 46.2% 85.7% 8.6%(6) 1.4%(1) 10.0%(7) 80.0%(56)
Social Phobia 0.314 0.008 40.0% 50.0% 8.6%(6) 8.6%(6) 12.9%(9) 70.0%(49)
Any Mood Disorder 0.307 0.006 50.0% 25.0% 1.4%(1) 4.3%(3) 1.4%(1) 92.9%(65)
Bipolar Disorder - - - - 0.0%(0) 0.0%(0) 0.0%(0) 100.0%(0)
Dysthymic Disorder 0.379 0.001 50.0% 33.3% 1.4%(1) 2.9%(2) 1.4%(1) 94.3%(66)
Major Depressive Disorder - - - - 0.0%(0) 1.4%(1) 0.0%(0) 98.6%(69)
ADHD 0.474 <0.001 48.1% 81.3% 18.6%(13) 2.9%(2) 20%(14) 58.6%(41)
Conduct disorder - - - - 0.0%(0) 1.4%(1) 0.0%(0) 98.6%(69)
Oppositional Defiance Disorder 0.462 <0.001 50.0% 60.0% 8.6%(6) 5.7%(4) 8.6%(6) 77.1%(54)
Any Psychotic disorder - - - - 0.0%(0) 0.0%(0) 0.0%(0) 100.0%(0)
Selective Mutism 0.652 <0.001 66.7% 66.7% 2.9%(2) 1.4%(1) 1.4%(1) 94.3%(66)
Tic Disorder 0.307 0.006 25.0% 50.0% 1.4%(1) 1.4%(1) 4.3%(3) 92.9%(65)
Trichtillomania - - - - 0.0%(0) 0.0%(0) 0.0%(0) 100.0%(0)
ASD screening (SCQ) 0.726 <0.001 94.7% 72% 28.1%(18) 10.9%(7) 1.6%(1) 59.4%(38)
Diagnostic stability Category of diagnosis change
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4.6.3 Aim 3: Examine the prevalence of psychotic experiences longitudinally in 
22q11.2DS and controls and describe their nature and content 
The prevalence of psychotic experiences increased in 22q11.2DS from 2.9% (n=2) to 21.4% (n=15) 
(McNemar’s p<0.001). Psychotic experiences were present in one control at wave 1 (3.4%) but these 
did not persist at wave 2. Prevalence in 22q11.2DS is elevated compared to controls at wave 2 (χ2 
p=0.005) but not at wave 1 (χ2 p=0.999). There were two 22q11.2DS individuals with psychotic 
experiences at wave 1 which persisted at wave 2, and thirteen individuals where psychotic 
experiences emerged between waves.  
At wave 1 all cases of psychotic experiences were identified by child report. At wave 2, one case was 
identified by parent report, thirteen cases by child report, with only one case where there was both 
child and parent report. Psychotic experiences in 22q11.2DS were reported from age 10 upwards.  
Table 8 describes psychotic experiences identified in children with 22q11.2DS and controls. Table 9 
shows for 22q11.2DS individuals with psychotic experiences the percentage of individuals who 
reported each type of psychotic phenomena. The majority of experiences were hallucinatory, 
particularly auditory and tactile experiences. Other phenomena identified included perceptual 
changes, delusions and abnormalities in thought. 
Children with psychotic experiences did not differ in terms of age, gender, 22q11.2DS inheritance, 
ethnicity, household income and maternal education. 
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Table 8: Psychotic experiences in 22q11.2DS and controls 
 
Table 9: Nature of psychotic experiences in 22q11.2DS 
   
Gender Age Wave 1 parent report Wave 1 child report Age Wave 2  parent report Wave 2 child report
22q11.2DS 1 M 7 - - 10 - Auditory hallucinations
22q11.2DS 2 F 7 - - 10 -
Auditory pseudo-hallucinations, 
tactile halucinations
22q11.2DS 3 F 11 -
Auditory 
hallucinations
13 -
Changed perception of time, 
auditory and tactile 
hallucinations, partial delusion 
of assistance
22q11.2DS 4 F 10 - - 13
Non-specifc verbal 
hallucinations
Auditory hallucinations
22q11.2DS 5 F 14 - - 16
Delusions & delusional 
interpretation
-
22q11.2DS 6 M 8 - - 11 - Jamais vu
22q11.2DS 7 F 12 - - 14 -
Auditory and tactile 
hallucinations
22q11.2DS 8 M 12 - - 15 -
Auditory, olfactory, tactile and 
visual hallucinations
22q11.2DS 9 M 13 - - 16 -
Abnormalities in thought 
processes
22q11.2DS 10 M 11 - - 14 - Auditory hallucinations
22q11.2DS 11 M 12 - Depersonalisation 15 -
Derealisation, 
depersonalisation, tactile 
hallucinations
22q11.2DS 12 M 9 - - 12 -
Partial delusion of grandiose 
ability
22q11.2DS 13 F 11 - - 13 - Tactile hallucinations
22q11.2DS 14 M 12 - - 14 -
Auditory pseudo-hallucinations, 
tactile halucinations
22q11.2DS 15 F 9 - - 12 - Visual hallucinations
Control F 11 -
Visual pseudo-
hallucinations
13 - -
Wave 1 Wave 2
Phenomena %(n)
Hallucinations 73.3%(11)
Auditory 53.3%(8)
Olfactory 6.7%(1)
Tactile 40.0%(6)
Visual 33.3%(5)
Perceptual changes 20.0%(3)
Jamais vu 6.7%(1)
Derealisation 6.7%(1)
Depersonalisation 6.7%(1)
Changed perception of time 6.7%(1)
Delusions 13.3%(2)
Abnormalities in thought 
processes
6.7%(1)
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4.6.4 Aim 4: Examine whether psychopathology is associated with psychotic experiences 
at wave 2 
Psychiatric disorder at wave 1 or wave 2 was not strongly associated with psychotic experiences at 
wave 2 (Table 10). Anxiety disorder has been previously highlighted in the 22q11.2DS literature to 
be a risk factor for the emergence of psychotic experiences; it is therefore worth noting that out of 
the associations examined the presence of anxiety disorder at wave 1 had a relatively higher 
correlation (rho=0.250). However, in absolute terms, the magnitude of correlation was low and 
indicated anxiety disorder at wave 1 only predicts 6.25% of variability in psychotic experiences. Level 
of comorbidity at either wave 1 or wave 2 was not associated with the presence of psychotic 
experiences (independent samples Mann-Whitney U test, wave 1 p=0.205, wave 2 p=0.435). 
67 
 
Table 10: Association between psychiatric disorder and psychotic experiences in 22q11.2DS 
 
  
Rho Fisher's p-value Rho Fisher's p-value
Any DSM IV Psychiatric Disorder 0.192 0.133 0.174 0.244
Any Anxiety Disorder 0.250 0.056 -0.006 0.999
Agoraphobia -0.019 0.999 -0.058 0.999
Generalised Anxiety Disorder -0.019 0.999 0.061 0.691
OCD 0.137 0.348 - -
Panic Disorder -0.085 0.999 -0.090 0.999
Separation Anxiety Disorder 0.037 0.999 0.126 0.290
Specific Phobia 0.144 0.254 -0.058 0.999
Social Phobia 0.192 0.142 -0.053 0.999
Any Mood Disorder -0.085 0.999 0.171 0.199
Bipolar Disorder - - - -
Dysthymic Disorder -0.085 0.999 0.061 0.521
Major Depressive Disorder - - 0.231 0.214
ADHD 0.141 0.346 -0.018 0.999
Conduct disorder - - -0.063 0.999
Oppositional Defiance Disorder -0.029 0.999 0.185 0.205
Any Psychotic disorder - - - -
Selective Mutism 0.260 0.091 0.061 0.521
Tic Disorder 0.037 0.999 -0.090 0.999
Trichotillomania - - - -
ASD screening -0.038 0.999 -0.065 0.765
Wave 2 diagnosis               Wave 1 diagnosis               
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4.6.5 Aim 5a: Establish the prevalence of ASD in the ECHO cohort using the ADI-R 
In 22q11.2DS 44.2% met ASD criteria and 15.4% met autism criteria, as measured by the ADI-R 
(Table 11). No controls met criteria for autism, ASD, or clinical cut-offs on functional domains. ASD 
prevalence was found to be significantly elevated in 22q11.2DS compared to controls (p<0.001) but 
prevalence of autism was not (p=0.096). In 22q11.2DS more individuals met the clinical cut-offs in 
the domains of Reciprocal Social Interaction (51.9%) and Communication (50.0%) compared to the 
Restricted, Repetitive and Stereotyped Patterns of Behaviour domain (23.1%). 92.3% of children with 
22q11.2DS exhibited abnormality in development before the age of 36 months compared to 20% of 
controls (p<0.001). 
Table 11: Prevalence of ASD phenomenology in 22q11.2DS and controls as measured by the ADI-R 
 
63.5% of children with 22q11.2DS met the clinical cut-off for impairment in at least one functional 
domain compared to 0.0% of controls (Table 12). 
Table 12: Number of ADI-R functional domains in 22q11.2DS and controls 
 
22q11.2DS Controls Fishers 
n (22q11.2DS=52, Controls =20) %(n) %(n) p-value
Diagnosis
Autism criteria 15.4%(8) 0.0%(0) 0.096
ASD criteria 44.2%(23) 0.0%(0) <0.001
Proportion who meet domain cut-offs
Reciprocal Social Interaction 51.9%(27) 0.0%(0) <0.001
Communciation 50.0%(26) 0.0%(0) <0.001
Restricted, Repetitive and 
Stereotyped Patterns of Behaviour
23.1%(12) 0.0%(0) 0.029
Abnormaility of Development Evident 
at or Before 36 months
92.3%(48) 20.0%(0) <0.001
0 36.5%(19) 100.0%(20)
1 17.3%(9) 0.0%(0)
2 30.8%(16) 0.0%(0)
3 15.3%(8) 0.0%(0)
Functional 
Domains
22q11.2DS       
%(n)
Controls       
%(n)
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Individuals who met ADI-R ASD criteria did not differ in age, 22q11.2DS inheritance, ethnicity, 
household income and maternal education 
4.6.6 Aim 5b: Examine inter-method reliability between the SCQ and ADI-R in 22q11.2DS 
SCQ and ADI-R data were available for 51 children with 22q11.2DS. Prevalence of ASD using the SCQ 
(41.2%, n=21) and ADI-R (43.1%, n=22) was found to be similar (p=0.999) and so the same was found 
for autism (SCQ, 5.9%, n=3; ADI-R, 13.7%, n=7; p=0.318).  
However, a discrepancy was found between the SCQ and ADI-R in identifying individuals as meeting 
criteria for ASD and autism (Table 13).  
The SCQ ASD cut-off misidentified 6/22 individuals who met ADI-R ASD criteria (Table 13a) and 2/7 
individuals who met ADI-R autism criteria (Table 13c). The SCQ ASD cut-off has 72.7% sensitivity and 
82.8% specificity in identifying those who met ADI-R ASD criteria. Sensitivity is similar (71.4%) but 
specificity is lower (63.6%) for the SCQ ASD cut-off in identifying those who met ADI-R autism 
criteria. Meeting SCQ ASD cut-off was found to be associated with meeting ADI-R SCQ criteria 
(rho=0.558, p<0.001).  
The SCQ autism cut-off did not identify any individuals who met ADI-R autism criteria (Table 13b), 
sensitivity 0.0% and specificity 95.3%. Meeting SCQ autism cut-off was not associated with meeting 
ADI-R autism criteria (rho=-0.100, p<0.999).  
Table 13: Discrepancy between SCQ and ADI-R  
 
a)SCQ ASD vs ADI-R ASD    b)SCQ autism vs ADI-R autism        c)SCQ ASD vs ADI-R autism 
SCQ total score correlated with ADI-R total score (rho=0.695 p<0.001) and was found to be similar to 
the correlation magnitude reported in the idiopathic literature (0.71). Shared variance between SCQ 
and ADI-R total score was 48.3%. Scores for individual domains correlated (Table 14).                           
ASD- ASD+ Autism- Autism+ ASD- ASD+
ASD- 47.1% (24) 9.8% (5) Autism- 80.4% (41) 5.9% (3) Autism- 54.9% (28) 31.4% (16)
ASD+ 11.8% (6) 31.4% (16) Autism+ 13.7% (7) 0.0% (0) Autism+ 3.9% (2) 9.8% (5)
SCQ
A
D
I-
R
SCQ
A
D
I-
R
SCQ
A
D
I-
R
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Table 14: Correlation between SCQ and ADI-R scores in 22q11.2DS 
 
4.6.7 Aim 5c: Examine whether there is a gender difference in the ASD phenotype of 
22q11.2DS 
Prevalence of those who met the SCQ ASD cut-off was greater for males (male-to-female ratio=2.63, 
p=0.021). For SCQ autism, ADI-R autism and ADI-R ASD, although there was a trend for male 
preponderance there was no significant gender difference (Table 15). Analysis included 51 
22q11.2DS individuals with both SCQ and ADI-R scores. 
Table 15: ASD and autism prevalence by gender in 22q11.2DS 
 
On average males had a higher total score on both the SCQ (p=0.017) and the ADI-R (p=0.012) (Table 
16). 
Table 16: SCQ and ADI-R total score by gender in 22q11.2DS 
 
Correlation 
Rho
p-value
Shared 
variance
Total Score 0.695 <0.001 48.3%
Domain score
Reciprocal Social Interaction 0.581 <0.001 33.8%
Communciation 0.614 <0.001 37.7%
Restricted, Repetitive and 
Stereotyped Patterns of Behaviour
0.443 0.001 19.6%
Correlation Fishers
Rho p-value
n 28 23
ADI-R ASD %(n) 53.6%(15) 30.4%(7) 1.76 0.232 0.115
Autism %(n) 21.4%(6) 4.3%(1) 4.92 0.247 0.112
SCQ ASD %(n) 57.1%(16) 21.7%(5) 2.63 0.358 0.021
Autism %(n) 10.7%(3) 3.7%(0) - 0.227 0.227
Male Female
Male-to-
female ratio
Mann-Whitney
Mean SD Mean SD p-value
ADI-R total score 24.5 13.8 15.5 10.4 0.012
SCQ total score 14.1 6.5 9.7 5.9 0.017
Male Female
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4.6.8 Aim 5d: Investigate whether ASD indexes comorbidity in 22q11.2DS 
59.1% of individuals who met ADI-R ASD criteria had a comorbid psychiatric disorder but this did not 
significantly differ from those without ASD (44.8%, p=0.400). The prevalence of comorbid psychiatric 
disorder (59.1%), anxiety disorder (36.4%), ADHD (27.3%) and ODD (18.2%) in children with 
22q11.2DS and ASD (ADI-R) was high and similar to that reported for idiopathic ASD (Simonoff, 
Pickles et al. 2008). However prevalence of psychiatric disorder was also high in those without ASD 
(Table 17).  
Meeting SCQ ASD criteria was found to be associated with the presence of anxiety disorder 
(rho=0.422, p=0.004) whereas meeting ADI-R ASD criteria was not (rho=0.133, p=0.371). No other 
psychopathology measure was associated with SCQ and ADI-R criteria. This analysis included 51 
22q11.2DS individuals who had both SCQ and ADI-R scores. The association between meeting SCQ 
ASD criteria and anxiety disorder was also present at a similar magnitude in the larger sample of 64 
individuals who completed the SCQ (rho=0.425, p=0.001). 
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Table 17: Association between ASD and other psychopathology in 22q11.2DS 
ASD+ = ASD present, ASD- = ASD not present 
 
Those who met SCQ ASD criteria had on average more DSM diagnoses (p=0.034), however this was 
not the case for those who met ADI-R ASD criteria (p=0.186) (Table 18). 
ASD+ (%) ASD- (%) Rho
Fisher's 
p-value
ASD+ (%) ASD- (%) Rho
Fisher's  
p-value
Any DSM IV Psychiatric Disorder 66.7 40.0 0.263 0.089 59.1 44.8 0.141 0.400
Any Anxiety Disorder 52.4 13.3 0.422 0.004 36.4 24.1 0.133 0.371
Agoraphobia 14.3 0.0 0.299 0.064 9.1 3.4 0.119 0.571
Generalised Anxiety Disorder 33.3 10.0 0.289 0.070 27.3 13.8 0.168 0.295
OCD - - - - - - - -
Panic Disorder 9.5 0.0 0.241 0.165 8.3 0.0 0.232 0.181
Separation Anxiety Disorder 14.3 3.3 0.200 0.293 9.1 6.9 0.040 0.999
Specific Phobia 19.0 3.3 0.260 0.146 18.2 3.4 0.245 0.152
Social Phobia 28.6 10.0 0.240 0.136 22.7 13.8 0.116 0.474
Any Mood Disorder 0.0 10.0 -0.209 0.259 9.1 3.4 0.119 0.571
Bipolar Disorder - - - - - - - -
Dysthymic Disorder 0.0 10.0 -0.209 0.259 9.1 3.4 0.119 0.571
Major Depressive Disorder - - - - - - - -
ADHD 33.3 16.7 0.193 0.196 27.3 20.7 0.077 0.741
Conduct disorder 0.0 3.3 -0.118 0.999 0.0 3.4 -0.123 0.999
Oppositional Defiance Disorder 14.3 13.3 0.014 0.999 18.2 10.3 0.113 0.447
Any Psychotic disorder - - - - - - -
Selective Mutism 0.0 6.7 -0.169 0.506 0.0 6.9 -0.176 0.500
Tic Disorder 4.8 0.0 0.169 0.412 4.5 0.0 0.162 0.431
Trichotillomania - - - - - - - -
Psychotic Experiences 19.0 33.3 -0.158 0.346 18.2 34.5 -0.181 0.225
ASD SCQ               ASD ADI-R              
Prevalence of 
psychopathology in
Prevalence of 
psychopathology in
Association Association
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Table 18: Number of DSM diagnoses by ASD status 
ASD+ = ASD present, ASD- = ASD not present 
 
Level of comorbidity was correlated with both ADI-R (p=0.020) and SCQ (p<0.001) total score (Table 
19). SCQ total score indexed a greater proportion of variance in level of comorbidity compared to 
ADI-R total score (SCQ=22.2%, ADI-R=10.6%). 
Table 19: Correlation between number of DSM diagnoses and total score of SCQ and ADI-R 
 
4.7 Vignettes 
REMOVED TO RESPECT PARTICPANT’S PRIVACY 
4.8 Discussion 
This is one of the few longitudinal 22q11.2DS studies to examine a wide range of psychopathology 
including subthreshold psychotic symptoms and ASD symptomatology at both waves of 
assessments. Analysis has focused on characterising diagnostic stability and also change at the level 
of the individual.  
4.8.1 Findings 
1. High burden of psychopathology in 22q11.2DS 
Across waves of assessment (mean age, wave 1=10 years, wave 2=12.5 years) there was a high 
burden of psychopathology in children with 22q11.2DS, with at least 50% meeting criteria for a 
DSM-IV-TR psychiatric disorder, in contrast to 10% of controls. Prevalence in controls is 
consistent to prevalence of psychiatric disorder in large population study of children that used 
the CAPA (13%) (Costello, Mustillo et al. 2003). This replicates previous cross-sectional and 
Mann-Whitney
Mean SD Mean SD p-value
ADI-R 1.6 1.8 0.9 1.2 0.186
SCQ 2.0 1.9 0.8 1.1 0.034
ASD+ ASD-
Number of DSM diagnoses
Correlation 
Rho
p-value
Shared 
variance
ADI-R total score 0.325 0.020 10.6%
SCQ total score 0.471 <0.001 22.2%
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longitudinal studies that report high psychiatric morbidity in 22q11.2DS (Green, Gothelf et al. 
2009, Antshel, Shprintzen et al. 2010, Fung, McEvilly et al. 2010).  Prevalence of ADHD, anxiety 
disorders and ASD (using the SCQ) was robustly elevated in 22q11.2DS in relation to controls. 
Overall psychopathology had high stability across age and level of comorbidity did not change 
with age. 74.4% of those who met criteria for any diagnosis at wave 1 met criteria again at wave 
2. 82.9% of those with any diagnosis at wave 2 had a diagnosis at wave 1. This highlights the 
utility and potential for early, targeted intervention in children with 22q11.2DS and 
psychopathology. 
2. The longitudinal course of individual disorders differs 
i. ADHD prevalence declined in 22q11.2DS 
 
ADHD prevalence declined across adolescence from 38.6% at wave 1 to 21.4% at 
wave 2 in 22q11.2DS whereas prevalence was 3.4% at both waves of assessment in 
controls. ADHD persisted in 13/27 which is a rate of 48.1% which is lower than that 
previously reported for 22q11.2DS (65% from age 11 to 15) (Antshel, Hendricks et al. 
2013) and for idiopathic ADHD (70% from age 9.4 to 14.5) (Langley, Fowler et al. 
2010). This decline was not due to medication as only one child with ADHD was on 
medication, which was prescribed for aggression and did not ameliorate ADHD 
symptomatology. The longitudinal course of ADHD in 22q11.2DS fitted that expected 
of a neurodevelopmental disorder as there was strong retrospective consistency in 
that the majority of those with diagnosis at wave 2 had ADHD at wave 1. Though 
there were two individuals with subthreshold symptomatology at wave 1 who met 
ADHD diagnostic criteria at wave 2. Although perhaps unexpected, this has been 
documented in 22q11.2DS (Antshel, Hendricks et al. 2013) and may indicate that 
ADHD measures index features of the 22q11.2DS that increase during adolescence. 
Alternatively this may reflect measurement error or stochastic fluctuation. 
 
ii. Longitudinal course differed amongst anxiety disorders 
  
In children with 22q11.2DS there was an elevated prevalence of anxiety disorder 
(wave 1=35.7%, wave 2=27.1%) in comparison to controls (wave 1=0.0%, wave 
2=6.9%). There are dynamic changes in anxiety disorders across early adolescence. 
48% of those with an anxiety disorder at wave 1 did not meet criteria at wave 2. 
Although there was low persistence, there was strong retrospective consistency in 
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that of those with an anxiety disorder at wave 2 68.4% previously met criteria at 
wave 1.  
 
Amongst individual anxiety disorders longitudinal course differed. At wave 1, only 
specific phobia and social phobia were elevated in prevalence in relation to controls 
and at wave 2 only generalised anxiety disorder prevalence was elevated. Though, it 
should be noted that these are not large changes in prevalence. These findings 
suggest that the type of anxiety that emerges in the early adolescence of 22q11.2DS 
is more generalised whereas anxiety at younger ages is more specific in nature. This 
replicates a previous study that found phobia prevalence decreases whereas 
generalised anxiety disorder prevalence increases with age (Antshel, Shprintzen et 
al. 2010). There were two individuals on anxiety medication who no longer met 
social phobia criteria at wave 2, so although medication is contributory to change, it 
is by no means fully responsible. 
 
Generalised anxiety disorder had a large prospective consistency but a low 
retrospective consistency suggesting that it is both an emerging as well as a 
persistent disorder in early adolescence.  
 
Specific phobia had the opposite pattern with a low prospective consistency and a 
high retrospective consistency suggesting low persistence, but that the majority of 
those with specific phobia at wave 2 met criteria at wave 1.  
 
Social phobia had low diagnostic stability across with low prospective and 
retrospective consistency values and low diagnostic agreement (kappa=0.314).  
 
Anxiety has been associated with the emergence of psychotic phenomenology in 
22q11.2DS (see sections 2.1.4 and 2.1.5). Given that anxiety disorders differ in 
longitudinal course, future studies should consider the nature of the anxiety that is 
predictive of psychotic phenomenology. 
 
iii. In some 22q11.2DS individuals ASD symptomatology emerged in adolescence  
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ASD prevalence (using the SCQ) is elevated in 22q11.2DS in comparison to controls 
(wave 1=29.7%, wave 2=39.1%). Overall ASD (SCQ) had the highest stability out of 
the psychopathology assessed (kappa=0.726). SCQ total score correlated highly 
between assessment waves (rho=0.817, p<0.311). Although some SCQ domain 
scores declined slightly between assessment waves, there was not decline relative 
to controls. It also had the highest prospective consistency, 94.7% of individuals who 
met the screening cut-off at wave 1 also did so at wave 2.  
 
However in several individuals ASD symptomatology emerged between waves to the 
extent they met the cut-off at wave 2, which is unexpected for a 
neurodevelopmental disorder.  These findings are consistent with the IBBC study, 
which found ASD prevalence peaks in adolescence (Schneider, Debbané et al. 2014). 
This was driven by an increase in score on domains of Reciprocal Social Interaction 
(p=0.001) and Communication (p=0.003). Also there was evidence that severity of 
current behaviour may influence parents’ reporting of past behaviour as increased 
scores were found both on items that asked about current and past behaviours. 
Overall emergence of ASD symptoms in these individuals cannot be attributed to 
age-related change in a specific domain and emergence may reflect measurement 
error.  
 
iv. Prevalence of mood disorder remained low in early adolescence 
 
Prevalence of mood disorder in 22q11.2DS was low (wave 1=2.9%, wave 2=5.7%) 
and was not elevated in relation to controls (wave 1=0.0%, wave 2=3.4%). This is in 
contrast to a previous longitudinal study that reported mood disorder prevalence of 
21 % at wave 1 and 64% at wave 2, though their waves of assessment occurred at an 
older age (wave 1=11.8 years, wave 2=15.0 years) and they used a different measure 
of psychiatric disorder (Antshel, Shprintzen et al. 2010). 
 
v. ODD not elevated in longitudinal cohort 
 
ODD prevalence was not greatly elevated in 22q11.2DS (wave 1=17.1%, wave 
2=14.3%) in relation to controls (wave 1=3.4%, wave 2=3.4%)(p-value, wave 
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1=0.101, wave 2=0.167). This could be due to a lack of power as ODD prevalence 
was found to be significantly elevated (22q11.2DS=18.8%)  compared to controls in a 
study that reported findings from the larger cross-sectional ECHO cohort sample 
(Niarchou, Zammit et al. 2014), despite the reported prevalence being similar 
(17.1%) to that reported in this chapter.  
 
vi. Conduct disorder prevalence was low 
 
Consistent with the IBBC consortium study, there was a low prevalence of conduct 
disorder (Schneider, Debbané et al. 2014). There was only one 22q11.2DS individual 
who met criteria. 
3. Psychotic phenomenology emerges during early adolescence 
This longitudinal study captures the emergence of the first signs of psychotic phenomena in 
22q11.2DS. Prevalence of psychotic experiences increased across waves from 2.9% to 21.4%. 
Only one control reported psychotic experiences. In 22q11.2DS experiences were reported from 
age 10 and were most commonly reported by the child in the absence of parental awareness. 
This highlights the importance of child report, which is lacking in some studies of 22q11.2DS 
(Hooper, Curtiss et al. 2013). Experiences were varied in content with the most commonly 
reported experience being auditory hallucinations. No individuals met criteria for psychotic 
disorder as experiences were transient and generally did not impact on the individual’slevel of 
functioning. This cohort can be seen to capture the premorbid phase of psychosis when 
symptoms are emerging but not yet florid nor greatly impacting. Psychotic experience 
prevalence is lower than in a previous study that used the CAPA interview in an older sample 
(Baker and Skuse 2005). 
The development of subthreshold psychotic phenomenology in 22q11.2DS appears independent 
of other psychopathology as the presence of psychotic experiences at wave 2 was not associated 
with psychopathology at wave 1 or wave 2. The lack of association between ASD and psychotic 
experiences suggests that ASD in 22q11.2DS is not explained by misdiagnosed prepsychotic 
phenomena as argued by some authors (Vorstman, Morcus et al. 2006, Eliez 2007). Findings do 
not replicate previous studies that find anxiety precedes emergence of psychotic phenomena in 
22q11.2DS (Antshel, Shprintzen et al. 2010). These results are not necessarily contradictory as 
these studies have measured prodromal symptoms, which are potentially greater in severity 
than psychotic experiences assessed in the ECHO sample. It may be that early psychopathology 
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plays more of a role in the emergence of more severe psychotic phenomena. In the general 
population there is not always overlap in risk factors for differing severity of psychotic 
phenomena (Zammit, Hamshere et al. 2014). 
4. Prevalence of ASD and autism using the ADI-R 
Using the ADI-R, a gold-standard measure, ASD prevalence was found to be high with 44.2% of 
children with 22q11.2DS meeting criteria for ASD compared to 0.0% of controls. Approximately a 
third of individuals who met ASD criteria also met autism criteria (15.4%).  ASD prevalence was 
found to be in the upper end of the range of previous studies that used the ADI-R and autism 
prevalence at the lower end of the range (see Table 3). There were high rates of subthreshold 
ASD symptomatology with 65.3% of children with 22q11.2DS meeting clinical cut-off for at least 
one autism domain compared to 0.0% of controls. Fewer children with 22q11.2DS met the 
clinical cut-off for Restricted, Repetitive and Stereotyped Patterns of Behaviour domain (23.1%) 
than Reciprocal Social Interaction (51.9%) and Communication (50.0%) domains. 
5. The SCQ and ADI-R measure overlapping but different constructs 
i. Inter method reliability differs for ASD and autism 
 
Prevalence of autism and ASD was similar using the SCQ however the SCQ did not 
identify the same individuals as the ADI-R. 
 
The SCQ is advocated as a screening measure for ASD to help identify those who should 
undergo an in depth assessment such as the ADI-R. An effective screening tool should 
have a high sensitivity and specificity but arguably if screening is followed by a more in 
depth assessment then the main concern is sensitivity - avoiding false negatives. 
Findings suggest the SCQ is not an effective screener in 22q11.2DS.  The SCQ ASD cut-
cut-offoff had a sensitivity of 72.7% for identifying those who met ADI-R ASD criteria, 
which is lower than sensitivity of the SCQ in identifying ASD in the general population 
(96%). The SCQ ASD cut-off misidentified those who met ADI-R autism criteria as well as 
those who met ADI-R ASD criteria. This indicates that the SCQ was not just misidentifying 
individuals whose score was on the borderline of the ADI-R ASD cut-off. 
 
The SCQ and ADI-R were found to capture overlapping but different aspects of the ASD 
phenotype. On one hand their total scores correlated highly (rho=0.695, p=<0.001), 
however this only means 48.3% shared variance between measures leaving over half 
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unexplained. There was no overlap in the SCQ and the ADI-R when higher cut-offs for 
autism were applied, no individual who met the autism cut-off on the SCQ met autism 
criteria on the ADI-R.  
 
ii. The SCQ indexes other psychopathology more than the ADI-R 
 
In idiopathic ASD the presence of comorbid psychiatric disorder is common (Simonoff, 
Pickles et al. 2008) so it would not be unexpected for ASD to be associated with other 
psychopathology, however scoring on the SCQ seems to be more influenced by the 
presence of comorbid psychiatric disorder than is the case for the ADI-R. Meeting SCQ 
ASD criteria was found to be associated with the presence of anxiety disorder 
(rho=0.422, p=0.004) whereas meeting ADI-R ASD criteria was not (rho=0.133, p=0.371). 
22q11.2DS individuals who met SCQ ASD criteria had a greater level of comorbidity than 
those who did not (ASD+=2.0 DSM diagnoses, ASD-=0.8 DSM diagnoses, p=0.034), 
whereas such relationship was not found using the ADI-R (ASD+=1.6 DSM diagnoses, 
ASD-=0.9 DSM diagnoses, p=0.186). When the SCQ and ADI-R were considered 
dimensionally, the total scores of both measures correlated with level of comorbidity 
(SCQ, rho=0.471, p<0.001; ADI-R, rho=0.325, p=0.020). However, the shared variance 
between level of comorbidity and SCQ total score (22.2%) was found to be greater than 
that for ADI-R total score (10.6%). 
 
Overall this suggests that in a population with high level of psychopathology and 
comorbidity, such as 22q11.2DS, the ADI-R maybe a better measure as scoring on the 
ADI-R is relatively more independent of psychiatric disorder compared to the SCQ. The 
fact the SCQ indexes more comorbid psychiatric disorder than the ADI-R may explain 
why there is a discrepancy between the SCQ and ADI-R measures.  
 
Meeting ASD criteria on the ADI-R was found to be independent of the presence of all 
psychiatric disorders and psychotic experiences. Previous authors have argued that 
autism measures in 22q11.2DS are misdiagnosing prepsychotic phenomena and anxiety 
(Eliez 2007, Angkustsiri, Goodlin-Jones et al. 2014). However this chapter has 
demonstrated that this depends on the instrument used with present findings indicating 
that the ADI-R is independent of such psychopathology. 
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6. Gender difference at the symptom level of the autism phenotype 
When ASD is considered in terms of symptomatology a gender difference is observed. At the 
level of categorical diagnosis a gender difference in ASD was observed using the SCQ (male-to-
female ratio 2.63:1) but not the ADI-R, but there was a trend for male preponderance using the 
ADI-R (ASD=1.76:1, autism=4.92:1). This discrepancy could be due to the SCQ indexing other 
psychopathology which may contribute to gender differences, however Chapter 4 did not find 
gender differences in psychiatric disorder in 22q11.2DS. 
Overall findings suggest that a gender difference in ASD in 22q11.2DS is present, albeit less 
pronounced than in idiopathic ASD. ASD male-to-female ratio was 1.76:1 using the ADI-R and 
2.63:1 using the SCQ. These values are less than the male-to-female ratio for ASD in the general 
population (4.3:1) but similar to that in those with ID (2:1) (Newschaffer, Croen et al. 2007). The 
presence of a trend for a male preponderance at the level of categorical diagnosis using the ADI-
R and a difference at the symptom level indicates this study may be underpowered to detect 
gender differences at the level of categorical diagnosis.   
7. Psychiatric comorbidity is prevalent but not specific to ASD in 22q11.2DS 
In children with 22q11.2DS and ASD (ADI-R) there was a high prevalence of comorbid psychiatric 
disorder (59.1%), anxiety disorder (36.4%), ADHD (27.3%) and ODD (18.2%). These values are 
consistent with those reported in a study that assessed comorbid psychiatric disorder in 
idiopathic ASD using the same psychiatric measure as the ECHO study cohort (CAPA) (Simonoff, 
Pickles et al. 2008). However prevalence of psychiatric disorder did not differ greatly from those 
with 22q11.2DS without ASD. This suggests that although ASD and 22q11.2DS is associated with 
high levels of psychiatric disorder, the combination of both is not associated with higher 
prevalence. The similarity in the profile of psychiatric disorder between 22q11.2DS and 
idiopathic ASD suggests neurodevelopmental deviance regardless of aetiology confers risk for 
psychiatric disorder. This is in contrast to the finding that ADI-R total score is correlated with 
level of comorbidity. This is not necessarily contradictory as relationships found at symptom 
level are not always reflected at the level of diagnosis in 22q11.2DS (Sobin, Kiley-Brabeck et al. 
2009). 
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4.8.2 Limitations 
1. No comparison with idiopathic groups 
The lack of an idiopathic psychopathology group meant it was not possible to examine whether 
the 22q11.2DS psychopathology phenotype differs from idiopathic psychopathology . A previous 
22q11.2DS study has found the ASD phenotype in individuals with 22q11.2DS and ASD is less 
severe than in idiopathic ASD (Kates, Antshel et al. 2007).  
2. Factors that may bias prevalence of psychotic experiences  
Not all children with 22q11.2DS may be able to report internal phenomena such as psychotic 
experiences and this may lead to an underestimation in prevalence. Also there may be bias in 
the experiences children with 22q11.2DS are able to report. From my experience children seem 
to understand the questions regarding hallucinations more so than those on delusions. In one 
case the parent reported that the child experienced delusional thinking but the child did not 
have insight. Also as mentioned in Chapter 3, the longitudinal cohort is underrepresented in 
terms of those who reported psychotic experiences at wave 1 so prevalence at wave 2 is likely to 
be an underestimate.    
3. No external criterion of ASD 
In analysis it has been assumed that the ADI-R is a better measure of ASD than the SCQ. To some 
extent this is a safe assumption to make. The ADI-R is semi-structured interview that is 
investigator driven whereas the SCQ is a parent report questionnaire. The creators of the SCQ 
and ADI-R state that the SCQ is not appropriate for individual diagnoses, whereas the ADI-R is 
(Berument, Rutter et al. 1999). However it cannot necessarily be assumed that this is the case 
for 22q11.2DS. There could be ADI-R items which are biased in the context of 22q11.2DS. It 
would be ideal if the SCQ and ADI-R could be compared to expert clinician diagnosis. From my 
experience many children with 22q11.2DS do not receive a formal diagnosis of ASD from 
clinicians. However much cannot be interpreted from this as many parents anecdotally report 
reluctance of clinicians to diagnose neurodevelopmental disorders in the context of 22q11.2DS. 
4. No observational measure of ASD 
The gold standard of ASD assessment is to use the ADI-R to assess developmental history and to 
use the ADOS which is an observational measure (Charman and Baird 2002, Johnson and Myers 
2007). The use of the ADOS in combination with the ADI-R in the ECHO study sample may 
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identify fewer individuals as meeting criteria for ASD and autism compared to the ADI-R alone. 
Therefore prevalence rates reported in this chapter are likely to be an overestimate. 
5. ADI-R was completed at wave 2 
The ADI-R was introduced into the ECHO study assessment protocol at wave 2. However ideally 
it would have been more reliable if administered at wave 1 as it would not require the parent to 
remember as far back.  
6. Power 
The sample size, although large for 22q11.2DS studies, may be underpowered to detect more 
subtle trends. Indeed for specific phobia, social phobia and generalised anxiety disorder 
prevalence is differentially elevated at waves, which would indicate change in prevalence. 
However when change was directly tested for with McNemar’s test, p-values were above the 
0.05 threshold.  
7. Issues of multiple comparisons 
Analysis should be considered exploratory as analysis was not adjusted for multiple 
comparisons. This increases the risk of type 1 errors occurring, whereby the null hypothesis is 
incorrectly rejected.  For instance when investigating change in psychopathology prevalence, 
there was not a correction for the number of psychopathology categories investigated. Whilst 
this is an important issue it should also be considered in the context of 22q11.2DS as a rare 
disorder which limits sample size and thus power. 
8. Ascertainment bias 
Children with 22q11.2DS referred for medical genetic testing will probably be more likely to have 
neurodevelopmental disorder or developmental delay than children with 22q11.2DS who remain 
untested. This means prevalence rates reported in this chapter are likely to be an overestimate. 
9. Categorical diagnosis 
The use of categorical diagnosis reduces variation in psychopathology to a binary variable. This 
reduction in variation reduces the power to detect change in psychopathology.  On the other 
hand categorical diagnoses provide a way to distinguish whether a change in an individual’s 
psychopathology has reached clinically impacting levels.  
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4.8.3 Future work 
1. Approaches based on symptom counts and dimensional measures 
This chapter has examined psychopathology at the level of psychiatric disorder and has not 
focused on symptoms in depth. Future work could examine the longitudinal course of the 
22q11.2DS symptom profile to understand what underlies changes in diagnosis.  
In the future dimensional measures which cross traditional diagnostic boundaries could be used 
to examine longitudinal psychopathology continuously rather than categorically. 
2. Further waves of assessment 
A third wave of assessment would allow the next stage of development to be examined in the 
ECHO 22q11.2DS cohort and this is now underway. Also the use of a prodromal measure to 
capture phenomenology between the severity of psychotic experiences and psychotic disorder 
will be crucial as the cohort enters the risk period of psychosis development and this has been 
incorporated into the ECHO study wave 3 assessments. 
3. Contrast neuropsychiatric phenotype of 22q11.2DS to that of other psychiatric-risk CNVs 
The neuropsychiatric phenotype of 22q11.2DS could be contrasted to the phenotype of other 
psychiatric risk CNVs. At 22q11.2 there is a mirror phenotype for schizophrenia risk, with 
22q11.2 deletion conferring risk and 22q11.2 duplication being protective of schizophrenia 
(Rees, Kirov et al. 2014). Both 22q11.2 deletion and duplication have elevated prevalence in 
developmental disorder cohorts (Malhotra and Sebat 2012), but it would be interesting to 
investigate whether the nature of the neuropsychiatric phenotype differs in duplication carriers. 
 
4.8.4 Conclusions 
Schizophrenia has been associated with early psychopathology in the general population but a lot 
remains unknown. 22q11.2DS provides a rare opportunity to examine the early psychopathology 
that precedes psychosis development. Previous longitudinal studies of children with 22q11.2DS 
report high psychiatric morbidity. This chapter aimed to examine psychiatric disorder, psychotic 
phenomenology and ASD symptomatology concurrently and longitudinally. Particular consideration 
was given to diagnostic stability and change at the level of the individual. 
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22q11.2DS is one of the strongest genetic risk factors for schizophrenia and findings from this 
chapter confirm that genetic risk for schizophrenia is also associated with significant psychiatric 
morbidity before adulthood. This overlap in risk brings into question the utility of current diagnostic 
criteria and suggests that at least some of the genetic risk for schizophrenia may be non-specific at 
the level of diagnosis. ADHD, ASD and anxiety disorders were found to be particularly elevated in 
22q11.2DS.  
There does not appear to be a core neuropsychiatric deficit in 22q11.2DS, as different disorders 
were found to have their own distinct longitudinal course, with differing stability and persistence. 
Across early adolescence psychotic phenomena emerged whereas ADHD declined and within anxiety 
disorders there was considerable variation. There were individuals who unexpectedly gained 
diagnoses of neurodevelopmental disorders, suggesting diagnoses may be indexing psychopathology 
that is not neurodevelopmental. The emergence of psychotic experiences in 22q11.2DS was striking 
and was found to be independent of other psychopathology.  
Previous 22q11.2DS study investigators have argued that autism measures are simply indexing other 
features of 22q11.2DS and this is leading to misdiagnosis.  Findings in this chapter suggest the ADI-R 
is comparatively more independent of other psychopathology compared to the SCQ. This highlights 
that 22q11.2DS confers risk for ASD as well as schizophrenia and provides evidence against Crespi 
and Badcock’s proposal that autism and psychosis are reciprocal disorders (Crespi and Badcock 2008, 
Crespi, Summers et al. 2009). However the finding that in children with 22q11.2DS ASD was not 
associated with psychotic experiences indicates that within 22q11.2DS these are distinct phenotypic 
manifestations. The presence of ASD in 22q11.2DS has been greatly debated in 22q11.2DS and there 
should be caution when assessing ASD in 22q11.2DS, given its complex clinical presentation. 
However, given the findings in this chapter, ASD should be considered by clinicians who support 
individuals with 22q11.2DS. 
The neuropsychiatric phenotype in 22q11.2DS is complex. The next chapter will examine 
development further by considering cognition. 
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5. Cognitive development in 22q11.2DS 
This chapter aims to examine cognitive development in 22q11.2DS.  Characterising cognitive 
trajectories associated with 22q11.2DS provides an opportunity to uncover endophenotypes 
associated with psychiatric risk. First I will introduce general issues relating to the consideration of 
cognitive change. Then I will review cognitive development associated with psychiatric disorder and I 
will critically assess findings from the 22q11.2DS literature. Finally I will investigate cognitive 
development within the longitudinal 22q11.2DS ECHO cohort. 
5.1 Capturing cognitive development  
Behaviour is not a static construct; rather it is dynamic and can be highly variable between and 
within individuals. First I describe cognitive development in the typical population. Then I discuss the 
factors that influence variation within individuals when they undergo serial cognitive assessment 
and the issues that should be considered in longitudinal studies of cognition. I hope to highlight the 
unique consideration that has to be given to variables derived from test-retest situations. 
5.1.1 Cognitive development is relatively stable in the general population 
An individual’s performance may fluctuate depending on their sharpness of mind and concentration 
that day, but generally measures of intelligence have long-term stability (Mackintosh 2011). The 
correlation between childhood IQ and IQ at age 40 is over 0.70 (McCall 1977) and the correlation of 
childhood IQ with IQ at age 77 is 0.73 (Deary, Whalley et al. 2000). Measures of executive function, 
attention and processing speed also show stability across childhood and adolescence, albeit modest 
in magnitude (Kail and Miller 2006, Polderman, Posthuma et al. 2007, Harms, Zayas et al. 2014).  
Stability does not necessarily mean cognitive performance remains constant. IQ is standardised by 
ranking an individual’s ability in relation to others the same age in the typical population. The 
distinction between absolute ability and age-adjusted ability is important. Absolute ability refers to 
the raw score on a test, i.e. the number of actual marks received. Age-adjusted ability takes account 
of the individual’s performance relative to their age group and allows comparability of ability across 
ages.  
Absolute intellectual ability changes across the life course with an increase in childhood and decline 
in old age, which is driven by changes in processing speed and executive function (Mackintosh 2011). 
It is proposed that increased processing speed triggers a developmental cascade whereby working 
memory capacity is enhanced which in turn leads to greater intelligence (Fry and Hale 1996). In old 
age, prevalence of white matter lesions in the brain is correlated with decline in processing speed, 
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though this is not necessarily causal of decline in intelligence (Rabbitt, Scott et al. 2007). Growth in 
executive function is associated with brain maturation during childhood and adolescence, 
particularly in the prefrontal cortex (Gogtay, Giedd et al. 2004) and in old age decline is accompanied 
by a reduction in prefrontal cortex volume (West 1996, Raz 2000).  
Overall, absolute cognitive ability changes across the lifespan and is driven by many dynamic 
processes but an individual’s age-adjusted ranking remains relatively stable.  
5.1.2 Factors affecting test-retest cognitive performance 
Given the general stability of cognition one would expect the cognitive performance of a typical 
individual to be the same at initial testing and at retest. However, in reality there are numerous 
factors affecting an individual’s test-retest performance. 
1. Variable of interest 
Within research and clinical settings there are many variables that potentially cause cognitive 
change such as surgery, medical intervention and disease progression (Lineweaver and Chelune 
2003). In this chapter the variable of interest is disease progression in 22q11.2DS. Ability to 
attribute meaningful change to 22q11.2DS will depend on being able to separate out effects 
associated with 22q11.2DS from other factors. 
2. Statistical Errors 
Test-retest scores have unique statistical properties that have to be considered when 
interpreting findings. 
i. Measurement Error  
 
Cognitive measures are imperfect and test scores will represent both the underlying 
cognitive construct as well as measurement error. If a measure is less reliable, retest 
scores are more likely to deviate from the true value. This is an important 
consideration when interpreting change scores as they are influenced by the 
measurement error present at both test and retest assessments (Lineweaver and 
Chelune 2003). 
 
ii. Regression to the Mean  
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This concept, referred to by Galton as “reversion to mediocrity” (Galton 1886) is a 
bias whereby direction of change is related to baseline ability. That is, an individual 
scoring highly at baseline is more likely to perform worse at retest and conversely an 
individual with a low score at baseline is more likely to improve at retest. This 
relationship is not causal, rather it occurs by chance. In a hypothetical situation 
where an individual’s performance is based purely on chance the probability of a 
baseline score above the population mean is 0.5 and below the mean is 0.5. Baseline 
scores would be normally distributed around the mean. If an individual’s baseline 
score deviates from the group mean then at retest the probability of a score higher 
or lower than baseline score will not be 0.5. Clinically this could lead to false 
conclusions, for example a patient undergoing rehabilitation could appear to 
improve simply due to the effects of regression to the mean. Regression to the mean 
should be considered when interpreting observed change in research studies 
(Barnett, van der Pols et al. 2005).  
 
The magnitude of the effect of regression to the mean is dependent on two factors. 
One factor is the reliability (test-retest correlation) of the cognitive measure, 
whereby highly reliable measures are less susceptible to the effects of regression to 
the mean.  The other factor is the magnitude of deviation at baseline ability from the 
population mean. The greater the deviation the greater the chance that retest 
performance regresses to the mean (Lineweaver and Chelune 2003).  
 
To control for the effects of regression to the mean many studies control for 
baseline ability, however this introduces bias due to mathematical coupling. This 
occurs when variables which are mathematically related are included in the same 
regression model. This violates one of the assumptions of the null hypothesis that 
variables are not correlated (Tu and Gilthorpe 2012).   
3. Natural individual differences in test-retest change scores  
Cognitive ability is relatively stable and within a group of individuals one would expect the 
average test-retest change to be minimal. However, strong correlations over time disguise 
considerable individual differences. For instance a correlation coefficient of 0.7, indicating high 
stability, still leaves over 50% of variation unexplained. Considerable variation in cognitive 
development has been reported in adolescents from the typical population with changes ranging 
from -18 to +21 IQ points over a 3.5 year time gap. The same study found IQ change score 
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correlates with structural brain changes occurring during adolescence, suggesting IQ change has 
construct validity and does not simply represent only measurement error (Ramsden, Richardson 
et al. 2011).  
4. Practice effects 
A common form of bias is a positive practice effect whereby performance is enhanced because 
of previous exposure to the testing materials or situation. For some tasks practice effects are 
expected, for instance the average test-retest change for the Wechsler Memory Scale-III (WMS-
III) General Memory Index is 12.15 points (Wechsler 1997). This effect has been attributed to 
explicit memory for test content, procedural learning of task completion and development of 
effective strategies (Benedict and Zgaljardic 1998). Other factors may also play a role such as 
familiarity with the testing procedure, environment and examiner. Conversely an unpleasant 
experience at initial testing may heighten anxiety at retest and dampen a potential practice 
effect (Lineweaver and Chelune 2003).  
A common misconception is that practice effects can be diminished by using an alternative 
measure of the same construct. Whilst some carefully designed alternative forms dampen 
content-specific practice effects (Benedict and Zgaljardic 1998), they do not control for 
procedural learning or familiarity with testing environment and significant practice effects are 
still reported (Goldstein, Materson et al. 1990, Benton, Hamsher et al. 1994, Franzen, Paul et al. 
1996, Ruff, Light et al. 1996). Alternative forms also introduce other issues such as lower 
reliability as the test-retest correlation of a single measure will be higher than the correlation 
between two different measures. This makes the interpretation of test-retest change scores 
more difficult (Lineweaver and Chelune 2003). 
5. Test-retest time gap  
The longer the time gap the less test-retest change is expected due to practice effects. Practice 
effects diminish after 1 year for verbal tasks and 1-2 years for spatial tasks (Rapport, Brines et al. 
1997, Canivez and Watkins 1998, McCaffrey, Duff et al. 2000, Canivez and Watkins 2001, 
Wechsler and Hsiao-pin 2011).  
6. Flynn effect 
The Flynn effect is a well-documented cohort effect whereby performance on IQ tests by 
modern cohorts is higher than cohorts from previous generations (Flynn 1984, Flynn 1987, Flynn 
2007).  IQ performance in a modern cohort will be greater for an old test than a current one. A 
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recent meta-analysis examined IQ performance across over 100 years from 271 studies and 
reported an annual increase of 0.28 Full Scale IQ points (Pietschnig and Voracek 2015). This 
differs across domains with greater effects for fluid and spatial intelligence than crystallized 
intelligence (0.41, 0.30, 0.21 IQ points annually, respectively). It is important to emphasise that 
this is a cohort effect which is not the same as IQ increasing with age within individuals. 
Suspected causes of generational gains in IQ are manifold and include current generations being 
more accustomed to testing, demographic changes, improvement in nutrition and health and 
changes in education. It has been pointed out that this does not necessarily mean older 
generations were less intelligent, but rather the nature of intelligence differed from that 
captured by IQ tests (Mackintosh 2011). 
The Flynn effect has consequences for longitudinal studies that use the same measures over 
time. It is not that the IQ test has become inappropriate, but rather that the normative sample 
has. Normative samples are used to standardise raw performance into an age-adjusted IQ score 
and although they include a wide range of ages the sample is cross-sectional rather than 
longitudinal. The norms calculated are generation specific, therefore at retest the normative 
sample will be outdated and IQ performance will be an overestimate (Hiscock 2007). 
Revised versions of IQ tests are released partly to overcome the Flynn effect. It is debatable 
whether longitudinal studies should use new standardised measures as they become available. 
Administering the same test across time points could lead to overestimation at later time points. 
Also the Flynn effect differentially affects IQ domains, making it difficult to interpret longitudinal 
change within domains (Hiscock 2007). However, as discussed before for practice effects, 
changing measures decreases reliability. One possible solution is to have a control group to see if 
change is specific to the group of interest, though the nature of the Flynn effect may differ 
between groups. The Flynn effect is a gradual effect so will particularly impact those studies with 
larger time gaps.  
7. Demographic factors 
Demographic factors impact on test-retest change. Age has an effect, even though cognitive 
tests adjust for age. This does not necessarily control for the effect of age on the benefit from 
practice. In children a positive maturational effect is reported and in the elderly there is a 
negative effect for test-retest change. Education level, gender and ethnicity also systematically 
influence test-retest scores (Lineweaver and Chelune 2003). Baseline performance has an effect 
with those with higher overall ability benefitting more from practice (Rapport, Axelrod et al. 
1997, Rapport, Brines et al. 1997).  
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8. Extraneous variables 
Differences in test administration and testing environment at time points may have an effect. 
For instance time of day affects performance in executive function and processing speed with 
college students having optimal performance in the afternoon and evening (Allen, Grabbe et al. 
2008). Group rather than individual assessment has a negative effect (Moser, Schatz et al. 2011). 
It is important that studies control for these factors. 
9. Random effects 
There will naturally be stochastic error and random, uncontrolled events that influence test-
retest performance. 
There are many factors that influence test-retest performance. Change scores have unique 
properties which warrant specific statistical considerations. This highlights the need for specific 
longitudinal methodology that critically and reliably distinguishes true change attributable to the 
variable of interest from other potential sources. 
5.1.3 Longitudinal methodology considerations 
Here I summarise issues of study design, statistical analysis and interpretation that should be 
considered when examining cognitive change. 
1. Having a control group 
Many of the factors discussed above, such as practice effects and extraneous variables, can be 
controlled for by having an appropriate control group. This allows change due to the variable of 
interest to be distinguished from change due to the study methodology (provided this is kept the 
same for the two groups). However it should be noted that factors such as a practice effect may 
differ between the group of interest and the control group. 
2. Minimising potential extraneous variables 
Controlling extraneous variables across time points minimises the impact on change scores. It is 
important that there is consistency of the testing environment and protocol across time points. 
3. The reliability of the cognitive measure 
The reliability of a change score is dependent on the magnitude of the test-retest correlation of 
the cognitive measure. Change scores from cognitive measures with a high coefficient are 
considered more reliable as the proportion of variance that represents the underlying cognitive 
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construct is high and noise is reduced (Lineweaver and Chelune 2003). Test-retest correlation 
coefficients for cognitive measures are often available in the test manual. On the other hand, a 
very high correlation across time indicates rank stability, reduced individual differences and so in 
fact change scores could still be unreliable (Rogosa, Brandt et al. 1982).   
4. Utilising the same measures across time points 
The use of different versions of a cognitive test across time points decreases the reliability of the 
cognitive construct being measured. Though if the same measure is used, one should be wary of 
practice effects and the Flynn effect. 
5. Change scores alone are not sufficient for examining true change 
Change scores although simple to calculate, are related to many systematic biases. They do not 
necessarily represent true change and researchers are recommended to use other procedures to 
critically examine change (Cronbach and Furby 1970, Rogosa, Brandt et al. 1982, Lineweaver and 
Chelune 2003).  Later in this chapter I will discuss approaches which help to capture true change 
and take account of statistical error. 
6. Ecological validity 
It is important to emphasise that if cognitive change is shown to have statistical validity this does 
not necessarily correspond to ecological validity. Change identified as being reliable may or may 
not correspond to functional or clinical outcomes (Lineweaver and Chelune 2003).  
5.2 Cognitive trajectories associated with psychiatric disorder 
As previously mentioned 22q11.2DS offers an opportunity to investigate cognitive development 
associated with psychiatric risk. In this section I discuss what is currently known about cognitive 
development in idiopathic psychiatric disorder. Within 22q11.2DS research there has been a 
particular focus on the cognitive pathways to schizophrenia, so first I will cover cognitive 
development associated with schizophrenia and then briefly cover other psychiatric disorders. 
Finally I explore to what extent genetic risk for psychiatric disorder is associated with cognitive 
deficits.  
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5.2.1 Cognitive development in idiopathic schizophrenia 
1. Cognitive impairment is a core feature of schizophrenia 
Neuropsychological deficits are observed in the majority of schizophrenia patients (Goldberg, 
Ragland et al. 1990, Palmer, Heaton et al. 1997, Kremen, Seidman et al. 2000, Keefe, Eesley et al. 
2005). Cognitive impairment is considered a core feature which impacts functional outcome and 
is not simply an artefact of medication or a secondary consequence of illness progression 
(Elvevag and Goldberg 2000, Kremen, Seidman et al. 2000). Cognitive impairment is persistent 
and enduring as it is present when psychotic phenomenology remits and is not ameliorated by 
current antipsychotic medications (Reichenberg and Harvey 2007). It has been suggested that 
cognitive impairment rather than psychotic phenomenology underlies variability in functional 
outcome and schizophrenia recovery (Elvevag and Goldberg 2000).  
Impairment is observed across a range of domains with patients exhibiting approximately a one 
standard deviation deficit in attention, processing speed, working and episodic memory, 
executive function and social cognition (Fioravanti, Carlone et al. 2005). Deficits in language and 
perceptual processes are present but are comparatively smaller in magnitude (Reichenberg and 
Harvey 2007).  
2. Cognitive impairments are premorbid 
Cognitive impairment in adult schizophrenia is the result of cognitive decline associated with 
schizophrenia onset, but pre-existing deficits also contribute (Woodberry, Giuliano et al. 2008). 
When examining cognitive performance over time, the differentiation between a static deficit 
versus decline in age-adjusted cognitive ability is important. The former refers to no change 
from the individual’s base level and the latter to a relative decline. Currently it is uncertain 
whether premorbid deficits are static or decline with age. Several studies find no evidence for 
cognitive decline relative to comparison samples (Lane and Albee 1968, Watt and Lubensky 
1976, Jones, Murray et al. 1994, Ott, Spinelli et al. 1998, Cannon, Bearden et al. 2000, Cannon, 
Caspi et al. 2002), but not all (Reichenberg, Caspi et al. 2010).  
Hypotheses for the developmental course of premorbid deficits have been suggested and are 
illustrated in Figure 1. Static deficits characterise the developmental deficit hypothesis 
(Weinberger 1987), whereby impaired cognition manifests early in development but remains 
stable with age. Decline in age-adjusted scores could be underpinned by either the 
developmental deterioration hypothesis or the developmental lag hypothesis and can only be 
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distinguished by examining raw scores of cognitive ability (see section 5.5.3). The developmental 
deterioration hypothesis (Jones and Done 1997, Fuller, Nopoulos et al. 2002, Reichenberg, 
Weiser et al. 2005, Bilder, Reiter et al. 2006) predicts decline in raw cognitive ability whereas the 
developmental lag hypothesis (Fish, Marcus et al. 1992, Bedwell, Keller et al. 1999, Wood, De 
Luca et al. 2004) predicts growth in raw cognitive ability, but growth that lags behind the rate of 
the general population resulting in a decline in age-adjusted score. Conceptualising the 
developmental nature of cognitive deficits in this way may give insight into the aetiology of 
schizophrenia. For example if cognitive development follows the developmental deficit 
hypothesis this could indicate early atypical brain development whereas the developmental 
deterioration hypothesis may indicate neurodegeneration. 
Figure 1: Schematic representation of three hypotheses of the developmental course of premorbid 
deficits in schizophrenia from (Reichenberg, Caspi et al. 2010) 
Reprinted with permission from The American Journal of Psychiatry (Copyright ©2010). American Psychiatric 
Association 
 
The green line represents healthy comparison subjects and the red line represents children who later develop 
schizophrenia.  
3. Developmental nature may differ by domain 
Few studies have examined a range of domains and instead most have focused on global 
cognitive measures such as IQ. Findings from the Dunedin longitudinal birth cohort study 
suggest developmental trajectory varies across cognitive domains (Reichenberg, Caspi et al. 
2010). These authors report developmental deficits for verbal tasks and developmental lags in 
nonverbal cognitive domains (processing speed, attention, visual-spatial problem solving ability 
and working memory) in children who would later develop schizophrenia. There was no 
evidence of cognitive deterioration. They conclude that both an early static neuropathology and 
a later developmental lag contribute to the development of schizophrenia.  
Cross-sectional studies report greater nonverbal deficits than verbal deficits in childhood, 
though this difference seems to be driven by a discrepancy in the comparison group rather than 
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a true discrepancy in children who later develop schizophrenia (Ott, Spinelli et al. 1998, 
Amminger, Schlogelhofer et al. 2000, Sørensen, Mortensen et al. 2006). A meta-analysis reports 
no overall difference in the magnitude of verbal and nonverbal deficits (Woodberry, Giuliano et 
al. 2008). It is important to note that these findings are cross-sectional so do not necessarily 
conflict with the longitudinal findings of the Dunedin study. 
4. Development in different domains is related  
The development of cognitive domains does not appear to be entirely independent. The 
Dunedin study found that children who exhibit verbal developmental deficits are more likely to 
have non-verbal developmental lags (Reichenberg, Caspi et al. 2010).  
5. Specificity of deficits to schizophrenia 
An important question is whether premorbid cognitive impairments are specific to schizophrenia 
or are common to other psychiatric disorders. Deficits in global cognition (IQ) appear nonspecific 
as they have been linked to increased risk of many psychiatric disorders, particularly depression 
(van Os, Jones et al. 1997, Zammit, Allebeck et al. 2004, Gale, Deary et al. 2008, Koenen, Moffitt 
et al. 2009). However, the pattern of deficits across cognitive domains reported in the Dunedin 
study is specific to schizophrenia and is not observed in children who later develop depression 
(Reichenberg, Caspi et al. 2010).     
6. The importance of having a suitable comparison group 
A comparison group is important for critically examining cognitive change, especially for 
distinguishing the nature of cognitive development in terms of the hypotheses described earlier. 
There are longitudinal studies in the schizophrenia literature where interpretation has been 
altered by the comparison group. Two studies report cognitive decline in individuals who later 
develop schizophrenia but the rate of decline was similar to that in controls (Watt and Lubensky 
1976, Jones, Murray et al. 1994). 
The nature of the comparison group is an important consideration. A study by Lane and Albee of 
the educational records of schizophrenia inpatients initially found cognitive decline in the 
schizophrenia group but not in other children within the same school system (Lane and Albee 
1963). 5 years later the authors re-examined the data due to concerns that the groups were not 
socioeconomically matched. They reported cognitive decline was non-specific to the 
schizophrenia group as it was present in siblings of the schizophrenia group and in controls 
matched for school and IQ (Lane and Albee 1968). Additionally, when cognitive measures were 
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standardised in a larger group of controls cognitive decline was not present in the schizophrenia 
group or in any of the control groups.  
5.2.2 Cognitive development in other psychiatric disorders 
1. Mood disorder 
Low premorbid IQ is a risk factor for depression (Zammit, Allebeck et al. 2004) and longitudinal 
findings from the Dunedin cohort suggest developmental deficits across several domains and a 
slight developmental lag in arithmetic in those who later develop depression (Reichenberg, Caspi 
et al. 2010), albeit a smaller effect size in comparison to those who develop schizophrenia. 
Aetiology may differ amongst mood disorders as premorbid deficits in IQ are associated with 
development of depression but not bipolar disorder (Zammit, Allebeck et al. 2004). For bipolar 
disorder there is indication that those with excellent academic achievement are at greater risk of 
developing the disorder (MacCabe, Lambe et al. 2010). Furthermore, individuals with bipolar 
disorder are overrepresented in creative professions whereas those with depression do not 
differ from controls (Kyaga, Lichtenstein et al. 2011).  
2. Anxiety Disorders 
There have been relatively fewer high-risk studies of anxiety. One study found however, that 
children who are at high risk of anxiety due to having an affected sibling are reported to have 
deficits in paired associative learning but also higher verbal IQ compared to controls 
(Merikangas, Avenevoli et al. 1999). 
3. Early developmental disorders 
There are few prospective studies of ASD and ADHD due to the early developmental onset in 
these disorders. A longitudinal study of infants with a family history of ASD reported that 
attentional deficits are precursors for later social and communication difficulties (Bedford, 
Elsabbagh et al. 2012). For ADHD, it has been suggested that deficits in metacognition and 
subclinical attention deficits may be precursors to the disorder (Perricone, Morales et al. 2013). 
5.2.3 Cognitive development in individuals at genetic risk for psychiatric disorder 
There is increasing evidence that risk variants for psychiatric disorder overlap with those for 
cognitive deficits. 
96 
 
1. Psychiatric-risk CNVs  
CNVs which confer risk for psychiatric disorder also confer risk for intellectual disability (Owen, 
O'Donovan et al. 2011, Kirov, Rees et al. 2015). The Icelandic DeCODE genetic population cohort 
found that psychiatric-risk CNV carriers who had not been diagnosed with psychiatric disorder 
still exhibited cognitive deficits (Stefansson, Meyer-Lindenberg et al. 2014). This highlights that 
cognitive deficits in CNV carriers are not necessarily secondary consequences of psychiatric 
disorder. 
2. Polygenic risk 
There is overlap in the genes that contribute to psychiatric disorder and cognitive ability. From 
genome wide association studies of psychiatric disorder, each single nucleotide polymorphism 
(SNP) can be attributed a risk for the psychiatric disorder being investigated. Then in non-clinical 
cohorts individuals can be genotyped and their polygenic risk calculated by summing risk across 
SNPs. This polygenic risk score can then be associated with cognitive measures administered in 
the non-clinical cohort. Conversely, genome-wide association studies of cognition in non-clinical 
cohorts can be used to generate polygenic scores of cognitive ability in psychiatric and control 
cohorts.  
One study reports both that polygenic risk score for schizophrenia is associated with lower 
cognitive ability in a non-clinical cohort and that polygenic score for cognitive ability is lower in 
schizophrenia cohorts compared to controls (Lencz, Knowles et al. 2014).  
Interestingly, findings from the non-clinical Lothian Birth Cohort suggest that schizophrenia 
polygenic risk score does not predict childhood cognitive ability, but rather cognitive decline 
(McIntosh, Gow et al. 2013). IQ scores from age 11 and 70 were analysed so it is uncertain 
whether this association is driven by development across a specific life stage or the whole life 
span.  
Polygenic risk for ADHD differentially predicts cognitive domains with reports of negative 
associations for IQ and working memory but not inhibitory control or emotion recognition 
(Martin, O'Donovan et al. 2015).   
It should be noted that the amount of trait variance explained by polygenic risk score is currently 
low but this could reflect that current studies are underpowered. 
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5.3 Cognition in 22q11.2DS 
It is important to make a distinction between the examination of cognitive development associated 
with 22q11.2DS and cognitive development associated with psychopathology in 22q11.2DS. This 
chapter will address the former and the next chapter the latter.  
5.3.1 Cognitive development in 22q11.2DS 
In section 1.2.2 I discussed how cognitive deficits in 22q11.2DS are prevalent across many domains 
and most but not all longitudinal studies report cognitive decline. It is clear from cross-sectional 
studies of children with 22q11.2DS that deficits are premorbid (Swillen, Devriendt et al. 1997, 
Woodin, Wang et al. 2001, De Smedt, Devriendt et al. 2007, Gur, Yi et al. 2014, Niarchou, Zammit et 
al. 2014), with one study reporting cognitive deficits in children aged 13–63 months (Gerdes, Solot et 
al. 2001). However it remains uncertain whether there is premorbid longitudinal decline in 
22q11.2DS.  
Deficits in different cognitive domains appear to be independent of each other in 22q11.2DS 
(Niarchou, Zammit et al. 2014). Longitudinal evidence from one study suggests that development 
across domains is related, however, as decline in two or more IQ subdomains predicts decline in the 
remaining IQ subdomains (Duijff, Klaassen et al. 2012). Though it is currently unclear to what extent 
this is true for cognitive measures other than IQ.  
5.3.2 Limitations of 22q11.2DS studies 
Table 20 describes 22q11.2DS studies that have examined longitudinal change in cognition. Below I 
discuss the limitations of these studies.  
1. Lack of comparison group 
Only five studies have included a comparison group, which is needed to control for extraneous 
variables and methodological artefacts. As mentioned in section 5.2.1, there are cases in the 
schizophrenia literature where availability of a comparison group has influenced interpretation.  
Out of the five studies with a comparison group, one study recruited children with idiopathic 
developmental delay who were IQ matched as controls (Gothelf, Eliez et al. 2005), three studies 
recruited typically developing community controls (Gothelf, Penniman et al. 2007, Schaer, 
Debbané et al. 2009, Hooper, Curtiss et al. 2013) and one study assessed both community 
controls and unaffected siblings (Antshel, Shprintzen et al. 2010).  
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Each type of control group has its benefits and limitations. IQ matched developmental delay 
controls allow cognitive development specific to 22q11.2DS to be distinguished from 
development related to low IQ. Contrasting development in 22q11.2DS to that in typically 
developing community controls allows the magnitude of the impact of 22q11.2DS to be 
characterised. It is worth noting here, however, that the Lane and Albee schizophrenia study 
mentioned in section 5.2.1 found utilising community controls led to misleading conclusions 
because they were not necessarily matched for socioeconomic background (Lane and Albee 
1968). Comparison to unaffected siblings allows for family specific genetic and environmental 
factors to be controlled for. However unaffected siblings may not be truly representative of the 
general population as they have developed in a family with a child with a genetic syndrome. One 
study that included both community and unaffected sibling controls found increased mood 
disorder with age in the unaffected siblings but not the community controls (Antshel, Shprintzen 
et al. 2010). To some extent the suitability of a control group depends on the hypothesis under 
examination and the variables the investigator wishes to control for. 
2. Different IQ test versions 
No longitudinal 22q11.2DS study to date has reported administering the same IQ test across the 
whole sample and across time points. Sometimes this is the case because the sample includes 
data collected from various sites (Gothelf, Schneider et al. 2013, Vorstman, Breetvelt et al. 
2015). On the one hand performance on different IQ measures does highly correlate, but the use 
of different measures across time points does decrease reliability (Lineweaver and Chelune 
2003).  
In many studies Wechsler scales are used for the whole sample but different versions for 
children and adults. Comparative studies of Wechsler scales report that performance on the 
adult test version is inflated relative to the child version, with an effect of between two to five IQ 
points (Strauss, Sherman et al. 2006), and this disparity is greater in individuals with intellectual 
disabilities (Spitz 1988, Gordon, Duff et al. 2010). One 22q11.2DS study adjusted for this by 
deducting five IQ points from their adult scores (Antshel, Shprintzen et al. 2010). Another study 
argues that this means the decline reported in their sample is actually an underestimate 
(Vorstman, Breetvelt et al. 2015). However, it is not necessarily justified to extrapolate that the 
magnitude and direction of disparity between measures is the same in 22q11.2DS as the general 
population. Indeed one study reports decline rather than an increase in the group that changed 
from child to adult IQ test version and the magnitude of decline was greater in this group than in 
the rest of the sample (Gothelf, Schneider et al. 2013). 
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The use of different IQ test versions within a study means raw scores cannot be examined across 
the whole sample. This along with the lack of comparison groups has meant 22q11.2DS studies 
have not been able to characterise cognitive development using hypotheses described in the 
schizophrenia literature (section 5.2.1). Only one 22q11.2DS study has examined raw scores 
(Duijff, Klaassen et al. 2012) in a subsample where 29 out of 69 participants were assessed using 
the same measure (Duijff, Klaassen et al. 2012). 
3. Focus exclusively on IQ 
Seven of the ten studies have focused exclusively on IQ. As different neural processes underlie 
performance on different neuropsychological tests, it is important that other cognitive processes 
such as executive function and attention are examined. In children who later develop 
schizophrenia there is differential development in cognitive domains (Reichenberg, Caspi et al. 
2010) and in other psychiatric disorders development of IQ can be typical while deficits are 
present in other cognitive domains (see section 5.2.2.). Therefore focusing exclusively on IQ in 
22q11.2DS will not give a full picture of the developmental processes occurring. Though it is 
worth noting that some studies which have exclusively used IQ have explored the differential 
development of IQ domains such as verbal and performance IQ and subdomains such as 
processing speed, arithmetic and comprehension (Duijff, Klaassen et al. 2012, Duijff, Klaassen et 
al. 2013, Gothelf, Schneider et al. 2013, Vorstman, Breetvelt et al. 2015).   
4. Inability to distinguish whether change is premorbid or due to psychosis onset 
There is only one study where it is clear that cognitive development is premorbid as cognition 
and psychotic disorder were assessed concurrently and no individuals met criteria for a 
psychotic disorder at either time point (Antshel, Shprintzen et al. 2010).  
One study created an IQ growth chart from 829 individuals and although assessment of 
cognition and psychotic disorder was not concurrent in this study the growth chart shows 
decline occurs at a greater rate early in development, suggesting decline is premorbid and not 
necessarily due to disorder onset (Vorstman, Breetvelt et al. 2015).  
Two studies did not assess psychosis so it is unclear whether cognitive development reflects 
premorbid development. However one of these studies did examine early childhood (ages 5.5, 
7.5 and 9.5) so is likely to reflect premorbid development.  
In six of the studies individuals had already developed psychotic disorder so it is unclear whether 
cognitive development reflects changes in the premorbid period or disorder onset (Gothelf, Eliez 
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et al. 2005, Gothelf, Penniman et al. 2007, Schaer, Debbané et al. 2009, Gothelf, Schneider et al. 
2013, Hooper, Curtiss et al. 2013, Schneider, Schaer et al. 2014). This is partly due to the wide 
age ranges in these studies or because they examined later developmental periods. In one sense 
the presence of psychotic disorder in 22q11.2DS adolescents is to be expected and therefore 
makes it difficult to capture longitudinal development before disorder onset. There could also be 
differential interpretation and application of psychotic disorder diagnosis amongst 22q11.2DS 
studies as the Antshel, Shprintzen et al. 2010 study did include individuals in late adolescence, 
yet no individuals met criteria for psychotic disorder. Overall there is a need for 22q11.2DS 
studies to delineate the developmental processes associated with the different stages of 
psychosis development.  
5. Variability in cognitive development is not always considered 
22q11.2DS studies have related variability in cognitive development to psychopathology (this 
will be discussed in greater depth in Chapter 6) but only two studies have attempted to 
characterise variability in cognitive development. One study reports that a third of 22q11.2DS 
children exhibit deterioration in raw score (Duijff, Klaassen et al. 2012). Another study has 
created an IQ growth chart with percentile bands (Vorstman, Breetvelt et al. 2015). However 
with neither study including a comparison group it is uncertain to what extent this differs from 
the general population.  
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Table 20: Characteristics of longitudinal 22q11.2DS studies assessing cognition 
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5.4 Aims 
In this chapter I present cognitive findings from the ECHO study 22q11.2DS cohort. This cohort has 
several features that address limitations of previous studies of 22q11.2DS: 
i. A comparison group of unaffected siblings were assessed, allowing cognitive 
development in 22q11.2DS to be contrasted to controls. 
ii. The same cognitive measures were administered to all participants at both waves of 
assessment.  
iii. Cognitive measures other than IQ were administered. 
iv. No individual has developed psychotic disorder (see chapter 4), thus findings will reflect 
premorbid development.  
 
The specific aims of analysis in this chapter are: 
1. Examine the magnitude and stability of deficits in 22q11.2DS. 
2. Characterise premorbid cognitive development in terms of the developmental deficit, 
developmental deterioration and developmental lag hypotheses. 
3. Examine variability in change by: 
a) Comparing the distribution of cognitive change in 22q11.2DS children with that in 
controls. 
b) Reliably categorising individuals into improving, stable and declining groups based on 
their age-adjusted cognitive performance. 
c) Categorising individuals based on their raw scores to examine the prevalence of 
cognitive deterioration. 
4. Investigate whether cognitive development in different domains is related. 
5.5 Methodology 
Sample description and assessment details have been presented in Chapter 3. Cognitive test-retest 
data was available for 64 children with 22q11.2DS and 27 controls. Missing data occurred because in 
some cases psychiatric assessment was conducted by video call with the primary carer for 
geographical reasons so the cognitive measures could not be administered (22q11.2DS n=5, controls 
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n=2) and one 22q11.2DS individual could not complete any of the cognitive tests. Missingness was 
variable across cognitive measures (reported in Table 22). 
5.5.1 Transformation of raw scores to age-adjusted standardised scores. 
Raw scores reflect absolute performance on the cognitive measure. Standardised scores allow 
comparison of ability across ages and reflect the extent an individual’s ability deviates from the 
general population. Cognitive measures often have their own standardisation procedures, with one 
of the steps often including an adjustment for age. Here I document the transformations that occur 
when generating standardised scores for the WASI, WCST and CANTAB.     
1. WASI 
Each individual receives a raw score for each of the four IQ subtests completed. These raw 
scores are converted to age-adjusted t-scores according to the WASI manual normative sample 
tables (Wechsler 1999). The transformation is such that the resulting distribution has a mean of 
50 and a standard deviation of 10.  
The final FSIQ score is the result of transforming the additive total of the age-adjusted t-scores 
from the four subtests according to the WASI manual. VIQ is the result of transforming the 
additive total of the Vocabulary and Similarities subtests. PIQ is the result of transforming the 
additive total of the Block Design and Matrix Reasoning subtests. The transformation is such that 
the resulting FSIQ, VIQ and PIQ score distributions have a mean of 100 and a standard deviation 
of 15. For all of the above, a higher score reflects greater performance. 
2. WCST 
The number of perseverative errors is calculated from the WCST transcripts according to the 
WCST manual (Heaton, Chelune et al. 1993). A higher raw score reflects poorer performance. 
The raw score is transformed to an age-adjusted standardised score according to the WCST 
normative sample tables. The transformation is such that the resulting distribution has a mean 
of 100 and a standard deviation of 15. A higher score reflects greater performance. 
3. CANTAB 
For MTS, RVP, and SOC a higher raw score reflects better performance, whilst for SWM and RTI a 
higher raw score indicates poorer performance. The raw scores for RTI, RVP, SOC and SWM are 
transformed to an age-adjusted standardised score according to the CANTAB normative sample 
tables. CANTAB standardised scores are calculated as a z-score, i.e. a mean of 0 and a standard 
deviation of 1. A higher score reflects greater performance.  
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In my analyses I will use both standardised scores and raw scores depending on the question being 
addressed. Analysis of MTS performance will be based on just raw scores as standardisation was not 
possible as there is no normative data for this measure.  
5.5.2 Aim 1: Examine the stability and magnitude of deficits in 22q11.2DS 
To examine stability, test-retest correlations for standardised cognitive performance were calculated 
separately for 22q11.2DS and controls. To examine the average deficit across waves, repeated 
measures ANOVA was conducted and the mean difference in performance between 22q11.2DS 
children and controls was estimated. The mean deficit was then standardised to a z-score 
representing 22q11.2DS cognitive performance relative to controls.  
5.5.3 Aim 2: Characterise premorbid cognitive development in terms of the 
developmental deficit, developmental deterioration and developmental lag 
hypotheses. 
The ECHO longitudinal sample can be conceptualised as an accelerated longitudinal study. 
Individuals have been assessed at two waves, but the age of assessment is variable at each wave. 
Linear mixed modelling was used to investigate the effect of age rather than wave on cognitive 
performance. This approach allowed trajectories to be fitted across the age range of the whole 
sample (age range 6 -17 years), beyond the mean age at each wave. It is possible to estimate the 
average change in cognitive score per year for children with 22q11.2DS and controls. 
A trajectory of cognitive performance by age was fitted for 22q11.2DS and controls whilst taking 
account of collinearity as well as familial clustering. The model included age, deletion status and the 
interaction between age and deletion status as fixed effects, familial clustering was controlled for by 
including family number as a random effect and repeated effects were included. This was conducted 
for both raw scores and standardised scores. Results from these analyses were used to answer the 
following questions.  
1. Does absolute cognitive ability change with age?  
In typically developing children, absolute cognitive performance increases with age. However it 
is important to test whether this true for both children with 22q11.2DS and controls, indeed 
deterioration in raw score may occur in children with 22q11.2DS. Linear mixed modelling was 
conducted on raw cognitive scores to investigate the effect age has on raw cognitive score. Each 
cognitive measure was classified as either showing an increase or decrease with age.  
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2. Does standardised cognitive ability change with age? 
In typically developing children one would expect cognitive ability standardised for age to not 
have a relationship with age. Linear mixed modelling was conducted on standardised scores for 
children with 22q11.2DS and controls to reveal whether there was deviation in cognitive 
development. Significant trajectories were classified as showing improvement if positive and as 
decline if negative. This approach did not control for potential methodological factors. 
Investigating the interaction between deletion status and age on standardised cognitive score 
reveals whether cognitive development in 22q11.2DS deviates from controls. Interaction slope 
parameter terms from linear mixed modelling provide a measure of the extent to which 
cognitive development in 22q11.2DS diverged from controls. An interaction with a positive sign 
indicates maturation and a negative sign a worsening deficit. This approach helped control for 
potential methodological factors that may of been causing deviation in both groups. 
3. Which model best describes cognitive development in 22q11.2DS? 
Development was classified using the following criteria. See section 5.2.1 for an introduction to 
the following models of cognitive development. 
Developmental deficit. Indicated by the absence of an interaction between deletion status and 
age, and increased raw score with age in both children with 22q11.2DS and controls. 
Developmental lag. Indicated by a worsening deficit in 22q11.2DS relative to controls (negative 
interaction) and increased raw score with age in both children with 22q11.2DS and controls. 
Developmental deterioration. Indicated by a worsening deficit in 22q11.2DS relative to controls 
(negative interaction) and decreased raw score with age in children with 22q11.2DS but not 
controls. 
No strong evidence. If there was no relationship of raw score with age in controls, this suggested 
there was no evidence of a developmental relationship in controls or alternatively there was not 
the power to detect a relationship. To be cautious it was decided it would not be appropriate to 
contrast 22q11.2DS cognitive development to controls in this situation. 
Raw scores were not available for composite scores (VIQ, PIQ and FSIQ) and it would of not been 
correct to total the raw scores of the subtests that comprise each composite score as each is 
scaled differently. However direction of change of absolute ability was able to be inferred if the 
raw score of all comprising subtests changed in the same direction. 
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5.5.4 Aim 3a: Comparing the variance of cognitive change in 22q11.2DS children with 
that in controls. 
Levene’s test for equality of variance was conducted on standardised scores to compare the variance 
of cognitive change in 22q11.2DS children to the variance of change in controls. For MTS, raw scores 
were analysed. 
5.5.5 Aim 3b: Reliably categorising individuals into improving, stable and declining 
groups based on their age-adjusted cognitive performance  
Within children with 22q11.2DS and controls change was categorised (wave 2 - wave 1) for all 
standardised cognitive measures. To distinguish true change from noise, cut-offs were specified, 
based on reliable change indices (RCI) (Lineweaver and Chelune 2003). This approach took account 
of the measurement error at each wave of assessment and regression to the mean. 
The following formula was used: 
RCI = ±1.96 SEP  
where 
SEP = SD2*(1- r
2
12)
1/2 
and  
SEP = standard error of prediction 
SD2 = standard deviation of observed retest  
r212 = the test-retest reliability coefficient  
SEP describes the spread of the distribution of change scores that would be expected to occur in the 
absence of true underlying change. 95% of change scores would be expected to fall between ±1.96 
SEP from the expected mean difference, therefore any change scores that lie outside this range 
represent reliable change and would be classified as improving or declining depending on direction 
of effect.  
r212 values were provided by the WASI manual (Wechsler 1999), WCST manual (Heaton, Chelune et 
al. 1993) and current literature for the CANTAB (Harrison, Iddon et al. 2006). However it should be 
noted that CANTAB do not provide values specific to children and adolescents. SD2 was provided by 
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the WASI manual but was not available for WCST and CANTAB so the population standard deviation 
was used instead for these measures. See Table 21 for r212, SD2 and RCI values.  
Table 21: Reliable Change Indices for cognitive assessments 
Cognitive Measure r212  SD2 
95% 
RCI 
WASI FSIQ 0.93 14.17 ±10.2 
 VIQ 0.92 13.58 ±10.4 
 PIQ 0.88 14.92 ±13.9 
     
WASI subtest Vocabulary 0.85 9.57 ±9.9 
 Similarities 0.86 8.55 ±8.6 
 Block design 0.81 10.46 ±12.0 
 Matrix Reasoning 0.77 9.6 ±12.0 
     
CANTAB  RTI 0.57 1 ±1.6 
 RVP 0.64 1 ±1.5 
 SWM 0.70 1 ±1.4 
 SOC 0.64 1 ±1.5 
     
WCST perseverative errors 0.52 15 ±25.1 
 
Subsequently the sample was subdivided into those who were improving, stable or declining. To 
focus on cognitive decline in 22q11.2DS, the declining group was compared to the combined group 
of those who were either stable or improving. Fisher’s exact test was conducted to test whether 
deletion status was associated with cognitive decline.  
5.5.6 Aim 3c: Categorising individuals based on their raw scores to examine the 
prevalence of cognitive deterioration. 
To examine cognitive deterioration wave 1 raw scores were subtracted from wave 2 raw scores for 
all the cognitive measures. For RTI, SWM and WCST the sign of the change scores was reversed as a 
lower raw score reflects better performance for these tasks. Fisher’s exact test was conducted to 
investigate whether deterioration compared to one’s earlier performance is associated with deletion 
status. 
5.5.7 Aim 4: Investigate whether cognitive development in different domains is related. 
When establishing change over time, it is important to take into account mean level at each wave of 
assessment. Principal Components Analysis was conducted on 22q11.2DS test-retest standardised 
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cognitive scores. For MTS, raw scores were analysed. This identified two factors saverage and schange 
where saverage represents the average cognitive performance across both waves and schange cognitive 
change (Niarchou, Zammit et al. 2013). To investigate whether the development in different 
cognitive domains was related, separate correlation matrices were produced for the saverage and 
schange components for cognitive measures.  
5.6 Results 
5.6.1 Aim 1: Examine the magnitude and stability of deficits in 22q11.2DS. 
Table 22 displays cognitive test-retest correlations for both 22q11.2DS and controls. Metrics derived 
from the WASI had a higher reliability than other cognitive measures. This is consistent with values 
reported in the test manuals (see Table 21). Overall there was a trend for higher correlations in 
22q11.2DS individuals than controls. 
Children with 22q11.2DS had significant deficits across all cognitive measures compared to controls. 
There was approximately a 2 SD deficit in all the IQ metrics (p<0.001), attention (RVP, p<0.001) and 
set shifting ability (WCST, p<0.001) in contrast to approximately a 1 SD deficit in processing speed 
(RTI, p=0.011), spatial planning (SOC, p<0.001) and spatial working memory (SWM, p<0.001) (see 
Table 23 and Figure 2). 
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Table 22: Test-retest correlations of cognitive measures in 22q11.2DS children and controls 
 
 
Cognitive measure n r p n r p
WASI FSIQ 62 0.832 <0.001 27 0.751 <0.001
VIQ 62 0.728 <0.001 27 0.628 <0.001
PIQ 63 0.904 <0.001 27 0.829 <0.001
WASI 
subtest
Vocabulary 62 0.726 <0.001 27 0.749 <0.001
Simi lari ties 62 0.593 <0.001 27 0.252 0.205
Block des ign 63 0.855 <0.001 27 0.783 <0.001
Matrix reasoning 63 0.713 <0.001 27 0.724 <0.001
CANTAB MTS 60 0.548 <0.001 27 0.235 0.238
RTI 60 0.411 0.001 26 0.182 0.373
RVP 54 0.544 <0.001 26 0.183 0.371
SOC 58 0.323 0.013 26 0.231 0.257
SWM 63 0.520 <0.001 27 0.521 0.005
WCST
Perseverative 
errors
61 0.350 0.004 27 0.238 0.232
22q11.2DS Control
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Table 23: Mean cognitive performance for 22q11.2DS and controls by wave and mean deficit in 
22q11.2DS 
Mean deficit is the mean cognitive performance of children with 22q11.2DS subtracted from the mean 
performance of controls. Standardised mean deficit is the number of SD 22q11.2DS children are below 
controls. These standardised values are plotted in Figure 2. 
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Figure 2: Visualisation of Table 23, cognitive deficits in 22q11.2DS relative to controls  
Error bars represent 95% CI 
 
5.6.2 Aim 2: Characterise premorbid cognitive development in terms of the 
developmental deficit, developmental deterioration and developmental lag 
hypotheses. 
Table 24 displays the findings from the linear mixed modelling. Change in raw score is displayed 
followed by standardised change for children with 22q11.2DS and controls, then change in 
22q11.2DS relative to controls and the final column describes the model that best describes 
cognitive development.  
Children with 22q11.2DS showed a decline in FSIQ of -0.98 IQ points per year (p=0.002, 95% CI -
1.61,-0.36). Though there was no evidence of a developmental deterioration as raw scores for all the 
subtests increased with age. As expected, there was no relationship between IQ and age in controls 
(p=0.305). However when cognitive development was directly compared there was not strong 
evidence that the rate of decline in 22q11.2DS differed from controls (p=0.231) and therefore 
development of IQ in 22q11.2DS fitted a developmental deficit model (see Figure 3 for visualisation).  
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Clearer patterns of development were observed when VIQ and PIQ components of IQ were 
considered separately (see Figure 4 and Figure 5).  
Development in VIQ fitted a developmental deficit model because although there was a decline of    
-1.06 VIQ points per year in 22q11.2DS (p=0.005) a similar decline was also present in controls 
(p=0.002) and there was no strong evidence that the trajectories differed in slope (p=0.337).   
Development of PIQ fitted a developmental lag model. 22q11.2DS children had a worsening deficit 
of -1.90 points per year relative to controls (p<0.001). Examination of the subtests that comprise PIQ 
indicated this was driven by both block design (p=0.001) and matrix reasoning performance 
(p=0.035). The raw scores of both subtests increased with age (block design p<0.001, matrix 
reasoning p<0.001), confirming that a developmental lag rather than developmental deterioration 
underlies the worsening deficit in PIQ. 
Development of spatial planning (SOC), spatial working memory (SWM) and sustained attention 
(RVP) fitted a developmental deficit model.  For processing speed (RTI) and set shifting ability 
(WCST) developmental models were not applied to the data as there was not strong evidence that 
raw score had a relationship with age in controls. Children with 22q11.2DS improved in processing 
speed (RTI, p=0.011), and sustained attention (RVP, p=0.001). Development of executive function 
differed across subdomain. Set shifting ability improved (WCST, 0.006), spatial working memory 
declined (SWM, p=0.033) and there was no relationship with age for spatial planning (SOC, p=0.656).  
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Table 24: Cognitive development in 22q11.2DS relative to controls: linear mixed modelling  
# inferred from subtest raw score change 
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Figure 3: FSIQ development in 22q11.2DS and controls 
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Figure 4: VIQ development in 22q11.2DS and controls 
 
Figure 5: PIQ development in 22q11.2DS and controls 
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5.6.3 Aim 3a: Comparing the variance of cognitive change in 22q11.2DS children with 
that in controls in standardised scores. 
Table 25 displays separately for 22q11.2DS children and controls the range of change scores and the 
standard deviation of change for each cognitive measure.  Change scores for 22q11.2DS children 
were more variable for tasks of attention (MTS p=0.009, RVP p=0.034) when compared to controls. 
For all other measures there was no strong evidence for a difference in change score variability. 
Table 25: Minimum, maximum and standard deviation of change scores for 22q11.2DS and controls 
 
5.6.4 Aim 3b: Reliably categorising individuals into improving, stable and declining 
groups based on their standardised score  
Reliable change indices (RCIs) were utilised to establish the percentage of participants who showed 
reliable cognitive decline (Table 26). For all cognitive measures, there was not strong evidence that 
children with 22q11.2DS differed from controls in terms of the percentage who exhibited reliable 
cognitive decline.  
Comparison
Cognitive Measure Minimum Maximum SD Minimum Maximum SD
Levene's test for 
equality of variance
FSIQ -15 23 6.91 -17 12 8.18 0.113
VIQ -23 28 8.78 -28 10 8.78 0.351
PIQ -13 12 5.98 -11 20 7.78 0.149
Vocabulary -15 17 6.17 -19 7 6.32 0.899
Simi lari ties -24 31 8.92 -19 19 8.58 0.681
Block Des ign -10 10 4.76 -9 15 6.66 0.084
Matrix Reasoning -16 22 8.07 -10 12 6.25 0.278
MTS -20.00 19.00 6.42 -6.00 10.00 3.25 0.009
RTI -3.75 7.52 1.93 -2.00 2.02 0.98 0.089
RVP -8.69 6.34 2.37 -1.55 3.26 1.14 0.034
SWM -2.28 2.64 1.06 -1.61 1.69 1.01 0.706
SOC -3.01 2.41 1.16 -2.02 2.12 1.20 0.553
Perseverative 
errors
-54.00 75.00 24.15 -36.00 59.00 25.71 0.380
22q11.2DS change scores Controls change scores
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Table 26: Reliable change in 22q11.2DS and controls 
 
5.6.5 Aim 3c: Categorising individuals based on their raw scores to examine the 
prevalence of cognitive deterioration. 
For all cognitive measures, the proportion of children with 22q11.2DS who exhibited deterioration in 
raw score did not differ from controls (Table 27). 
Table 27: Cognitive deterioration in 22q11.2DS and controls 
 
Cognitive 
measure
Association of 
deletion status 
with declining
Declining % Stable % Improving % Declining % Stable % Improving %
Fishers exact      
p-value
FSIQ 12.9 83.9 3.2 11.1 77.8 11.1 0.999
VIQ 17.7 77.4 4.8 29.6 70.4 0 0.262
PIQ 0.0 100.0 0.0 0 88.9 11.1 -
Vocabulary 9.7 83.9 6.5 11.1 88.9 0 0.999
Similarities 21.0 71.0 8.1 29.6 59.3 11.1 0.421
Block design 0.0 100.0 0.0 0 88.9 11.1 -
Matrix reasoning 6.3 85.7 7.9 0 96.3 3.7 0.312
RTI 11.7 73.3 15.0 3.8 84.6 11.5 0.426
RVP 13.0 53.7 33.3 3.8 80.7 15.4 0.264
SOC 10.3 79.3 10.3 11.5 76.9 11.5 0.999
SWM 9.5 82.5 7.9 11.1 74.1 14.8 0.999
Perseverative 
errors
3.7 68.9 21.3 3.7 66.7 29.6 0.431
22q11.2DS Controls
Cognitive measure
22q11.2DS Cognitive 
Deterioration %
Controls Cognitive 
Deterioration %
Fishers exact 
p-value
Vocabulary 22.6 11.1 0.253
Simi lari ties 14.5 11.1 0.999
Block des ign 12.7 3.7 0.269
Matrix reasoning 20.6 11.1 0.374
MTS 29.3 22.2 0.609
RTI 31.7 23.1 0.604
RVP 33.3 23.1 0.439
SOC 25.9 23.1 0.999
SWM 36.5 29.6 0.632
Perseverative 
errors
41.0 40.7 0.459
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5.6.6 Aim 4: Investigate whether cognitive development in different domains is related. 
Table 28 displays the correlation matrices for the saverage principal component of cognitive 
performance and the schange principal component of cognitive change for children with 22q11.2DS. 
 saverage reflects performance on each of the cognitive tasks averaged over the two waves. FSIQ 
correlated with visual attention (MTS, p=0.010) and executive function (SOC, p=0.005; SWM, 
p<0.001; WCST, p=0.001) but not processing speed (RTI, p=0.112) nor sustained attention (RVP, 
p=0.068). This pattern of association of FSIQ with other cognitive domains remained when IQ was 
unpacked into VIQ and PIQ. There were correlations between different cognitive domains but also 
within executive function (SOC, SWM, and WCST) and attention (MTS, RVP) domains.  
schange reflects change in performance between waves 1 and 2 on each cognitive task. Change in FSIQ 
was not associated with change in other cognitive domains. Though within FSIQ, VIQ and PIQ were 
strongly correlated (p<0.001). Also change in sustained attention was correlated with change in set-
shifting ability (RVP, WCST, p=0.003). 
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Table 28: Correlation matrix for saverage and schange components in 22q11.2DS 
saverage correlations are in the top right triangle and schange correlations are in the bottom left triangle 
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5.7 Discussion 
This is the first longitudinal 22q11.2DS study that has administered the same cognitive measures 
across all participants and waves of assessment and is one of the few studies that has assessed a 
range of cognitive domains and that has included a comparison group. Cognitive development 
examined in this chapter represents the premorbid period as no 22q11.2DS individual met criteria 
for psychotic disorder at either wave of assessment (see Chapter 4). By utilising raw scores, this is 
the first study to investigate whether worsening deficits in 22q11.2DS represent a developmental lag 
or developmental deterioration model of cognitive development.  
5.7.1 Findings 
1. Measurement of cognition in 22q11.2DS had high reliability 
Despite a high burden of psychopathology in children with 22q11.2DS, test-retest correlations 
for all cognitive measures were high. Correlation magnitudes varied by cognitive measure with 
high values for IQ and its subcomponents and lower values for other neurocognitive domains. 
This pattern reflects test-retest correlations in the general population (compare Table 21 and 
Table 22).  
2. The magnitude of premorbid deficits in 22q11.2DS differs by cognitive domain 
Children with 22q11.2DS had a premorbid deficit of -33.2 IQ points (95%CI=-38.4,-28.0). 
Premorbid deficits in IQ, attention and set shifting ability were approximately twice the 
magnitude of deficits in processing speed, spatial planning and spatial working memory. This is 
consistent with a cross sectional 22q11.2DS study that reported greater deficits in complex 
cognition and relative strengths in working memory and spatial processing (Gur, Yi et al. 2014). 
Deficits in processing speed, spatial planning and spatial working memory in 22q11.2DS are 
similar in magnitude to the deficits present in patients with schizophrenia (Fioravanti, Carlone et 
al. 2005), whereas attention deficits are greater in 22q11.2DS. VIQ and PIQ deficits were found 
to be similar in magnitude whereas previous studies have indicated greater deficits for PIQ 
(Moss, Wang et al. 1995, Swillen, Devriendt et al. 1997, Moss, Batshaw et al. 1999, Woodin, 
Wang et al. 2001).  
3. Premorbid deficits were not independent of each other 
Different cognitive measures were positively correlated in 22q11.2DS, both between measures 
capturing the same domain and between measures of different domains. IQ was correlated with 
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visual attention, executive function but not processing speed. This differs from cross-sectional 
findings from wave 1 of the ECHO study where IQ was found to be independent of other 
domains (Niarchou, Zammit et al. 2014). This disparity could be because, in comparison to cross 
sectional data, test-retest data provides extra power to detect associations. Also Principal 
Components Analysis helped distinguish core ability, saverage, from measurement error.  
4. Intelligence declined in 22q11.2DS but not relative to controls 
IQ declined in 22q11.2DS by approximately -1 FSIQ point/year. This magnitude of decline falls 
within the middle of the range of previously reported IQ change (see Table 20). However, there 
was not strong evidence that developmental change in IQ differed from controls. This could be 
due to power as on average children with 22q11.2DS did diverge from controls -0.51 IQ 
points/year, but the 95% confidence interval was wide (-1.61 to 0.60 IQ points). Also, only 12.9% 
of children with 22q11.2DS had a FSIQ change greater than the reliable change index. Overall, 
there was some suggestion that IQ declines in 22q11.2DS but there was no evidence of a large 
IQ decline relative to controls and there did not appear to be a large subgroup of children with 
22q11.2DS that exhibited IQ decline.  
5. The longitudinal course of premorbid deficits differs by domain 
This study highlights the importance of considering the subcomponent IQ scores as differing 
developmental patterns were observed. Children with 22q11.2DS exhibited a developmental lag 
in PIQ and a developmental deficit in VIQ relative to controls. PIQ captures spatial ability, 
perceptual organization, nonverbal concept formation, spatial reasoning and fluid intelligence, 
whereas VIQ captures verbal concept formation, verbal reasoning and crystallized intelligence 
(Wechsler 1999). The magnitude of the developmental lag was approximately 2 PIQ points/year. 
This decline was not driven by a subgroup of 22q11.2DS children exhibiting extreme decline, as 
none of the participants had a PIQ decline greater than the reliable change index. Rather this 
would suggest a gradual decline in the majority of 22q11.2DS children.  
This pattern of verbal developmental deficits and nonverbal developmental lags is consistent 
with premorbid cognitive development observed in idiopathic schizophrenia (Reichenberg, Caspi 
et al. 2010). Some, (Duijff, Klaassen et al. 2012, Vorstman, Breetvelt et al. 2015) but not all 
(Gothelf, Schneider et al. 2013), previous 22q11.2DS studies have found greater decline for VIQ 
than PIQ, but it should be noted that these studies lacked a comparison group. Although VIQ 
deficit in this cohort was static, there was decline within both 22q11.2DS and control groups. It 
could be that the control group is not representative of the general population; however decline 
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has been described in comparison groups from idiopathic schizophrenia studies (Lane and Albee 
1968, Watt and Lubensky 1976, Jones, Murray et al. 1994). These findings question whether 
previously reported VIQ decline in 22q11.2DS is a true effect or attributable to study artefacts. 
Children with 22q11.2DS also exhibited developmental deficits in spatial planning, spatial 
working memory and sustained attention. This is in contrast to the Dunedin study and suggests 
spatial tasks as measured by the IQ test (WASI) differ in development from spatial tasks as 
measured by the CANTAB. However CANTAB tasks do have lower test-retest reliability, so 
measurement error is likely to have a greater effect making it difficult to detect a developmental 
lag. Indeed there was a trend for spatial planning and spatial working memory to decline with 
age relative to controls but these findings were not robust.  
Developmental change differs across aspects of executive function in 22q11.2DS, though this 
could reflect differing methodological artefacts such as differing practice effects.  
None of the cognitive domains exhibited development that fitted the model of developmental 
deterioration. 
6. Development of attention is more variable in 22q11.2DS but the same is not true for other 
domains, including IQ  
Development of attention in children with 22q11.2DS was more variable than in controls. The 
standard deviations of change scores for attention measures were twice the magnitude of 
controls. Attentional deficits are reported both in patients with schizophrenia (Cornblatt and 
Malhotra 2001) and as premorbid deficits in those who later develop schizophrenia 
(Reichenberg, Caspi et al. 2010). Variability in the development of IQ, executive function and 
processing speed were not specific to 22q11.2DS as controls were just as variable. 
There was a subgroup of children with 22q11.2DS who exhibited large reliable changes in 
cognition (as defined by RCIs). 12.9% of children with 22q11.2DS declined in IQ -10.2 IQ points 
(RCI for IQ) or more between assessments. However, this was not specific to 22q11.2DS as a 
similar size subgroup of declining children was present in controls. Both children with 22q11.2DS 
as well as intrafamilial controls displayed large individual FSIQ changes, ranging from -15 to +23 
FSIQ points (Table 25), which is similar to adolescents from the general population (Ramsden, 
Richardson et al. 2011).  
One previous study of 22q11.2DS has examined IQ subtest raw scores and identified a subgroup 
with cognitive deterioration (Duijff, Klaassen et al. 2012). This finding was replicated across 
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measures in the ECHO cohort, but it was also found that prevalence of cognitive deterioration 
did not differ from controls. Findings indicate that cognitive deterioration is not specific to 
children with 22q11.2DS.   
7. Premorbid decline in IQ is independent of change in other cognitive domains 
Intelligence did not co-vary with other neurocognitive domains over time which is in contrast to 
the earlier finding that ability in different domains was related (see 5.7.1.3). This could reflect 
that the brain processes underlying different cognitive domains are related but over time these 
processes develop differentially in 22q11.2DS.  
8. Different aspects of impulsivity change together in 22q11.2DS 
Set-shifting ability positively co-varies over time with sustained attention. This could reflect that 
both tap into impulsivity. Although set-shifting ability is conceptualised as an aspect of executive 
function, it is dependent on modulating impulsive responding (Heaton, Chelune et al. 1993). 
5.7.2 Limitations 
1. Sample size of controls 
The sample size of the control group was smaller than the 22q11.2DS group thus reducing power 
to contrast development. However, strong relationships within the dataset were still able to be 
identified.  
2. Reliability of neurocognitive measures 
Test-retest reliability was lower for the cognitive measures other than IQ. Although this is 
consistent with normative data this may have affected power to detect patterns of cognitive 
development.  
3. Issues of multiple comparisons 
Analysis should be considered exploratory as analysis was not adjusted for multiple comparisons. 
This increases the risk of type 1 errors occurring, whereby the null hypothesis is incorrectly 
rejected.  For instance in the linear mixed model analysis, there was not a correction for the 
number of cognitive measures investigated.  Analysis could have been confined to fewer 
domains, however as investigation into the longitudinal change of multiple neurocognitive 
domains is not common in the 22q11.2 literature it was decided to not restrict analysis. This 
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exploratory analysis has highlighted sustained attention, a cognitive domain not previously 
focused on much in the 22q11.2DS literature. 
4. Ascertainment bias 
It is likely many children with 22q11.2DS were referred for medical genetic testing because of 
developmental delay and individuals with higher cognitive ability are perhaps less likely to be 
referred for testing. Together this could mean the magnitude of cognitive deficits calculated may 
be an overestimate.  Conversely, families with severely affected children may be less likely to 
volunteer as part of a research project so findings could be an underestimate. Also it should be 
considered that Chapter 3 found there was a bias for children with lower IQ (by -5.8 IQ points) to 
take part again at wave 2. 
5. Representativeness of controls 
Controls in this study were unaffected siblings and may not be fully representative of the general 
population. Their FSIQ was higher than 100 at both waves of assessment (wave 1=106.6, wave 
2=105.6). Also a previous study found increased mood disorder in unaffected siblings (Antshel, 
Shprintzen et al. 2010). However findings in Chapter 4 indicate that the prevalence of psychiatric 
disorder in unaffected siblings (controls) within the ECHO cohort was representative of that in 
the general population. 
6. Potential cohort effects 
The accelerated longitudinal design allowed examination of cognitive development from 6-17 
years (age range of current data set), however a potential issue is that there may be cohort 
effects that change with age.  
7. Linear cognitive development was assumed 
In the linear mixed models analysis linear trajectories were fitted for 22q11.2DS children and 
controls. However development may be non-linear. If so, this could account for why 22q11.2DS 
studies report differing magnitudes of change as each study has examined a different snapshot 
of development.  
8. Other factors could be affecting test-retest performance 
Practice effects, the Flynn effect and extraneous factors could be contributing to the change 
examined, however their effect is likely to be minimal. The time gap of 2.5 years means practice 
effects are likely to be diminished (see section 5.1.2). The Flynn effect has been estimated to be 
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an increase of 0.28 IQ points per year (Pietschnig and Voracek 2015) and it could affect children 
with 22q11.2DS and controls differently. However, if it was inflating control performance 
relative to children with 22q11.2DS its effect would still be smaller than the magnitude of the 
changes observed.  As explained in Chapter 3 the testing environment, time of assessment, and 
order of test administration was kept as consistent as possible. However participants may be 
more familiar to cognitive assessment at the second wave of assessment and arguably this effect 
could be different for children with 22q11.2DS and controls. 
5.7.3 Future work 
1. Further wave of assessment 
Change between two waves of assessment could be due to methodological factors affecting one 
of the waves of assessment. A third wave of assessment would clarify this.   
“Two waves of data are better than one, but maybe not much better” (Rogosa, Brandt et al. 
1982) 
Also a third wave would give insight into how cognition in 22q11.2DS develops as individuals 
enter the risk period of schizophrenia development.  
The nature of early cognitive development in 22q11.2DS should also be considered. Deficits have 
been reported from age 13 months but it is uncertain whether deficits are present at birth and 
no study has examined longitudinal development across this period.  
2. Large collaborative studies 
Moving forward, studies of 22q11.2DS need to be more consistent in the cognitive measures 
they use. International collaboration of different research groups is occurring (Vorstman, 
Breetvelt et al. 2015) but research sites are yet to align their cognitive assessments.  
3. Investigate other psychiatric-risk CNVs 
Longitudinal development of cognition in other psychiatric-risk CNVs should be investigated. It is 
uncertain whether different schizophrenia-risk CNVs converge on the same cognitive trajectories 
or are specific in the cognitive domains and trajectories they affect. Cross-sectional evidence 
suggests that different CNVs affect different cognitive domains (Stefansson, Meyer-Lindenberg 
et al. 2014). Cognitive decline appears to be more severe in Kleefstra syndrome (9q34.3 
deletion) as there are reports of individuals showing regression in adolescence and adulthood 
(Willemsen, Vulto-van Silfhout et al. 2011). 
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5.7.4 Conclusions 
Schizophrenia has been associated with cognitive deficits, however, their developmental course 
remains uncertain. Because approximately 25% of children with 22q11.2DS develop schizophrenia 
(Murphy, Jones et al. 1999), carefully conducted studies of their cognitive development can provide 
important insights into the development of this severe and debilitating psychiatric disorder, with 
implications beyond this genetic syndrome, for the wider population of at risk individuals. 
This chapter has aimed to critically examine cognitive development in 22q11.2DS. The analysis of 
cognitive change is complex and has its own unique considerations. Previous longitudinal studies of 
cognition in 22q11.2DS have suffered various limitations. Study design and statistical methodology 
has allowed cognitive change to be examined critically, reducing risk of interpreting measurement 
error as meaningful bias over time. 
Findings confirmed that there is premorbid decline in intelligence in 22q11.2DS, though there was 
not a strong effect. Some authors have recommended regular cognitive testing for children with 
22q11.2DS (Swillen and McDonald-McGinn 2015). However findings in this chapter question the 
usefulness of this as no individuals reached cut-offs for reliable decline in nonverbal intelligence 
even though there was decline at the level of the group.  
The nature and development of intelligence in 22q11.2DS differed by IQ domain. There were 
developmental deficits in verbal and crystallized intelligence suggesting that there is early atypical 
brain development in 22q11.2DS that affects the acquirement of language and knowledge across 
childhood and adolescence. Developmental lags in nonverbal and fluid intelligence highlight that 
22q11.2DS children fall further behind their peers on visual-spatial and abstract tasks as they get 
older but not to the extent of losing ability in these areas. These patterns are observed in those who 
later develop idiopathic schizophrenia (Reichenberg, Caspi et al. 2010) and therefore 22q11.2DS 
represents a useful model for exploring the cognitive antecedents of schizophrenia. Developmental 
deficits were also present for spatial planning, spatial working memory and sustained attention. The 
mixture of developmental deficits and lags suggests that both processes early in development and 
later in childhood and adolescence may be associated with genetic risk of schizophrenia. 
The cognitive phenotype of 22q11.2DS is highly variable, though for many domains development of 
cognition was not more variable than for typically developing children.  
This chapter has characterised childhood cognitive development of 22q11.2DS, a high-risk condition 
for schizophrenia development. The next chapter will explore to what extent cognitive development 
in 22q11.2DS is associated with psychopathology, including the emergence of psychotic experiences. 
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6. Relations between cognition and psychopathology in 22q11.2DS 
This chapter aims to relate findings from Chapter 4 on psychopathology to those from Chapter 5 on 
cognition. Findings in Chapter 4 indicate a high burden of psychopathology in children with 
22q11.2DS. This chapter will explore how this high level of psychopathology relates to cognitive 
development.  I will also address whether cognitive development characterised in Chapter 5 relates 
to the emergence of psychotic experiences. In Chapter 4 ADHD persistence rate was 48.1%, in this 
chapter it will be investigated whether cognitive development predicts ADHD persistence.  
First I will discuss what is currently known about the relations between cognitive development and 
psychopathology from the idiopathic and 22q11.2DS literature before investigating these questions 
in the ECHO longitudinal 22q11.2DS cohort. 
6.1 Psychotic phenomena and cognition 
Section 5.2.1 has already given an introduction to cognitive development associated with the 
development of schizophrenia. Here I will discuss cognitive development that has been associated 
with psychotic experiences in idiopathic populations and subsequently in 22q11.2DS. 
6.1.1 Psychotic experiences and cognitive development in idiopathic populations 
Relatively little research has been conducted on the relationship between cognition and psychotic 
experiences in comparison to schizophrenia (Niarchou, Zammit et al. 2013). Studies have associated 
deficits in a number of cognitive functions with increased risk of psychotic experiences. Lower 
childhood IQ, decline in IQ and impairment in a range of neurocognitive domains have been 
associated with psychotic experiences (Cosway, Byrne et al. 2000, Cannon, Caspi et al. 2002, 
Horwood, Salvi et al. 2008, Niarchou, Zammit et al. 2015). One study has highlighted defective 
processing speed as a particularly strong predictor of psychotic experiences (Niarchou, Zammit et al. 
2013). Psychoeducational deficits are also reported to be associated with psychotic experiences 
(Hameed, Lewis et al. 2013). Some (Polanczyk, Moffitt et al. 2010, Thompson, Sullivan et al. 2011, 
Sullivan, Bentall et al. 2013), but not all (Thompson, Sullivan et al. 2011), measures of impaired social 
cognition are related to risk of psychotic experiences.  
6.1.2 Psychotic experiences and cognitive development in 22q11.2DS 
This was reviewed in section 2.1.5. Below are the cognitive risk factors that have been associated 
with subclinical psychotic phenomena. 
 VIQ decline 
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 Baseline IQ 
 Baseline neurocognitive ability 
6.1.3 Limitations of current 22q11.2DS studies 
Section 5.3.2 discussed some of the limitations of current longitudinal studies of cognition in 
22q11.2DS and some of these apply here as well, such as the use of different IQ test versions at 
different waves of assessment and an exclusive focus on IQ only. There are also limitations specific 
to the examination of the link between cognition and psychotic phenomena, including: 
1. Change is not always examined in relation to psychotic phenomena 
Studies have related baseline neurocognitive ability to psychotic phenomena for non-IQ domains 
(Antshel, Shprintzen et al. 2010, Hooper, Curtiss et al. 2013, Kates, Russo et al. 2014, Schneider, 
Schaer et al. 2014). However, the relationship between change in cognition and psychotic 
phenomena has received considerably less attention (e.g.,(Antshel, Shprintzen et al. 2010, 
Hooper, Curtiss et al. 2013)), despite a number of studies conducting longitudinal assessments of 
non-IQ neurocognitive domains. 
2. Longitudinal assessment of cognition and psychotic phenomena is not always concurrent 
Of the 10 studies that have examined cognition longitudinally in 22q11.2DS (see 5.3.2) only two 
have concurrently examined subclinical psychotic phenomena (Hooper, Curtiss et al. 2013, 
Schneider, Schaer et al. 2014). Some studies have assessed psychotic disorder concurrently but 
not subclinical symptoms (Gothelf, Penniman et al. 2007, Schaer, Debbané et al. 2009). In other 
studies a subclinical symptom based measure of psychotic phenomena is available but only at 
one assessment wave (Gothelf, Eliez et al. 2005, Antshel, Shprintzen et al. 2010, Gothelf, 
Schneider et al. 2013).  
3. Issues of mathematical coupling 
Some 22q11.2DS studies have included both baseline cognitive ability and change within the 
same regression analysis (Gothelf, Schneider et al. 2013, Vorstman, Breetvelt et al. 2015). This 
introduces bias due to mathematical coupling (see section 5.1.2).  
129 
 
6.2 Psychopathology and cognitive development 
In section 5.2.3 I have discussed the cognitive patterns that precede emergence of other psychiatric 
disorders. The current section considers to what extent the presence of psychopathology is related 
to cognitive development. 
6.2.1 Psychopathology and cognitive development in idiopathic populations 
1. ASD 
In children with ASD, development in many cognitive domains shows stability. There is evidence 
that development of domains often co-vary together and that cognitive development predicts 
later adult psychosocial outcomes. IQ from childhood to adulthood remains relatively stable 
(Lockyer and Rutter 1970, Venter, Lord et al. 1992, Ballaban-Gil, Rapin et al. 1996, Howlin, 
Goode et al. 2004). There is a positive relationship between intellectual functioning and 
academic attainment (Venter, Lord et al. 1992). Childhood IQ broadly predicts adult psychosocial 
outcome, with those with a childhood IQ below 70 having poor outcomes (Howlin, Goode et al. 
2004, Taylor and Seltzer 2010, Smith, Maenner et al. 2012, Ben-Itzchak, Watson et al. 2014), 
whereas variability of IQ within the normal range does not predict outcome (Howlin, Goode et 
al. 2004).  There is evidence from other cognitive domains that early childhood cognitive 
performance predicts later development. Strong executive function skills between the ages 4 to 
7 predicts theory of mind ability assessed three years later (Pellicano 2013). Language ability in 
adolescence is predicted by joint attention in childhood (Sigman and McGovern 2005). 
There is a disparity between development in verbal and nonverbal cognition. PIQ is generally 
higher than VIQ, though VIQ increases over time whereas, depending on study, PIQ remains 
stable (Gotham, Pickles et al. 2012) or declines (Mawhood, Howlin et al. 2000, Howlin, Goode et 
al. 2004, Gotham, Pickles et al. 2012). Language and comprehension improves with age, though 
in a majority of individuals deficits persist, with only a third achieving typical level of ability 
(Ballaban-Gil, Rapin et al. 1996). 
2. Anxiety 
The relationship between intelligence and anxiety has been heavily explored, but findings are 
mixed. Some studies report a negative correlation between intelligence and anxiety (Spielberger 
1958, Phillips, Hindsman et al. 1960). It is thought anxiety arises because individuals with a lower 
IQ are less likely to give a successful response in situations that are cognitively demanding.  
Others have argued that “the higher the IQ is, the greater the psychological fragility” but this 
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notion is based on case studies of gifted children with psychological disturbance and may not be 
generalisable to the broader category of high IQ individuals  (Catheline-Antipoff and Poinso 
1994).  The relationship between intelligence and anxiety appears to differ between clinical and 
non-clinical populations with one study reporting a positive relationship between intelligence 
and anxiety in individuals with generalised anxiety disorder but an inverse relationship in healthy 
volunteers (Coplan, Hodulik et al. 2011).  
A clear relationship in the literature is that the presence of anxiety disorders in adolescence 
increases the risk of educational underachievement and premature withdrawal from school 
(Woodward and Fergusson 2001, Van Ameringen, Mancini et al. 2003). This appears to be driven 
by adolescents feeling anxious in class rather than by cognitive impairment. 
3. ADHD 
Studies support a maturational lag hypothesis of ADHD, in that children with ADHD have 
cognitive deficits which lessen as they grow older (Øie, Sundet et al. 2010). Delayed 
development is seen for control of attention (Øie, Sundet et al. 2010) and is supported by 
neuroanatomical evidence of delayed cortical maturation in ADHD (Shaw, Eckstrand et al. 2007). 
In contrast, development of IQ, executive function, perceptual recognition and perceptual 
learning in ADHD appears to follow a developmental deficit model (Biederman, Petty et al. 2009, 
Coghill, Hayward et al. 2014). That is children with ADHD show deficits in these cognitive 
domains but their cognitive performance still improves over time at a similar rate as controls. 
It is clear that childhood psychopathology is related to later cognitive development and functioning, 
with particularly strong evidence for ASD and ADHD.  
6.2.2 Psychopathology and cognitive development in 22q11.2DS 
Longitudinal studies of cognition and psychopathology in 22q11.2DS have focused on predicting the 
emergence of psychosis (see section 2.1.4 and 2.1.5) and mood problems (Antshel, Shprintzen et al. 
2010). No longitudinal studies of cognition in 22q11.2DS have considered whether the presence of 
childhood psychopathology in 22q11.2DS predicts cognitive development. Given the high prevalence 
of psychopathology in 22q11.2DS and the fact that psychopathology influences cognitive 
development in idiopathic samples, it is important to investigate to what extent the developmental 
patterns identified in Chapter 5 are influenced by early psychopathology. 
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6.3 Cognition and the persistence of ADHD 
6.3.1 Persistence of idiopathic ADHD 
There is evidence that cognition can modulate the longitudinal course of ADHD. Perceptual learning 
has been found to predict clinical improvements (Biederman, Petty et al. 2009) but higher functions 
such as executive function and IQ do not (Biederman, Petty et al. 2009, Coghill, Hayward et al. 2014). 
Studies have also found that IQ does not predict persistence of ADHD into adolescence (Antshel, 
Faraone et al. 2008, Langley, Fowler et al. 2010), though IQ does predict comorbidity of conduct 
disorder in ADHD (Langley, Fowler et al. 2010). 
6.3.2 Persistence of ADHD in 22q11.2DS 
One study has examined cognitive predictors of the persistence of ADHD in 22q11.2DS and identified 
deficits in verbal learning (Antshel, Hendricks et al. 2013). Similar to idiopathic ADHD (Antshel, 
Faraone et al. 2008, Langley, Fowler et al. 2010), IQ does not predict ADHD persistence in 22q11.2DS 
(Antshel, Hendricks et al. 2013). 
6.4 Aims 
The aims of analysis in this chapter are to investigate the following questions: 
1. Psychotic experiences and cognitive development in 22q11.2DS  
a) Are psychotic experiences associated with cognitive differences? 
b) Are cognitive differences pre-existing to the emergence of psychotic experiences?  
c) Is the emergence of psychotic experiences associated with cognitive change? 
2. Does psychopathology influence cognitive development in 22q11.2DS? 
3. Does cognition predict persistence of ADHD in 22q11.2DS? 
6.5 Methods 
Sample description and assessment have been presented in Chapter 3. See Chapter 4 for detailed 
information on psychopathology including frequency of each disorder and vignettes of psychotic 
experiences. See Chapter 5 for description on how standardised cognitive scores are derived from 
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raw cognitive performance. Analysis in this chapter explores variation in 22q11.2DS individuals 
therefore there was no need to use data from controls. 
6.5.1 Aim 1: Psychotic experiences and cognitive development in 22q11.2DS 
Are psychotic experiences associated with cognitive differences? 
Cognitive difference attributable to psychotic experiences was calculated by subtracting wave 2 
cognitive performance of individuals with psychotic experiences (PE+) from the wave 2 cognitive 
performance of individuals without psychotic experiences (PE-). Independent t-tests were conducted 
to determine whether cognitive difference was significant. 
Are cognitive differences pre-existing to the emergence of psychotic experiences?  
To examine whether cognitive differences pre-exist the emergence of psychotic experiences, 
analysis excluded two individuals with psychotic experiences at both waves of assessment. Cognitive 
difference was calculated by subtracting the wave 1 cognitive performance of PE+ individuals from 
the wave 1 cognitive performance of PE- individuals. Independent t-tests were conducted to 
determine whether cognitive difference was significant. 
Is the emergence of psychotic experiences associated with cognitive change? 
Logistic regression analysis was used to test for associations between saverage, schange (from the 
previously described Principal Components Analysis in section 5.5.7) and psychotic experiences. The 
measurement of change is affected by mean performance at individual time points and this 
procedure allowed the link between change in cognition and psychotic experiences to be established 
without being biased by mean cognitive level. Also as the components extracted are not correlated, 
these analyses, unlike previous studies on this topic in 22q11.2DS (Gothelf, Schneider et al. 2013, 
Vorstman, Breetvelt et al. 2015) are not biased by mathematical coupling. 
Fisher’s exact test was conducted to investigate whether having a negative trajectory, as defined by 
reliable change indices (RCIs), or cognitive deterioration, as defined by a decrease in raw scores, was 
associated with wave 2 psychotic experiences.  As a reminder, reliable change indices are cut-offs 
applied to change scores to determine whether the magnitude of change is large enough to be a 
reliable change. Individuals were classified as exhibiting cognitive deterioration if they decreased in 
raw score. 
Again, analysis excluded two individuals with psychotic experiences at both waves of assessment to 
focus on the emergence of psychotic experiences. 
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6.5.2 Aim 2: Does psychopathology influence cognitive development in 22q11.2DS? 
The psychopathology variables used in this analysis were those that were found to be significantly 
elevated in children with 22q11.2DS compared to controls in Chapter 4; any DSM-IV-TR psychiatric 
disorder, any anxiety disorder, generalised anxiety disorder, specific phobia, social phobia, ADHD, 
ASD screening (using SCQ) and ASD diagnosis (using ADI-R)_. 
The cognitive variables used in this analysis were those from Chapter 5 which could be characterised 
reliably by models of cognitive development; FSIQ, VIQ, PIQ, Vocabulary, Similarities, Block Design, 
Matrix Reasoning, RVP, SOC and SWM. 
Cognitive differences were calculated by subtracting the cognitive performance of individuals who 
met psychopathology criteria from the cognitive performance of individuals who had not met 
psychopathology criteria. Independent t-tests were performed to investigate whether saverage and 
schange components of cognition differed in children with 22q11.2DS with and without 
psychopathology. 
6.5.3 Aim 3: Does cognition predict persistence of ADHD in 22q11.2DS? 
Analysis was conducted within children with 22q11.2DS and wave 1 ADHD diagnosis. Cognitive 
differences were calculated by subtracting the cognitive performance of individuals with persistent 
ADHD from the cognitive performance of individuals with ADHD that did not persist. Logistic 
regression analysis was used to test for associations between saverage, schange (from the previously 
described Principal Components Analysis in section 5.5.7) and ADHD diagnosis at wave 2. 
6.6 Results 
6.6.1 Aim 1: Psychotic experiences and cognitive development in 22q11.2DS 
Are psychotic experiences associated with cognitive differences? 
Children with 22q11.2DS and psychotic experiences had a -0.70 SD deficit (p=0.036) in spatial 
working memory (SWM) compared to other 22q11.2DS children (Table 29). No differences were 
observed for the other cognitive measures. It is important to note that in Chapter 4 it was found that 
children with psychotic experiences did not differ in terms of age, gender, 22q11.2DS inheritance, 
ethnicity, household income and maternal education. 
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Table 29: Cognitive differences in children with 22q11.2DS and psychotic experiences  
Cognitive differences were calculated by subtracting the cognitive performance of individuals with psychotic 
experiences (PE+) from individuals without psychotic experiences (PE-). Wave 1 analysis did not include two 
individuals who had psychotic experiences at wave 1 and wave 2. Wave 2 analysis included all individuals. 
  
Bold and underlined indicates p<0.05 
# This represents the cognition at wave 1 of individuals who later develop psychotic experiences (PE) at wave 2 
Are cognitive differences pre-existing to the emergence of psychotic experiences?  
At wave 1 a pre-existing deficit in spatial working memory (SWM) of -0.68 SD (p=0.032) was found in 
those who later developed psychotic experiences (Table 29). No pre-existing differences were 
observed for other cognitive measures. 
Is the emergence of psychotic experiences associated with cognitive change? 
A large decline in sustained attention (RVP), as defined by RCI, was associated with the emergence of 
psychotic experiences (r=0.379, p=0.020). The development of psychotic experiences seems 
particularly related to a large decline in sustained attention as a negative RCI is more strongly 
associated than cognitive deterioration (r=0.284, p=0.062) with wave 2 psychotic experiences. 
Across all cognitive measures schange, a continuous measure of cognitive change, was not associated 
with psychotic experiences (Table 30). There is further evidence of a relationship between spatial 
working memory deficits and psychotic experiences as spatial working memory (SWM) saverage was 
negatively associated (OR=0.39, p=0.020) with the emergence of psychotic experiences.  
Pre-exisiting at wave 1# Wave 2
Mean (p-value) Mean (p-value)
FSIQ 2.02 IQ points (0.601) 1.09 IQ points (0.768)
VIQ 2.24 VIQ points (0.602) 2.25 VIQ points (0.548)
PIQ 2.30 PIQ points (0.561) 0.03 PIQ points (0.994)
Vocabulary 1.50 (0.609) 1.85 (0.458)
Similarities 2.20 (0.542) 1.10 (0.726)
Block Design 0.46 (0.871) -1.13 (0.671)
Matrix Reasoning 2.63 (0.415) 0.99 (0.760)
MTS -0.13 (0.960) 1.80 (0.361)
RTI 1.00 SD (0.176) 0.35 SD (0.349)
RVP 0.26 SD (0.749) -1.25 SD (0.135)
SOC -0.01 SD (0.982) -0.07 SD (0.850)
SWM -0.68 SD (0.032) -0.70 SD (0.036)
Perseverative errors 0.96 (0.904) -2.16 (0.711)
Cognitive measure
Cognitive difference PE(-) - PE (+)
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Table 30: Association between cognition and the emergence of psychotic experiences in 22q11.2DS 
Analysis did not include two individuals who had psychotic experiences at wave 1 and wave 2.  
 
Bold and underlined indicates p<0.05 
6.6.2 Aim 2: Does psychopathology influence cognitive development in 22q11.2DS? 
Cognitive deficits were not observed in individuals with any DSM-IV-TR psychiatric disorder at wave 
1 (Table 31). However individuals with any psychiatric disorder at wave 1 did differ in terms of 
change over time in FSIQ (p=0.017) and on average exhibited cognitive decline (-3.91 FSIQ points) 
relative to those without any psychiatric disorder. This was driven by the VIQ similarities (p=0.049) 
and the PIQ matrix reasoning (p=0.022) subtests. Although there was decline in FSIQ in those with 
psychiatric disorder, mean FSIQ was in fact slightly elevated at both waves of assessment. It is 
important to note that in Chapter 4 it was found that children with psychiatric disorder did not differ 
in terms of age, gender, 22q11.2DS inheritance, ethnicity and maternal education but did on average 
come from families with a lower household income.  
 
saverage schange Negative RCI Cognitive deterioration
OR (p-value) OR (p-value) r (χ2 p‐value) r (χ2 p‐value)
FSIQ 1.25 (0.508) 1.17 (0.656) -0.175 (0.330) -
VIQ 1.30 (0.436) 1.24 (0.519) -0.212 (0.183) -
PIQ 1.20 (0.599) 0.85 (0.665) - -
Vocabulary 1.31 (0.422) 1.23 (0.526) 0.000 (0.999) -0.141 (0.427)
Similarities 1.28 (0.467) 1.04 (0.922 -0.122 (0.436) -0.063 (0.999)
Block Design 1.09 (0.797) 1.12 (0.749) - -0.020 (0.999)
Matrix Reasoning 1.25 (0.532) 0.78 (0.521) -0.117 (0.999) 0.094 (0.432)
MTS 1.05 (0.901) 1.12 (0.747) - 0.025 (0.999)
RTI 1.82 (0.234) 0.80 (0.403) -0.029 (0.999) -0.010 (0.999)
RVP 0.84 (0.635) 0.484 (0.080) 0.379 (0.020) 0.284 (0.062)
SOC 0.94 (0.844) 1.01 (0.981) -0.026 (0.999) -0.198 (0.255)
SWM 0.39 (0.020) 0.96 (0.918) -0.012 (0.999) -0.086 (0.731)
Perseverative errors 1.05 (0.901) 0.94 (0.854) -0.152 (0.577) -0.068 (0.729)
Cognitive measure
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Table 31: Cognitive differences of those with any psychiatric disorder at wave 1  
Cognitive differences were calculated by subtracting cognitive performance of individuals who meet criteria 
for psychiatric disorder from individuals who did not meet criteria. 
 
Bold and underlined indicates p<0.05 
The longitudinal profile of cognition differed between psychiatric disorders (Table 32). Those with 
any anxiety disorder at wave 1 differed in PIQ change (p=0.017), exhibiting a relative decline of -3.77 
PIQ points. This was driven by decline in the PIQ subtest matrix reasoning (p=0.040). The longitudinal 
profile of cognition differed amongst anxiety disorders, though all affected non-verbal cognition. 
Those with generalised anxiety disorder at wave 1 had a relatively increased ability in spatial 
planning (SOC p=0.008). Those with social phobia differed in FSIQ change (p=0.045), exhibiting a 
relative decline of -4.82 FSIQ points. This was driven by decline in performance on the matrix 
reasoning subtest (p=0.041).  Those with specific phobia at wave 1 had a deficit in spatial working 
memory (SWM p=0.008) and differed in PIQ change (p=0.034), exhibiting a relative decline of -4.12 
PIQ points which was driven by a decline in performance on the matrix reasoning subtest (p=0.035) 
Those with ADHD at wave 1 had a deficit in sustained attention (RVP p=0.046) but increased ability 
on the similarities IQ subtest. 
Meeting ADI-R ASD criteria was found not to be associated with reduced IQ or reduced performance 
in other cognitive domains (saverage Table 33). It was however associated with changes between 
assessment waves (schange Table 33); that is, a decline in performance on the similarities subtest and 
an increase on block design subtest performance. This is a different profile to that reported for SCQ 
ASD; those who met SCQ ASD criteria differed in spatial planning change (SOC, p=0.004) exhibiting a 
relative decline of -0.99 SD.  It should be noted that Chapter 4 found that children who met ASD 
saverage schange 
Wave 1 Wave 2
t-test   
p-value
t-test   
p-value
FSIQ 5.71 IQ points 1.80 IQ points 0.161 0.017
VIQ 5.75 VIQ points 2.15 VIQ points 0.205 0.073
PIQ 3.54 PIQ points 0.45 PIQ points 0.408 0.052
Vocabulary 2.67 1.61 0.284 0.536
Similarities 5.75 2.16 0.143 0.049
Block Design 1.32 1.04 0.428 0.661
Matrix Reasoning 4.00 -0.30 0.370 0.022
RVP -0.94 SD -1.41 SD 0.106 0.775
SOC 0.12 SD 0.23 SD 0.307 0.249
SWM -0.26 SD 0.00 SD 0.574 0.238
Cognitive 
measure
Cognitive difference 
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criteria did not differ in terms of age, 22q11.2DS inheritance, ethnicity, household income and 
maternal education but there was a male preponderance for ASD. 
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Table 32: Cognitive differences of those with psychopathology at wave 1 
Cognitive differences were calculated by subtracting the cognitive performance of individuals who meet 
criteria from individuals who did not meet criteria. 
 
Bold and underlined indicates p<0.05 
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Table 33: Cognitive differences of those with autism spectrum disorder 
Cognitive difference was calculated by subtracting cognitive performance of individuals who meet criteria from 
individuals who did not meet criteria. 
 
Bold and underlined indicates p<0.05 
6.6.3 Does cognition predict persistence of ADHD in 22q11.2DS? 
Of the 27 individuals with ADHD at wave 1, 13 continued to meet criteria at wave 2. A deficit in 
sustained attention (RVP) predicted ADHD persistence (p=0.034) (Table 34). Those with persistent 
ADHD had a deficit greater than 2 SD in sustained attention.  
Table 34: Cognitive differences of those with persistent ADHD 
Within children with 22q11.2DS and ADHD at wave 1, cognitive differences were calculated by subtracting the 
cognitive performance of individuals with ADHD at wave 2 from the cognitive performance of individuals with 
ADHD at wave 1 but not wave 2.  
 
Bold and underlined indicates p<0.05 
saverage schange saverage schange 
Wave 1 Wave 2
t-test    
p-value
t-test     
p-value
Wave 1 Wave 2
t-test    
p-value
t-test     
p-value
FSIQ -0.27 IQ points -0.13 IQ points 0.934 0.984 -1.24 IQ points -1.28 IQ points 0.595 0.611
VIQ -2.55 VIQ points -3.41 VIQ points 0.380 0.800 -2.17 VIQ points -5.28 VIQ points 0.304 0.267
PIQ 2.28 PIQ points 3.38 PIQ points 0.449 0.937 0.54 PIQ points 2.22 PIQ points 0.896 0.895
Vocabulary -1.36 -0.93 0.681 0.604 -2.30 -0.54 0.593 0.327
Similarities -1.57 4.59 0.232 0.203 0.12 -6.29 0.284 0.018
Block Design 1.38 3.65 0.288 0.126 -1.30 2.63 0.977 0.035
Matrix Reasoning 2.24 1.09 0.592 0.334 2.68 0.36 0.743 0.081
RVP 0.03 SD -0.60 SD 0.893 0.981 -0.89 SD 0.20 SD 0.360 0.231
SOC 0.24 SD -0.72 SD 0.905 0.007 0.18 SD -0.40 SD 0.823 0.053
SWM -0.44 SD -0.12 SD 0.223 0.239 -0.32 SD -0.08 SD 0.440 0.317
Cognitive 
measure
ASD: ADI-R 
Cognitive difference 
ASD: SCQ
Cognitive difference 
saverage schange
Wave 1 Wave 2 OR (p-value) OR (p-value)
FSIQ 1.53 IQ points -0.89 IQ points 1.02 (0.962) 0.52 (0.202)
VIQ 1.03 VIQ points -2.61 VIQ points 0.89 (0.752) 0.54 (0.178)
PIQ 2.59 PIQ points 2.50 PIQ points 1.31 (0.539) 0.82 (0.634)
Vocabulary -0.22 -1.76 0.84 (0.648) 0.77 (0.440)
Similarities 1.78 -1.89 1.01 (0.986) 0.53 (0.187)
Block Design -0.89 3.23 0.97 (0.940) 2.74 (0.063)
Matrix Reasoning 4.64 0.34 1.43 (0.428) 0.43 (0.108)
RVP -2.27 SD -2.65 SD 0.15 (0.034) 2.00 (0.274)
SOC -0.19 SD -0.69 SD 0.68 (0.481) 0.93 (0.873)
SWM 0.09 SD -0.31 SD 0.83 (0.631) 0.53 (0.255)
Cognitive measure
Cognitive Difference
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6.7 Discussion 
This is the first longitudinal 22q11.2DS study to consider how childhood psychopathology impacts 
cognitive development and one of few to assess cognition and psychotic phenomena concurrently. 
6.7.1 Findings 
1. IQ deficit was not associated with the emergence of psychotic experiences but other cognitive 
domains were. 
Children with 22q11.2DS and psychotic experiences did not exhibit deficits in IQ compared to 
children with 22q11.2DS without psychotic experiences and the emergence of psychotic 
experiences was not accompanied by a decline in IQ. However deficits in spatial working 
memory were present in those with psychotic experiences and this deficit was present before 
the emergence of psychotic experiences. The emergence of psychotic experiences was 
associated with a large decline in sustained attention, as defined by RCIs. This highlights the 
importance of assessing specific cognitive domains as well as IQ.  
2. Method of classifying cognitive change is important 
Cognitive change was analysed dichotomously by using RCIs to identify large reliable cognitive 
changes and also continuously by using principal components analysis to extract a component 
that represents change (schange). When change in the cognitive domain sustained attention was 
analysed dichotomously it was found to be associated with the emergence of psychotic 
experiences but not when analysed continuously. This suggests that the relationship between 
change in sustained attention and psychotic experiences may be non-linear and that there may 
be a cut-off where change becomes predictive of psychotic experiences. It is important that 
future studies consider the possibility of non-linear relationships. 
3. In 22q11.2DS psychopathology modulates cognitive development 
Children with 22q11.2DS and a psychiatric disorder exhibited decline in IQ relative to children 
with 22q11.2DS and no psychiatric disorder. This has not been investigated before in 22q11.2DS. 
Children with 22q11.2DS and psychiatric disorder did not exhibit cognitive deficits relative to 
those without psychiatric disorder (Table 31). This suggests that the -33.2 IQ deficit reported in 
Chapter 5 cannot be explained by the high burden of psychopathology reported in Chapter 4. 
This is consistent with cross-sectional findings from the ECHO cohort which report that 
141 
 
psychopathology and deficits in cognition are independent sequelae of 22q11.2DS (Niarchou, 
Zammit et al. 2014).  
4. Longitudinal cognitive profile differs amongst disorders 
When psychopathology is considered in terms of individual disorders, each disorder was 
associated with a distinct longitudinal profile but there was also overlap.  
i. Anxiety and ASD impact spatial cognition 
 
Anxiety and ASD were associated with decline in spatial cognition over time with 
anxiety and ADI-R ASD impacting PIQ and SCQ ASD affecting spatial planning.  They 
impact different aspects of the same cognitive domain and this is analogous to 
symptomatology as it has been argued that measures of anxiety and ASD in 
22q11.2DS are capturing the same underlying affective endophenotype (Angkustsiri, 
Goodlin-Jones et al. 2014). It is also interesting to note that different measures of 
ASD are differentially related to cognitive development. This provides further 
evidence that the SCQ and ADI-R index different constructs.  
 
ii. Longitudinal course differed amongst anxiety disorders  
 
Individual anxiety disorders differed in longitudinal cognitive profile. In Chapter 4 it 
was reported that anxiety disorders differ in terms of longitudinal persistence and 
emergence. Given that anxiety has been associated with the emergence of psychotic 
phenomenology (see sections 2.1.4 and 2.1.5), these findings add to my previous 
argument (see 4.7.1) that it is important for future 22q11.2DS studies to consider 
the nature of anxiety. 
 
Individuals with generalised anxiety disorder have increased spatial planning ability. 
This is consistent with findings in clinical cohorts that generalised anxiety disorder 
symptomatology is associated with increased cognitive performance (Coplan, 
Hodulik et al. 2011). 
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iii. ADHD and ADHD persistence were associated with deficits in sustained attention. 
 
At wave 1 children with 22q11.2DS and ADHD had approximately a 1 SD deficit in 
sustained attention. The deficit is greater by 2 SD in individuals whose ADHD persists 
to wave 2. In some respects this finding is expected but it is highlights that cognitive 
and symptomatology measures of attention are related in 22q11.2DS  as they are in 
the idiopathic ADHD literature (Barkley 1997). IQ was found not to predict 
persistence and this is consistent with previous idiopathic studies that found IQ did 
not predict ADHD persistence (Antshel, Faraone et al. 2008, Langley, Fowler et al. 
2010). 
5. Spatial cognition was related to both anxiety and the emergence of psychotic experiences 
Childhood anxiety and decline in VIQ have been previously identified as risk factors for the 
emergence of psychotic phenomena in 22q11.2DS (see sections 2.1.4 and 2.1.5). Findings from 
this chapter found non-verbal cognition was related to anxiety and the emergence of psychotic 
experiences, in particular spatial tasks. The presence of anxiety disorder at wave 1 was 
associated with decline in PIQ. Amongst anxiety disorders, phobias impacted negatively on 
spatial cognition whereas ability was actually increased in generalised anxiety. Social and specific 
phobias were both associated with decline in spatial reasoning (PIQ subtest matrix reasoning) 
and specific phobia was related to deficits in spatial working memory. Deficits in spatial working 
memory were also found in those individuals who developed psychotic experiences. However in 
Chapter 4 specific phobia was not found to be associated with the emergence of psychotic 
experiences. A clear causal pathway between anxiety, spatial cognition and psychotic 
experiences cannot be defined from the analyses conducted. However results suggest that 
future studies should investigate spatial cognition as a possible mediator between anxiety and 
the development of psychotic phenomena.  
Previous studies have implicated verbal cognition rather than spatial cognition in predicting 
psychotic phenomena in 22q11.2DS (Gothelf, Eliez et al. 2005, Gothelf 2014, Vorstman, Breetvelt 
et al. 2015). These findings are not necessarily contradictory as studies have measured cognitive 
change across the onset of psychosis. It could be that spatial cognition plays a role in the 
emergence of psychotic phenomena and that verbal cognition declines with onset of florid 
psychosis. It is important that future 22q11.2DS studies are developmentally specific and tease 
apart the cognitive changes associated with each stage of psychosis development.  
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6. Sustained attention was related to both ADHD and psychotic experiences 
In 22q11.2DS those with ADHD have deficits in sustained attention and decline in sustained 
attention was related to the emergence of psychotic experiences. However, Chapter 4 found 
ADHD was not associated with the emergence of psychotic experiences. It is important to 
emphasise that ADHD was found to be associated with a static deficit in sustained attention 
whereas change was associated with the emergence of psychotic experiences. These findings 
warrant further investigation and attention should be investigated as a mediating 
endophenotype of psychosis risk in 22q11.2DS. Attention is considered an endophenotype for 
schizophrenia in the idiopathic literature (Cornblatt and Malhotra 2001).  
6.7.2 Limitations 
1. Not able to infer chronology of development of cognition and psychopathology 
Psychopathology and cognition were assessed concurrently which means cognitive change 
cannot be said to have occurred before or after the presence of psychopathology. So although 
decline in sustained attention is associated with the emergence of psychotic experiences it is 
uncertain whether this is due to the onset of psychotic experiences or preceded onset. Also the 
direction of effect is uncertain regarding the findings that psychopathology at wave 1 is 
associated with cognitive change.  
2. Issue of multiple comparisons 
The findings reported in this chapter should be considered exploratory and treated cautiously as 
findings would not survive correction for multiple comparisons. This increases the risk of type 1 
errors occurring, whereby the null hypothesis is incorrectly rejected. However it is noteworthy 
that several findings converge on spatial cognition.  
6.7.3 Conclusions 
Chapter 4 demonstrated that there is a high burden of psychopathology in 22q11.2DS and that 
psychotic experiences start to be reported from age 10. Chapter 5 found the pattern of cognitive 
development in 22q11.2DS is similar to that observed in childhood preceding idiopathic 
schizophrenia. This chapter has aimed to relate psychopathology and cognitive development.  
Pre-existing deficits in spatial working memory were associated with the emergence of psychotic 
experiences but deficits in IQ were not. The presence of psychopathology had a modulatory effect 
on cognitive development but by no means accounted fully for the cognitive deficits present in 
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22q11.2DS. The presence of anxiety and ASD was associated with decline in spatial cognition. Deficit 
in sustained attention was associated with ADHD and also predicted the longitudinal persistence of 
ADHD. Overall cognitive development and psychopathology were related to some extent in 
22q11.2DS, but by no means fully overlapped. 
Across chapters there is converging evidence that non-verbal cognition and in particular spatial 
cognition may play a role in the development of psychotic phenomena in 22q11.2DS. Chapter 4 
found premorbid decline in PIQ (nonverbal ability) and this chapter found that a deficit in spatial 
working memory was associated with the emergence of psychotic experiences. It may be that PIQ 
and spatial working memory measures capture different aspects of an underlying non-verbal 
cognitive construct that predicts the emergence of psychotic experiences. This chapter suggests that 
the presence of anxiety and ASD in childhood may impact on the development of this non-verbal 
cognitive construct. 
This cohort now needs to be followed up again to gain insight into the development of psychotic 
disorder and whether the associated pattern of cognitive development differs from that identified 
for the emergence of psychotic experiences in this chapter.   
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7. Discussion 
7.1 Overview 
This thesis set out to examine the neuropsychiatric phenotype of 22q11.2DS through a 
developmental lens. The neuropsychiatric phenotype in 22q11.2DS is complex and spans diagnostic 
categories and cognitive domains. This thesis analysed data from the deeply phenotyped 
longitudinal ECHO cohort of children with 22q11.2DS and their unaffected siblings. Findings from a 
range of measures were utilised to characterise development. 
 Psychopathology - the CAPA provided longitudinal information on the presence of DSM-IV-
TR psychiatric disorder as well as subthreshold psychotic phenomena  
 ASD - examined using the SCQ longitudinally, a brief light touch assessment, and at wave 2 
the ADI-R provided a more in depth assessment of ASD and developmental history 
 IQ – the longitudinal development of global cognition including verbal and non-verbal 
domains of intelligence were examined using performance on the WASI 
 Specific neurocognitive domains - the longitudinal development of executive function, 
attention and processing speed were examined using performance on the WCST and the 
CANTAB 
This thesis has examined change across various developmental stages in 22q11.2DS. 
 Early development - in Chapter 4 findings from the ADI-R were analysed, which assesses 
developmental history with a particular focus between ages 4 to 5 
 Early adolescence - in Chapter 4 longitudinal stability and changes in psychopathology were 
examined across a 2.5 year period (average ages 10 to 12.5), capturing the crucial period of 
early adolescence 
 Development spanning childhood and adolescence - in Chapter 5 an accelerated longitudinal 
design was applied to cognitive data, allowing cognitive development to be examined from 
ages 6 to 17 
In Chapter 4 a high prevalence of psychiatric disorder was found across early adolescence in 
22q11.2DS, particularly ADHD, ASD and anxiety disorders. This confirms that 22q11.2DS as a risk 
factor for developing schizophrenia is also associated with significant psychiatric morbidity before 
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adulthood. Using the ADI-R, an in depth diagnostic interview that also assesses early development, 
prevalence of ASD and subthreshold symptomatology was found to be high in 22q11.2DS. This 
demonstrates that neurodevelopmental deviance is present in the early years of children with 
22q11.2DS. Particularly striking was the emergence of psychotic experiences in early adolescence, 
which was found to be independent of other psychopathology. Over the same period ADHD 
prevalence decreased. The neuropsychiatric phenotype was found to be complex and did not seem 
to be underpinned by a core deficit as different aspects had their own distinct longitudinal course.  
In Chapter 5, significant deficits spanning numerous cognitive domains were found in 22q11.2DS 
relative to controls. The longitudinal course of cognitive development differed by cognitive domain. 
In particular there were developmental deficits in verbal cognition and developmental lags in non-
verbal cognition. The pattern of cognitive development in 22q11.2DS was found to be similar to that 
observed in children who later develop idiopathic schizophrenia (Reichenberg, Caspi et al. 2010). The 
mixture of developmental deficits and lags found in 22q11.2DS indicates that genetic risk for 
schizophrenia is associated with both processes in early development and later in adolescence. This 
highlights the utility of 22q11.2DS as a model for exploring premorbid development associated with 
schizophrenia.   
Chapter 6 aimed to bring together psychopathology examined in Chapter 4 and cognition examined 
in Chapter 5. Each psychiatric disorder had a differing profile of cognitive development. However, 
psychopathology alone did not account for cognitive deficits; rather the presence of 
psychopathology had a modulatory effect on cognition. Chapter 6 also examined whether cognition 
predicted emergence of psychotic experiences and the persistence of ADHD. Pre-existing deficits in 
spatial working memory and a large drop in sustained attention were found to be associated with 
the emergence of psychotic experiences and deficits in sustained attention were associated with the 
persistence of ADHD. 
7.2 Themes 
7.2.1 22q11.2DS is associated with significant neuropsychiatric burden 
Across chapters it is clear that 22q11.2DS is associated with a significant neuropsychiatric burden. 
The prevalence of psychiatric disorder was found to be greater than 50% at both waves of 
assessment with children meeting criteria across many diagnostic categories. Subthreshold 
symptomatology was found to be prevalent in children with 22q11.2DS, 63.5% had deficits in at least 
one ASD domain and, at wave 2, 21.4% had psychotic experiences. Significant cognitive deficits were 
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found in global cognition (IQ) and across neurocognitive domains of executive function, attention 
and processing speed.  
7.2.2 Longitudinal trends and stability is present in 22q11.2DS  
Aspects of the neuropsychiatric phenotype in 22q11.2DS show longitudinal stability. ASD, as 
measured by the SCQ, showed stability both in terms of categorical ASD classification and symptom 
count. Global cognition in terms of IQ showed greater stability than the development of specific 
neurocognitive domains. This indicates that in 22q11.2DS if ASD traits and reduced IQ are present 
these are likely to persist through childhood and adolescence.  
There are threads that run through development in 22q11.2DS. Children with spatial working 
memory deficits were found to be at greater risk of developing psychotic experiences. Also children 
who exhibited a large drop in sustained attention were found to be more likely to have psychotic 
experiences. In children with 22q11.2DS and ADHD, deficits in sustained attention predicted ADHD 
persistence. 
7.2.3 The neuropsychiatric phenotype of 22q11.2DS is highly variable 
This thesis has found that the neuropsychiatric phenotype of 22q11.2DS is variable at many levels, 
including the range of psychiatric and cognitive manifestations present in 22q11.2DS.  
Different aspects of psychopathology and cognitive development were found to vary in terms of 
longitudinal course and stability over time. Individual psychiatric disorders were found to vary in 
terms of prevalence and persistence, and deficit magnitude differed amongst cognitive domains.   
Within 22q11.2DS it has been shown that the group mean of a trait masks considerable individual 
variation. For instance in Chapter 4 it was found that although there was no net change in 
prevalence of anxiety disorders, there were many individuals whose diagnostic status changed 
between assessment waves. In Chapter 5, children with 22q11.2DS were found to decline in IQ 1 
point per year, but individual change between assessment waves (2.5 years) ranged from -15 to 23 
IQ points. 
7.2.4 The extent to which neuropsychiatric measures are capturing valid constructs 
Although a general issue in research, it has been a particular pertinent concern in this thesis whether 
measures used are actually capturing intended constructs. Unique consideration has had to be given 
to how to assess longitudinal change. Chapter 5 considered in depth how to reliably capture 
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cognitive change and how best to distinguish this from error. Analytical methods such as reliable 
change indices and principal components analysis were used to critically examine change.  
The complexity of the neuropsychiatric phenotype in 22q11.2DS has meant the validity of 
psychopathology measures has been put under scrutiny. In 22q11.2DS measures of psychopathology 
should be interpreted critically and not necessarily taken at face value. In Chapter 4 it was found 
there were individuals who gained a diagnosis of neurodevelopmental disorder with age and that 
the SCQ measure of ASD indexes comorbid psychiatric disorder more so than the ADI-R.  
7.2.5 The extent to which aspects of the neuropsychiatric phenotype are specific to 
22q11.2DS 
Given the high risk 22q11.2DS confers for schizophrenia development, many studies have aimed to 
identify neuropsychiatric features associated with this genetic risk for schizophrenia. However it has 
not always been considered whether associated features are unique to 22q11.2DS.  
Many 22q11.2DS studies have reported high levels of psychiatric morbidity in 22q11.2DS (see 
Chapter 1). In Chapter 4 it was highlighted that the pattern of psychiatric morbidity in 22q11.2DS is 
similar to that in idiopathic ASD and may not be specific to the syndrome.  
It has been reported that development of IQ is highly variable in 22q11.2DS with many exhibiting 
decline (Duijff, Klaassen et al. 2012). However in Chapter 5 although it was found that longitudinal 
change in IQ is highly variable in 22q11.2DS, it was not more variable than in controls.  
7.3 Implications of this thesis 
7.3.1 22q11.2DS warrants clinical attention 
The neuropsychiatric burden present in 22q11.2DS warrants clinical attention, support and 
treatment. In Chapter 4 it was found that 82.9% of those with psychiatric disorder at wave 2 had a 
diagnosis at wave 1. This highlights the potential for early, targeted intervention in children with 
22q11.2DS. 
However currently psychopathology in 22q11.2DS is not adequately treated and followed (Young, 
Shashi et al. 2011). One study found that half of those at risk of psychosis were not receiving any 
mental health care (Tang, Yi et al. 2014).  
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7.3.2 Genetic risk of schizophrenia is associated with neurodevelopmental deviance 
Findings in this thesis support the neurodevelopmental hypothesis of schizophrenia. 22q11.2DS as a 
genetic risk factor for schizophrenia was found to be associated with a range of problems that 
manifest early in development.  
Chapter 5 reported developmental deficits across a range of cognitive domains. Although 
development through 6-17 was assessed, the static nature of these deficits, if extrapolated back, 
would suggest that cognitive deficits originate very early in development in 22q11.2DS.  
This thesis has confirmed previous reports that there is a high prevalence of neurodevelopmental 
disorder in 22q11.2DS. In particular, Chapter 4 found through a retrospective interview that ASD 
symptomatology was highly prevalent in the early development of children with 22q11.2DS.  
7.3.3 22q11.2DS has pleiotropic effects throughout development 
The neuropsychiatric phenotype of 22q11.2DS does not appear to be characterised by a core deficit 
that spans development. Findings in this thesis suggest 22q11.2DS has cross-sectional and temporal 
pleiotropic effects. 
22q11.2DS is associated with both ASD and psychotic experiences, however Chapter 4 found they 
were independent of each other. Interestingly none of those who met strict autism criteria on the 
ADI-R met the highest cut-off on the SCQ autism measure and vice versa. On one level this highlights 
the discrepancy between the two ASD measures but it also indicates that differing aspects of ASD 
phenomenology may not show overlap in 22q11.2DS.  
22q11.2DS is associated with both psychopathology and cognitive deficits. Chapter 6 found that 
although psychopathology was related to cognitive development, the effect is subtle and they by no 
means fully overlap.  
22q11.2DS has pleiotropic effects on cognition across childhood and adolescence. Chapter 5 found 
that cognitive development in 22q11.2DS was a mixture of both developmental deficits and lags 
which suggests that both processes early in development and later in childhood and adolescence 
may be associated with the syndrome. 
7.3.4 22q11.2DS is a useful model for investigating schizophrenia development 
This work confirms the utility of 22q11.2DS as an opportunity to prospectively investigate the 
development of schizophrenia. Chapter 5 found the pattern of cognitive development in 22q11.2DS 
to be similar to that in children who later develop idiopathic schizophrenia. Chapter 4 demonstrated 
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that longitudinal studies of 22q11.2DS are able to successfully capture the prospective emergence of 
psychotic phenomena. Chapter 6 was able to identify spatial working memory deficits and decline in 
sustained attention to be associated with the emergence of psychotic experiences in 22q11.2DS. 
7.3.5 Implications of this thesis for future research  
1. Implications for the 22q11.2DS research community 
This thesis has identified trends to be explored further in larger 22q11.2DS cohorts. The 
International 22q11.2DS Brain and Behaviour Consortium (IBBC) provides such an opportunity. 
22q11.2DS research investigators have highlighted the decline of VIQ in the syndrome 
(Vorstman, Breetvelt et al. 2015). However Chapter 5 found a declining developmental lag in PIQ 
but a static developmental deficit in VIQ, this finding needs replication, but it highlights that 
longitudinal change PIQ should receive research attention as well as VIQ.  
Previous longitudinal studies of cognition in 22q11.2DS have often focused exclusively on IQ 
measures. However findings in this thesis highlight that other neurocognitive domains warrant 
attention. Chapter 6 found that spatial working memory and sustained attention were related to 
the emergence of psychotic experiences. 
This thesis also indicates that previously identified trends in the 22q11.2DS literature may be 
more complex in nature. Childhood anxiety has been previously been identified as a risk factor 
for the emergence of psychotic phenomena (see sections 2.1.4 and 2.1.5). Chapter 4 found 
different anxiety disorders had differing trajectories and Chapter 6 found this was matched by 
predicting different cognitive trajectories.  This highlights that future studies should examine the 
nature of anxiety that predicts psychotic phenomena. Chapter 6 also found that anxiety and 
psychotic experiences were associated with differing aspects of spatial cognition. Although a 
clear causal pathway cannot be defined from the analysis conducted it does suggest that spatial 
cognition maybe a mediator between anxiety and the development of psychotic phenomena. 
This relationship could be explored in future studies. 
2. Methodological implications 
This thesis has focused on using methodology that critically examines longitudinal change. It has 
also considered what measures of cognition and psychopathology are really capturing. Here I 
summarise some of the main messages from this thesis regarding methodology which are 
applicable not just to 22q11.2DS research but wider developmental psychopathology research. 
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First, is the importance of having a control group to explore which neurodevelopmental features 
are specific to the group of interest, in this case 22q11.2DS, and which features are common to 
all children and adolescents. For example, a previous 22q11.2DS study identified a subgroup of 
children who exhibit cognitive deterioration on IQ domains and it was concluded that this is a 
feature of the syndrome (Duijff, Klaassen et al. 2012). However this study had no control group. 
This thesis has found that variability in IQ development and the proportion of those who exhibit 
cognitive deterioration does not differ from intrafamilial controls, suggesting that cognitive 
deterioration in IQ is not specific to 22q11.2DS. In contrast, development in attention was found 
to be more variable in 22q11.2DS compared to intrafamilial controls and thus specific to the 
syndrome. 
Second is to highlight that data from longitudinal studies have unique statistical properties and 
these should be taken into account accordingly in analysis. As mentioned through this thesis, it is 
apparent that previous 22q11.2DS studies have not always considered such issues. The 
methodology sections have discussed analytical techniques that help overcome such problems. 
Third is to be critical of what psychopathology assessments are actually measuring. This thesis 
found that the SCQ and ADI-R measured overlapping but different constructs and there was 
evidence that they were associated with different cognitive trajectories. The SCQ was found to 
index psychopathology other than ASD more so than the ADI-R. This highlights that in 
‘diagnostically challenging’ children, in depth semi-structured interviews such as the ADI-R are 
necessary. However it should be considered whether it would be feasible for the ADI-R to be 
administered as part of a protocol of a large consortium. Large phenotyping studies have to find 
a balance between the use of in-depth measures and keeping the assessment protocol feasible. 
One compromise would be to utilise a two tier level of phenotyping, whereby there would be a 
light-touch phenotyping approach in many individuals and then a more in-depth rigorous 
phenotyping in a subgroup top validate the light-touch assessments used. 
7.3.6 Limitations of this thesis 
This thesis has several limitations. Firstly there are issues of power, the sample size of the cohort 
reduces the power to detect relationships in the dataset and therefore it is likely that subtle 
developmental trends have been missed. This thesis has attempted to comprehensively examine the 
neuropsychiatric phenotype of 22q11.2DS, and in doing so many psychopathology and cognitive 
variables have been considered in analysis. A consequence of this is the issue of multiple 
comparisons. Analysis was not adjusted for multiple comparisons due to the power issues. This has 
been highlighted in the relevant sections of this thesis. 
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Another limitation is the use of psychopathology measures which are based on traditional diagnostic 
categories. It has been mentioned several times during this thesis that the use of current diagnostic 
classification systems is difficult in 22q11.2DS given the high level of comorbid psychiatric disorder 
and the presence of intellectual disability. Also Chapter 4 identified individuals who did not meet 
ASD criteria but who had subthreshold symptomatology. Moving forward it is important for studies 
to consider other approaches for characterising the neuropsychiatric phenotype in 22q11.2DS. 
Section 2.2.3 described some alternative approaches; symptom-cognitive domains, developmental 
brain dysfunction and research domain criteria.  
Finally, ascertainment bias is likely to operate at many levels in this longitudinal study of children 
with 22q11.2DS. There is likely to be bias in those children who are identified by medical genetics 
clinics as having 22q11.2DS. Chapter 3 found there was a slight bias in those families with a child 
with 22q11.2DS lost to follow-up. Overall this means this thesis may not be necessarily capturing the 
true longitudinal phenotype of 22q11.DS. It is likely that those identified by medical genetics clinics 
are likely to have more health problems than those who do not. Potentially the ECHO cohort is 
missing 22q11.2DS individuals with typical development. 
7.4 Future Directions 
7.4.1 Large, deeply phenotyped 22q11.2DS cohorts 
Large cohorts of 22q11.2DS individuals are needed to provide greater power for analysis. In practice, 
given the rarity of 22q11.2DS, individuals with the syndrome are difficult to recruit. The IBBC study is 
a step forward, bringing together 1402 22q11.2DS individuals from fifteen sites around the world. 
However measures are not consistent between sites, which as discussed in Chapter 5 can cause 
difficulties when examining longitudinal change in cognition. In this thesis I have discussed that 
22q11.2DS studies do not always assess psychopathology and cognition concurrently or do not 
always assess ASD. Moving forward it would be ideal if sites could synchronise and develop 
assessment protocols that capture the full neuropsychiatric phenotype of 22q11.2DS.   
7.4.2 22q11.2DS studies that examine development across the life course 
This thesis has examined development of psychopathology across early adolescence, and for 
cognitive development from ages 6 to 17. However it is important that other stages of development 
are considered. Section 7.3.2 summarises that this thesis points to disruption in early development 
in 22q11.2DS. Future studies should directly examine early development, including prenatal 
development, to investigate the origins of psychopathology and cognitive deficits in 22q11.2DS. It is 
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unknown at what point cognitive deficits emerge and are apparent in 22q11.2DS. There is one study 
that reports cognitive deficits in children aged 13 months with 22q11.2DS (Gerdes, Solot et al. 2001) 
but their origin and longitudinal course is currently unknown. 22q11.2DS could offer a rare 
opportunity to prospectively examine the early development of those at high risk of developing 
schizophrenia.  However, currently, 22q11.2DS is not routinely tested for during pregnancy or at 
birth so there is likely to be ascertainment bias in those identified early.   
As discussed in Chapter 5, future assessment waves in the ECHO study 22q11.2DS cohort would give 
insight into development across the risk period for the emergence of psychosis. A third wave of 
assessment is currently being undertaken in the ECHO study cohort. 
7.4.3 Longitudinal investigation of other psychiatric-risk CNVs 
In comparison to 22q11.2DS, many other psychiatric-risk CNVs have only been identified relatively 
recently (Levy, Xu et al. 2012) so longitudinal studies are relatively scarce. Although psychiatric-risk 
CNVs converge on the same disorders it is uncertain whether the pathway to psychiatric disorder 
differs amongst psychiatric-risk CNVs. Cross-sectional evidence suggests that different CNVs affect 
different cognitive domains (Stefansson, Meyer-Lindenberg et al. 2014).  Contrasting development 
amongst psychiatric-risk CNVs could reveal developmental trajectories specific to genomic regions 
and could help pinpoint genes involved in specific pathways to psychiatric disorder. Alternatively 
such studies may reveal that different genomic regions impact on the same developmental risk 
pathway for psychiatric disorder.  
7.4.4 Large population studies to reduce ascertainment bias 
One way to overcome ascertainment bias would be through studies which genotype a large 
population, identify individuals with 22q11.2DS and examine their phenotype. However given the 
rarity of 22q11.2DS this would require a very large cohort. The Icelandic DeCODE genetic population 
cohort (n=101,655) (discussed in section 2.2.1.5) was not large enough to give insight into 
22q11.2DS, although it was sufficient for less rare psychiatric-risk CNVs (e.g. 15q11.2 deletion and 
duplication) (Stefansson, Meyer-Lindenberg et al. 2014). Only 18 individuals with 22q11.2DS were 
identified, of which just 3 took part in assessments.  
7.5 Conclusion 
This thesis adds to the emerging literature on the neuropsychiatric phenotype of 22q11.2DS and 
more widely contributes to research on the development of schizophrenia. This is one of the few 
longitudinal 22q11.2DS studies that has used the same measures at both waves of assessment and 
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has examined both cognition and psychopathology. In the early adolescent period of 22q11.2DS 
psychotic experiences were found to emerge and this was associated with deficits in spatial working 
memory and attention, but emergence was independent of the high levels of other psychopathology 
associated with the syndrome. Retrospectively, ASD phenomenology was found to be highly 
prevalent in the early development of children with 22q11.2DS. Cognitive development in 
22q11.2DS was found to follow similar patterns to that observed in children who develop idiopathic 
schizophrenia. Psychopathology and cognitive development were found to be largely independent, 
but some specific relationships were identified. Together these findings demonstrate that 22q11.2DS 
as a genetic risk factor for schizophrenia has a range of pleiotropic effects on development and has 
highlighted the utility of longitudinal studies of 22q11.2DS in that they can prospectively examine 
the emergence of psychotic phenomena.  
22q11.2DS can pose challenges in research, given its rarity, complex neuropsychiatric phenotype and 
the likely presence of ascertainment bias. Hopefully large collaborative studies of clinical and 
population cohorts may help overcome some of these difficulties. 22q11.2DS is one of the strongest 
risk factors for schizophrenia and yet we still do not fully understand why. Solving this question has 
the potential to help those individuals with 22q11.2DS, and individuals with schizophrenia in the 
wider population, as well as understanding the aetiology of psychiatric disorder.  
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